ActivistsInvestorsTrumpPoliticiansSerenityCitriniSemianalysisTradeArbitrageSearch

Citrini Research

Latest Citrini's macro & equity research reports. My own summary + their long/short tickers, with PnL performance if you followed their call. The Mentions column flags who else is in each name — Big Investors (I), Serenity (S), Activists (A), Politicians (P), Trump (T).

48 reports · #080–#127 · Jan 09, 2025 – Jul 20, 2026 · updated Jul 28, 2026
#127 Thematic Update Jul 20, 2026

All Along the AI Watchtower

A violent, leverage-driven unwind of the most crowded AI expressions — not open-source competition, Kimi3, or the Iranian conflict — is what explains the recent selloff, and the unwind has mispriced stocks by category rather than by fundamentals. The market has been willing to pay for infrastructure software but has indiscriminately clobbered application software, data businesses, and anything wearing an old label. Citrini therefore hunts for AI upside in names filed under the wrong category: Qualcomm as a data-center architecture play rather than a handset laggard, developer and context tooling that gets called more even as seats shrink, database and search vendors that meter agentic context maintenance, and the enterprise hardware and security complex that IBM's miss revealed is absorbing redirected capex. The unifying causal chain is that agentic AI shifts retrieval from an occasional preprocessing step to continuous execution-loop context maintenance, and pushes enterprises toward owning their stack — which routes spend to servers, storage, memory, and cybersecurity. Meta is the capstone: it is the only hyperscaler whose compute converts directly to P&L through advertising, so the bears subtracting capex first are getting the order of operations wrong.

aineocloudaisemicybersecuritymag5saas
Positions & performance
-0.8%avg return31% win · 16 tracked · L -0.8%
PositionMentionsEntryLastReturn
LDELL:NYSE aineocloud DellISAPT381.25Jul 20 '26426.91 +12.0%
LHPE:NYSE aineocloud Hewlett Packard EnterpriseIPT44.56Jul 20 '2647.69+7.0%
LP:NYSE aineocloud Everpure69.93Jul 20 '2674.21 +6.1%
LNTAP:NASDAQ aineocloud NetAppPT161.16Jul 20 '26169.8 +5.4%
LNVDA:NASDAQ aisemi NvidiaISPT203.28Jul 20 '26206.84+1.8%
LESTC:NYSE saas ElasticAT56.24Jun 26 '2656.240.0%
LFFIV:NASDAQ saas F5PT394.53Jun 26 '26394.530.0%
LNTNX:NASDAQ saas NutanixIT55.11Jul 20 '2655.04-0.1%
LQCOM:NASDAQ aisemi QualcommISPT170.32Jul 20 '26170.04 -0.2%
LCVLT:NASDAQ saas CommvaultIPT146.72Jul 20 '26142.31-3.0%
LFIG:NYSE saas FigmaISAPT24.02Jul 20 '2622.94 -4.5%
LFTNT:NASDAQ saas FortinetIPT160.36Jul 20 '26152.37-5.0%
LMDB:NASDAQ saas MongoDBIPT323.36Jul 20 '26298.22-7.8%
LMETA:NASDAQ mag5 MetaISPT645.85Jul 20 '26593.87 -8.0%
LGTLB:NASDAQ saas GitLabIT34.07Jul 20 '2631.28-8.2%
LPLTR:NASDAQ saas PalantirISPT134.85Jul 20 '26122.92-8.8%
Non-US / no price2454 TT YUBICO:OMX cybersecurity 992:HKEX aineocloud 6702:TSE aineocloud
Also watchingPANW:NASDAQ cybersecurity CSCO:NASDAQ aisemi CRWD:NASDAQ saas NET:NYSE saas OKTA:NASDAQ cybersecurity RBRK:NYSE cybersecurity NTSK:NASDAQ saas VRNS:NASDAQ saas IBM:NYSE saas FROG:NASDAQ saas DDOG:NASDAQ saas DBX:NASDAQ saas GOOGL:NASDAQ mag5
Full summary 601 words

Citrini opens with a Dylan lyric to frame the AI value-accrual debate: everyone along the chain can price the piece in front of them, but nobody agrees what the whole is worth. Against a historic momentum correction, the firm argues the popular explanations for the selloff — open-source alternatives, cost competition, Kimi3, even the renewed Iranian conflict — do not hold up. Aggregate token spend is still growing rapidly and Kimi's K3 is itself compute-constrained. The likelier culprit is that a leverage-fueled breakout in the most crowded thematic expressions created its own fragility, with the unwind mirroring the vigor of the ascent. The report is explicitly a hunt for names sitting in the wrong category.

The first case is Qualcomm. Citrini killed an earlier piece after sources close to both Anthropic and Qualcomm denied a partnership implied by hidden HTML on QCOM's site, but publishes on the company anyway. The June 24 Investor Day nearly doubled FY29 non-handset guidance from $22bn to $40bn, driven by data center. The differentiator is architectural: High Bandwidth Compute stacks the accelerator directly beneath an LPDDR stack via through-silicon vias, routing bandwidth vertically rather than out the edges like HBM, eliminating the interposer and CoWoS constraints. EVP Tony Pialis claims 6x bandwidth per watt versus HBM. The broader implication — a theme Citrini has run since December — is that rising DRAM prices strengthen near-term memory revenue while strengthening the case for architectures that use fewer HBM bytes per token. Credibility comes from Alphawave SerDes, two hyperscaler custom-silicon programs contributing in FY27, a multi-generation Meta CPU agreement, and the pending Modular acquisition.

Section two argues the market has underwritten value accrual beyond the data center only for "hard software" — the FROGs and DDOGs — while application software and data businesses were clobbered by categorical classification rather than idiosyncratic factors. Citrini's April 2025 "Phase 2" basket beat both IGV and the SPX through the SaaSpocalypse. Rather than a blanket cheap-software call, they favor direct AI tailwinds: GitLab, whose Orbit platform turns the repository into a runtime context graph with a potential credit toll on Claude Code, Codex and Cursor via MCP/REST, though Orbit Remote is still beta and Duo queries are zero-rated; MongoDB, whose Atlas meters hot working-set capacity that agents touch compulsively; Elastic, which sells the queryable permission-aware copy of everything and is priced as ex-growth; and Figma, where 46% growth and 139% NRR argue hybrid human-machine design systems endure.

Section three reads IBM's July 14 pre-announcement as the key signal — clients redirected quarterly capex toward servers, storage, and memory ahead of price increases, and were distracted by cybersecurity concerns, with Arvind Krishna citing Mythos on CNBC. Since Mythos Preview, thousands of zero-days surfaced, including a 27-year-old OpenBSD bug. With software cyber already re-rated, Citrini pivots to physical and data security — Fortinet's FortiASIC moat and OT push, Yubico's YubiKey and OpenAI Trusted Access partnership, and the last listed DSPM pure-play Varonis — plus the sovereignty leg: Palantir/Nvidia's June 29 on-prem reference architecture and 88% CIO repatriation intent, expressed via Dell, HPE, Lenovo, Fujitsu, NetApp, Everpure, F5 and Nutanix in a new Enterprise Security and Sovereignty Basket.

The closer, PEMDAS, argues Meta is the Google setup of a year ago. Meta is the fastest-growing hyperscaler without external cloud revenue, so compute converts directly to P&L; MSL is treated as a free option; Muse is the cheapest quality US model; and Andromeda, GEM and Advantage+ already monetize GPUs at high margin. The unappreciated kicker is Meta's move on third-party CTV and programmatic inventory — a $40-50bn US pool — making the cloud-platform requirement a smokescreen.

Key metrics
Key insights
#126 Small Themes Jun 24, 2026

Small Themes: June 2026

With virtually all analyst attention crowded into the AI trade, Citrini argues attention itself is the scarcest input -- so under-owned, under-modeled names outside AI are where thematic money gets made as 'AI exhaustion' rotation risk rises. The June 2026 Small Themes lays out five trades that need no view on AGI: US mainline airlines (DAL, UAL) finally getting their supply-constrained cycle as exogenous shocks fade; senior housing riding an unstoppable Boomer demographic wave into collapsed supply (WELL, JAN, BKD); live events and scarce sports assets where economics migrate from resellers to owners (long LYV/SPHR/MSGS/FWONK-type names, short SEAT/STUB); the end of CME's futures monopoly as 24/7 perps go legal (short incumbents, long HOOD/COIN/SPGI, with MIAX the exception); plus retail broker consolidation and a misunderstood, inflecting BNPL sector (AFRM, KLAR, SEZL).

aineocloudconsumertravelfinancecryptofinancefintechhealthhealthsenior-home
Positions & performance
+1.8%avg return55% win · 40 tracked · L +2.4% · S -2.7%
PositionMentionsEntryLastReturn
SSTUB:NYSE consumertravel StubHubI11.27Jun 24 '268.25+26.8%
LMIAX:NYSE financefintech Miami International HoldingsAP36.49Jun 24 '2643.42 +19.0%
LVTR:NYSE healthsenior-home VentasIPT86.57Jun 24 '26100.11 +15.6%
LAHR:NYSE healthsenior-home American Healthcare REIT50.1Jun 24 '2657.44+14.7%
LBULL:NASDAQ financefintech WebullS6.71Jun 24 '267.54 +12.4%
LWELL:NYSE healthsenior-home WelltowerPT221.43Jun 24 '26248.34 +12.2%
LSNDA:NYSE healthsenior-home Sonida Senior LivingIAP38.58Jun 24 '2642.82 +11.0%
LJAN:NYSE healthsenior-home Janus LivingA28.58Jun 24 '2631.6 +10.6%
LLTC:NYSE financecrypto LTC PropertiesSA38.07Jun 24 '2641.94 +10.2%
LMANU:NYSE consumertravel Manchester UnitedA21.11Jun 24 '2622.99 +8.9%
LMSGS:NYSE consumertravel MSG SportsIA366.05Jun 24 '26396.4+8.3%
LFWONK:NASDAQ consumertravel Formula One (Liberty Media)P90.03Jun 24 '2697.05+7.8%
LNHI:NYSE healthsenior-home National Health InvestorsP75.21Jun 24 '2680.54+7.1%
LSPGI:NYSE financefintech S&P GlobalIAPT402.35Jun 24 '26426.4+6.0%
LCOIN:NASDAQ financecrypto CoinbaseISPT150.11Jun 24 '26158.29+5.4%
LBKD:NYSE healthsenior-home Brookdale14.69Jun 24 '2615.47 +5.3%
LLYV:NYSE consumertravel Live NationIPT171.47Jun 24 '26179.4 +4.6%
LCHDN:NASDAQ consumertravel Churchill DownsT84.61Jun 24 '2688.17 +4.2%
LETOR:NASDAQ financefintech eToroSAP36.53Jun 24 '2637.81 +3.5%
LSBRA:NASDAQ healthsenior-home Sabra Health Care19.09Jun 24 '2619.54+2.4%
LCNK:NYSE consumertravel CinemarkT33.16Jun 24 '2633.66 +1.5%
LMSGE:NYSE consumertravel MSG EntertainmentA76.51Jun 24 '2677.32 +1.1%
LIBKR:NASDAQ financefintech Interactive BrokersIST92.79Jun 24 '2692.27 -0.6%
LLLYVA:NASDAQ consumertravel Liberty Live HoldingsPT96.34Jun 24 '2695.65-0.7%
LBATRA:NASDAQ consumertravel Atlanta Braves HoldingsA56.16Jun 24 '2655.05 -2.0%
LHOOD:NASDAQ financefintech RobinhoodISPT97.19Jun 24 '2694.91-2.3%
LSEZL:NASDAQ financefintech SezzleAT159.27Jun 24 '26153.89-3.4%
SSEAT:NASDAQ consumertravel Vivid Seats7.42Jun 24 '267.72 -4.0%
LVIRT:NYSE financefintech Virtu FinancialST62.35Jun 24 '2659.74-4.2%
LDAL:NYSE consumertravel Delta Air LinesIT90.65Jun 24 '2686.67 -4.4%
LKLAR:NYSE financefintech KlarnaI18.39Jun 24 '2617.36-5.6%
LAFRM:NASDAQ financefintech AffirmIT77.66Jun 24 '2673.05 -5.9%
LIMAX:NYSE consumertravel IMAXA43.92Jun 24 '2641.08-6.5%
LUAL:NASDAQ consumertravel United AirlinesIPT130.54Jun 24 '26118.27-9.4%
LSPHR:NYSE consumertravel Sphere EntertainmentAPT155.12Jun 24 '26139.95 -9.8%
SCME:NASDAQ financefintech CME GroupIAPT231.68Jun 24 '26255.31-10.2%
LTKO:NYSE consumertravel TKO Group HoldingsIA203.51Jun 24 '26180.62-11.2%
SICE:NYSE financefintech Intercontinental ExchangeIPT130.02Jun 24 '26145.79-12.1%
SCBOE:NASDAQ financefintech Cboe Global MarketsIPT249.59Jun 24 '26285.07-14.2%
LGLXY:NASDAQ aineocloud Galaxy DigitalISA28.58Jun 24 '2622.68-20.6%
Non-US / no priceSIA:TSX healthsenior-home
Also watchingDOC:NYSE health SIA:TSX healthsenior-home LLYVK:NASDAQ consumertravel BATRK:NASDAQ consumertravel SOFI financefintech
Full summary 542 words

This June 24, 2026 'Small Themes' piece opens with the observation that AI has created a shortage of attention: capital crowding into one theme leaves everything else under-owned and under-modeled, and with Citrini trimming its AI allocation amid crowding, it goes hunting in 'AI's blind spot' with five themes that require no view on AGI timelines or token economics.

Airlines: the November 2024 structural-reset thesis (aircraft shortage as a capacity governor, premium-heavy legacies winning) was right but interrupted by two exogenous shocks -- 2025's tariff/border-detention tourism collapse (international arrivals fell 5.5% to 68 million; the US was the only country of 184 where inbound spending declined) and 2026's Iran war spiking Brent from $75 to over $120. Yet earnings held: Delta posted a record March quarter ($14.2B revenue, premium +14%) and United grew revenue almost 11%. Supply got tighter still -- Spirit ceased operations in May (removing 3.5 points of domestic capacity) -- and World Cup virality is flipping inbound sentiment (1.24 million visitors expected, ~$4,000 average spend). DAL and UAL remain the picks. Senior living: the oldest Boomers turn 80 this year, the 80+ population grows 56% over the next decade, occupancy hit 89.5% (nineteenth straight quarterly increase) while construction starts are down 77% and inventory growth is 0.4% -- a 'Post-Traumatic Supply Disorder' setup where rents must rise ~30% for new development to pencil. Operating leverage on filling built units is enormous (margins back above 25%); picks are Welltower ($10B deployed YTD while de-levering from 3.3x to 2.7x), the freshly spun Janus, and turnaround Brookdale, and Citrini pushes back hard on the 'it's just a rates trade' framing.

Live events: physical presence became a luxury good (Dallas Cowboys from $238M in 1995 to ~$13B; league media rights from $5.3B in 2006 to $21.9B in 2026). Live Nation sold 107M+ tickets through April (+11%), TKO posted Q1 revenue +26% on ~$12.9B of Netflix/Paramount deals, Sphere segment revenue grew 69%, and World Cup get-in prices hit ~$1,000 (+80% in 30 days). The twist: own the creators/owners and short the resellers being squeezed by the FTC's all-in pricing rule and anti-scalping laws -- Vivid Seats' EBITDA collapsed under $10M and StubHub trades at ~$11 vs a $23.50 IPO. Scarce sports assets (Braves, MSGS with 30-40% SOTP upside and a potential spin, Manchester United, Formula One/MotoGP, Churchill Downs) form the second long basket. Exchanges: legalized 24/7 perpetual futures end CME's twenty-year toll road -- S&P DJI licensed the S&P 500 to trade.xyz, weekend crude perp volume hit $1.7B in a day during the Iran war, and the CFTC cleared onshore Bitcoin perps; short CME/CBOE/ICE, long adopters Robinhood (prediction revenue $3M to $104M in a year) and Coinbase, long licensor S&P Global, with MIAX the exception via its retained 10% of MIAXdx and 17%+ options share. Finally, retail-trading consolidation (PDT minimum cut from $25,000 to $2,000; targets BULL, ETOR, GLXY; plus VIRT) and a BNPL defense: the 'subprime time bomb' framing misreads CECL accounting, as Klarna posted its first GAAP profit in five years, Affirm reached GAAP profitability on $37B volume with 30+ delinquencies in the high-2% range and a path to $100B GMV, and Sezzle's EBITDA margins are heading to ~38% -- all supported by an institutional bid for their paper and bank-charter ambitions.

Key metrics
Key insights
#125 Macro Memo Jun 14, 2026

Macro Memo: Spin Cycle

Citrini stays medium-term bullish on the US economy and equities despite a fresh inflation-and-rate-hike scare: the Iran/Hormuz energy shock created an 'Echo Shock' where measured inflation peaks just as source pricing pressure reverses, core inflation and wages show no spiral, and strong payroll prints overstate labor market heat. New Fed chair Kevin Warsh -- feared as a hawk and priced 70% for a December hike -- will do nothing, because no wage-price spiral exists and his own framework points dovish. The melt-up therefore continues (S&P 500 seen trading 8000 before real trouble) amid more frequent 10-15% drawdowns; trades are long SFRH7 to fade the priced hike and long gold as the credibility hedge.

Positions & performance
No single-stock positions tracked in this report.
Full summary 547 words

This June 14, 2026 Macro Memo addresses the market's swing from an AI-driven melt-up to an inflation and rate-hike scare. Since the war with Iran began February 28, short-term rate expectations jumped more than 100bps, and in May SOFR futures priced near-term hikes for the first time this cycle. The April FOMC held rates in an unusual 8-4 split, the ECB hiked 25bps citing energy costs, CPI printed its highest headline since 2023, and the May jobs report (172,000 vs 88,000 consensus) sent yields up and momentum names down after a seven-week straight rally. Citrini frames this as the perpetual 'thematic momentum vs. macro conditions' oscillation and calls the sell-off an overdue flush of leverage rather than a top.

The case against the inflation scare rests on three legs. First, Iran resolution looks more tangible than at any point in the war; spot energy has rolled over and some at-risk commodities (fertilizer, corn, wheat) are cheaper than pre-war. The report coins the 'Echo Shock': measured inflation peaking just as actual pricing pressure at the source reverses -- June and July prints may run hot on pre-Memorial Day dynamics, but a deal makes it easy for the Fed to look through them. Second, core stays calm: the April shelter pop (0.6% m/m) was payback for the October government shutdown's zero-rent assumption in BLS data, core goods inflation turned negative as tariff effects lap, and crucially there is no wage pressure -- real wage growth turned sharply negative, so the shock is supply-driven and unlikely to have legs. Third, the labor market has slack: jobless claims are low but hire and quit rates have not inflected, layoffs ticked up, Indeed's job-openings gauge is muted, and hiring remains below 2019 levels; NFP is likely overstating strength now just as it overstated weakness in fall 2025.

On the new Fed chair: Kevin Warsh took office May 22, and markets read him through G. William Miller -- the 1978 chair who jawboned through the Iranian oil shock and was replaced by Volcker -- which is partly why a December hike is 70% priced. Citrini argues 2026 is not 1979: COLA contracts no longer transmit oil into wages, the US uses less than half the oil per real GDP dollar and is a net petroleum exporter. Warsh spent confirmation praising trimmed-mean inflation and calling AI productivity disinflationary; Loretta Mester expects him to build consensus for lower rates. The call: Warsh does absolutely nothing -- no hike, no balance-sheet push. Watch the June 16-17 FOMC presser (listen for 'trimmed') and July 2 payrolls (May's strength was ~60% restaurants and local government). Equities: the melt-up has not topped; fundamentals support a run into late summer with more frequent 10-15% drawdowns, a potential scenario of the S&P jumping another 10-15% with AI names doubling, and S&P 500 trading 8000 before worries meaningfully materialize. Trades: (1) Fade the Warsh Hike -- long SFRH7 (March 2027 SOFR), worth ~30bps repricing in the base case and double if cuts return, while closing the 2s30s flattener from 26 Trades that has now fully paid; (2) The Credibility Hedge -- long gold, which has 'paid the hawk tax twice' (an 11% single-session drop on Warsh's nomination, then the Iran inflation angle) and can pop as rates decline and risk sentiment improves.

Key metrics
Key insights
#124 State of the Themes Jun 01, 2026

State of the Themes: June 2026

Citrini's June 2026 State of the Themes takes stock after a blistering AI-led rally: the dominant new narrative is 'Token Panic' -- exploding agentic token consumption colliding with labs' shift to usage-based pricing, so enterprise AI bills are blowing up budgets (Anthropic ARR hit $45B, up 5x YTD) and cost/efficiency themes now matter most. That favors edge AI and on-device inference, flash-based workarounds to the DRAM tax, agentic utilities that win on usage regardless of token cost, and selective 'AI loser' rebounds, while robotics custom silicon, EU Chips Act 2.0 beneficiaries, Colombia's rightward election, a tightening oil capex cycle, and new ideas (Shopify, Hyperliquid, healthcare's cyclical inflection) round out the thematic map. The unifying view: the AI trade broadens and rotates rather than ends.

aimemoryaiopticalairobotaisemiconsumershoppingcybersecurityenergyaienergywarfinancecryptofinancefintechhealthindexarindexcomag5saas
Positions & performance
-6.5%avg return30% win · 27 tracked · L -6.9% · S +1.8%
PositionMentionsEntryLastReturn
LCIB:NYSE financefintech Grupo Cibest73.37Jun 01 '2687.93 +19.8%
LTMO:NYSE health Thermo FisherIPT494.04Jun 01 '26568.26+15.0%
LRVMD:NASDAQ health Revolution MedicinesT163.68Jun 01 '26188.07 +14.9%
LDHR:NYSE health DanaherIPT179.87Jun 01 '26196.5 +9.2%
LMOH:NYSE health Molina HealthcareIT183.25Jun 01 '26197.55+7.8%
LRGEN:NASDAQ health RepligenIT123.1Jun 01 '26131.96+7.2%
LFSLY:NASDAQ saas Fastly19.08Jun 01 '2620.24+6.1%
SFDS:NYSE saas FactSetIPT270.85Jun 01 '26265.9 +1.8%
LFROG:NASDAQ saas JFrog88.31Jun 01 '2687.58-0.8%
LEC:NYSE energywar Ecopetrol16.25Jun 01 '2616.01-1.5%
LNET:NYSE saas CloudflareISPT270.82Jun 01 '26262.15-3.2%
LDT:NYSE saas DynatraceIAT44.47Jun 01 '2641.62-6.4%
LOIH:NYSE energywar VanEck Oil Services ETF420.59Jun 01 '26385.68 -8.3%
LSHOP:NASDAQ saas ShopifyISP124.12Jun 01 '26113.75-8.4%
LSIMO:NASDAQ aimemory Silicon MotionS268.05Jun 01 '26244.45 -8.8%
LAMBA:NASDAQ aisemi Ambarella75.67Jun 01 '2668.23 -9.8%
LHP:NYSE energywar Helmerich & Payne39.23Jun 01 '2635.34-9.9%
LDDOG:NASDAQ saas DatadogIPT277.49Jun 01 '26246.86-11.0%
LPDS:NYSE energywar Precision Drilling92.31Jun 01 '2680.24 -13.1%
LNBR:NYSE energywar NaborsA92.45Jun 01 '2678.65 -14.9%
LPTEN:NASDAQ energywar Patterson-UTIT11.53Jun 01 '269.59-16.8%
LRES:NYSE energywar RPC6.8Jun 01 '265.47 -19.6%
LSAIL:NASDAQ cybersecurity SailPointIT19.25Jun 01 '2614.95-22.3%
LOUST:NASDAQ airobot OusterIS44.93Jun 01 '2634.04-24.2%
LAKAM:NASDAQ saas AkamaiIPT154.01Jun 01 '26115.37-25.1%
LHSAI:NASDAQ airobot Hesai20.03Jun 01 '2614.6-27.1%
LSNDK:NASDAQ aimemory SandiskISPT1761.43Jun 01 '261278.23 -27.4%
Non-US / no price8299:TWSE aimemory SINCH:OMX saas HUBN:SIX aioptical BESI NA CANATU:OMX aisemi AMS:SIX aisemi NOD:OSL aisemi AIXA GR SOI FP GPRK:NYSE energywar MC FP KER:EURONEXT consumershopping 004170:KRX consumershopping 069960:KRX consumershopping 023530:KRX consumershopping 278470:KRX consumershopping
Also watchingQCOM:NASDAQ aisemi HIMX:NASDAQ aisemi 000660 KS OUST:NASDAQ airobot HSAI:NASDAQ airobot AMZN:NASDAQ mag5 6954:TSE airobot TER:NASDAQ aisemi IFX:XETRA energyai STM:NYSE aisemi ARGT:NYSE indexar COLO:NYSE indexco AVAL:NYSE financefintech TIGO:NASDAQ saas V:NYSE financefintech PYPL:NASDAQ financefintech COIN:NASDAQ financecrypto FICO:NYSE saas EFX:NYSE financefintech BHYP:NYSE financecrypto SDGR:NASDAQ health RXRX:NASDAQ health TWST:NASDAQ health ABCL:NASDAQ health
Full summary 597 words

This flagship June 2026 review updates Citrini's whole thematic universe, opening with a victory lap on the August 2025 edition (Google doubled, KOSPI tripled, Taiwan beat QQQ by 60%+) before turning to the narrative that will shape flows: Token Panic. In weeks the market went from tokenmaxxing to cost shock -- Uber reportedly burned its entire AI budget in four months, Anthropic's ARR reached $45B in May (5x since January per The Economist), Sam Altman admitted 'my company spent my entire 2026 budget in Q1' has become a meme, and Microsoft's AI chief called Anthropic 'extremely expensive' after cancelling Claude Code licenses. Labs are all flipping to usage pricing (OpenAI Codex April 2, Google Gemini May 19, GitHub Copilot June 1), while Claude's new tokenizer can consume up to 35% more tokens for the same text. Chinese models (Qwen 3.7, DeepSeek V4) are 10-25x cheaper and DeepSeek passed Anthropic on OpenRouter tokens. Citrini's conclusion: revenue still grows, but cost, efficiency, routing, observability and 'good enough' models become the investable themes.

That leads to Edge AI and inference-on-device (a thesis first published July 2024, 'regrettably way too early'): Nvidia's Spark AI PC (1 petaflop FP4, 128GB unified memory), OpenAI's io/device roadmap, Google glasses and Apple's hardware-focused CEO transition validate a hybrid local-plus-cloud model. 'Flash Point' explores ways past the DRAM tax -- HBM eats ~a quarter of DRAM wafer capacity and contract prices rose ~90% in a quarter -- via controller optimization, NAND stacking, and the Sandisk/SK Hynix High Bandwidth Flash standard (8-16x HBM4 capacity), with flash ~55x cheaper per bit; SIMO and Phison are the plays, and HBF could eventually dent HBM's scarcity premium. The Agentic Utilities update tallies wins: Bandwidth +300% since the primer (Salesforce Agentforce contract), Twilio's Conversation Memory, SailPoint (11% of governed SaaS identities already non-human), Palo Alto's Idira, observability beats at Datadog/Dynatrace, JFrog, and the CDN triad where Fastly RPO exploded 63% and Akamai landed a 7-year $1.8B compute commitment from a frontier lab. Agentic payments disappoint so far; on AI Losers, the rally is an undiscerning short squeeze, but FactSet (MCP-driven seats could drive shares 50-70% higher), FICO, Equifax, Shopify and Guidewire are selectively buyable.

Robotics focuses on custom silicon: Hesai's Picasso and Ouster's Rev8 SPAD-based color LiDAR collapse the camera-vs-LiDAR debate (Ouster L4: 42.9 GMACs, 10.4M points/sec; Hesai: >40% photon detection efficiency, 600m range), with Ambarella watched; Amazon is investing EUR 10B in European robotics and Figure AI began production at 12,000 units/year peak. Fiscal Primacy covers the EU Chips Act 2.0 (June 3 proposal pivoting from the failed 20%-share supply push to demand-side measures, EUR 15-30B for European memory), with picks Huber+Suhner (optical circuit switches, CHF 432M record backlog), BESI, Canatu (only listed CNT pellicle pure-play), ams-OSRAM and Nordic Semiconductor; plus Colombia, where a likely De la Espriella win could trigger a Milei-style re-rate (Ecopetrol, COLO, Cibest). NatGas & Energy argues the four-month Hormuz closure is draining OECD inventories to decade lows, favoring contract drillers (NBR, PTEN, HP, PDS), RES and OIH. Updates cover the Girlfriend Index (Korean luxury: Shinsegae jewelry +147%; APR/Medicube), GOP losing the House (Molina: normalized EPS >$28, >$30 by 2028), and RVMD's RAS(ON) platform. New ideas: Shopify (14%+ of US e-commerce, ~$380B GMV +30%, Shop Pay $160B annualized, UCP protocol with Google, Thrive Capital's $100M stake), Hyperliquid (HYPE: $40-50B weekly perp volume, $2B+ cumulative buybacks, ~7% annual buyback yield, $1B token burn, HIP-3 tokenized equities/HIP-4 outcome contracts), and healthcare's cyclical inflection finally arriving (Cytiva orders +30% YoY, 173 AI-originated drug programs vs ~24 in 2023, McKinsey's $60-110B annual savings estimate) -- with picks-and-shovels preferred over TechBio.

Key metrics
Key insights
#123 Semis Memo May 01, 2026

Semis Memo: Supply Chain Inheritance

The AI infrastructure trade has matured past first-order picks, so Citrini's third Semis Memo hunts mispriced second-order bottlenecks. The core idea is 'Supply Chain Inheritance': Nvidia's 800V DC rack architecture inherits the silicon carbide/GaN supply chain built for EVs and solar, so power semis still valued on a weak EV cycle (STM, ON, Infineon, and above all post-bankruptcy Wolfspeed) get a second demand cohort just as the first wobbles. Around that anchor, the memo argues CPUs and the orchestration plane become strategic in the agentic era (ASPEED, LOTES, Qualcomm), an inference shortage re-rates neoclouds (CoreWeave, Hut 8), AI materials bottlenecks keep worsening (Ibiden, WF6 gases via Kanto Denka), and Samsung Foundry's re-rating as TSMC's realistic second source unlocks Korean beneficiaries (Doosan Tesna, Wonik IPS, Samsung Electro-Mechanics, LG Innotek).

aimemoryaineocloudaisemienergyai
Positions & performance
-5.7%avg return31% win · 13 tracked · L -5.7%
PositionMentionsEntryLastReturn
LHUT:NASDAQ aineocloud Hut 8IS76.98May 01 '26109.99+42.9%
LWYFI:NASDAQ aineocloud WhiteFiberS16.65May 01 '2623.15 +39.0%
LHIMX:NASDAQ aisemi HimaxS12.31May 01 '2612.62+2.5%
LDGXX:NASDAQ aineocloud Digi Power XS3.76May 01 '263.84 +2.1%
LQCOM:NASDAQ aisemi QualcommISPT177.01May 01 '26170.04 -3.9%
LSTM:NYSE aisemi STMicroelectronicsSP55.75May 01 '2653.45 -4.1%
LACLS:NASDAQ aimemory Axcelis TechnologiesIST139.99May 01 '26128.11 -8.5%
LON:NASDAQ aisemi ONSemiIT103.03May 01 '2689.04 -13.6%
LMPWR:NASDAQ aisemi Monolithic Power SystemsISPT1583.48May 01 '261339.08 -15.4%
LAEHR:NASDAQ aisemi Aehr Test SystemsS93.07May 01 '2677.48 -16.8%
LVICR:NASDAQ energyai VicorIST268.36May 01 '26211.01-21.4%
LWOLF:NYSE energyai WolfspeedIS36.76May 01 '2623.09-37.2%
LCRWV:NASDAQ aineocloud CoreWeaveIST119.01May 01 '2671.88-39.6%
Non-US / no priceIFX:XETRA energyai 6723:TSE aisemi 5274:TWSE aisemi 3533:TWSE aisemi 6088:HKEX aisemi 6809:HKEX aisemi 4004:TSE aisemi 5706:TSE aisemi 8358:TWSE aisemi 2383:TWSE aisemi 6213:TWSE aisemi 4062 JP 4047:TSE aisemi 005930 KS 131970:KRX aisemi 240810:KRX aisemi 009150:KRX aisemi 011070:KRX aisemi
Also watchingTXN:NASDAQ aisemi NXPI:NASDAQ aisemi 6981 JP VSH:NYSE aisemi ARM:NASDAQ aisemi AMD:NASDAQ aisemi EQIX:NASDAQ aineocloud DLR:NYSE aineocloud
Full summary 597 words

The May 2026 Semis Memo (third in the series, by semis analysts Zephyr and Jukan) opens by noting the easy phase of the AI infrastructure trade is over: valuations no longer forgive, so outperformance requires finding areas where forecasts still reflect non-AI overhangs that AI demand will overwhelm. The anchor thesis is 'Supply Chain Inheritance.' Nvidia's own May 2025 blog on 800V DC racks credits the underlying technology to the EV and solar industries: the transition to 800V -- the only path to 600kW racks -- requires SiC and GaN at every conversion stage, and that wide-bandgap supply chain was already scaled and cost-reduced by Porsche, BYD and solar inverter makers. SiC grew from a $300M niche in 2018 to $3.5B by 2024 on EVs; AI is estimated to reach half of total SiC demand by 2030, on the same wafers. Rack power BOM grows ~16% in the transition while wide-bandgap silicon plus high-voltage connectors go from 0% to ~64% of rack power BOM. Names like STM, ON and Infineon are still valued on the anemic EV cohort. The memo also maps solid-state transformers (Eaton, ABB, Siemens; Heron Power's $140M Series B) and the VRM 'thousand-amp problem' (Rubin Ultra GPUs drawing ~2,500W imply ~3,500 amps at 0.7V; MPWR, Vicor, Renesas). The single-stock highlight is Wolfspeed: it spent $6.5B on SiC capacity, went bankrupt in June 2025 when EVs didn't show up, and emerged debt-light owning the world's only commercial-scale 200mm SiC fab -- plus a 300mm SiC crystal demonstrated in January 2026 (matched only by Coherent), with a thermal/packaging kicker as SiC cold plates move toward the chip.

Section two argues agents move value to the CPU/orchestration plane: agents use 10-30x more tokens than chatbots and their loops (tool calls, RL environments, scheduling) run on CPUs. Highlights: ASPEED (80% BMC share overall, 100% in Nvidia Hopper/Blackwell; 87 BMCs per NVL72; TAM revised from 46.5M to 65M chips by 2030; Q1 revenue beat guidance by 17-21%), LOTES (~35% CPU socket share, sockets going from ~5,000 to 7,000+ pins), FIT Hon Teng, Montage Technology (36.8% memory-interface share), and pet-favorite Qualcomm (unpriced data center CPU and on-device inference optionality). Section three documents the inference shortage: OpenAI compute rose from 0.2 GW to 1.9 GW as ARR went from $2B to $20B+ (later $2-3B/month revenue, 15B tokens/minute); Anthropic's run-rate hit $45B by May 2026, up ~400% from ~$9B at end-2025, and it is grabbing capacity via Amazon (up to 5 GW), Google/Broadcom TPUs ($200B over five years), SpaceX (300+ MW, 220,000+ GPUs) and a $1.8B, 7-year Akamai deal. CoreWeave's RPO grew to $99.4B by Q1 2026, plus a $21B Meta expansion; Hut 8 signed a $9.8B, 15-year take-or-pay lease.

Remaining sections update AI materials (all severe bottlenecks worsened: T-glass relief pushed to 2027+, Korean CCL import prices +74.5% YoY; Ibiden is the top pick, WF6 specialty gas via Kanto Denka an emerging bottleneck) and 'Korea Unlocked': Samsung Foundry as the realistic second source to TSMC (per C.C. Wei, supply remains 'very tight'), benefiting Doosan Tesna (KRW 171.4B + 190.9B equipment buys tied to Apple CIS and Nvidia's Groq-derived LPU), Wonik IPS (Taylor fab tooling; Tesla's $16.5B deal anchors Taylor 1), Samsung Electro-Mechanics (FC-BGA plus MLCC shortage -- Rubin Ultra needs ~1.8M MLCCs, ~90x H100, with 24-week lead times), and LG Innotek (SiP substrate squeeze). Prior picks AEHR (+300%, $41M Google TPU burn-in order) and Himax (+125%) stay longs. The memo closes noting even Citrini's most bullish estimates proved conservative -- 2027 AI spending is now estimated above $3 trillion -- and that the cycle will end via macro/Fed tightening, not technology.

Key metrics
Key insights
#122 Flash Note Apr 27, 2026

Flash Note: Defense Production Act

On April 20, 2026 the President signed Presidential Determination 2026-10, a Defense Production Act Section 303 determination classifying grid infrastructure -- transformers, transmission, conductors, substations, breakers, relays and electrical core steel -- as essential to national defense. This converts Citrini's long-running Fiscal Primacy x AI power thesis into an actual federal priority regime: priority ratings compress lead times for grid customers, federal capital crowds in private investment, and a national-security frame replaces climate policy, making the spending durable across administrations. Winners are the already-known grid supply chain plus overlooked names, above all Cleveland-Cliffs, whose GOES electrical steel monopoly maps one-for-one onto the DPA designation, along with Quanta, Worthington Steel and Hammond Power.

energygrid
Positions & performance
-2.2%avg return20% win · 5 tracked · L -2.2%
PositionMentionsEntryLastReturn
LCLF Cleveland-CliffsIS10.61Apr 27 '2612.25 +15.5%
LPWR:NYSE energygrid Quanta ServicesPT637.28Apr 27 '26625.84-1.8%
LWS:NYSE energygrid Worthington SteelA37.71Apr 27 '2635.98-4.6%
LGEV:NYSE energygrid GE VernovaIPT1120.23Apr 27 '261014.75-9.4%
LPOWL:NASDAQ energygrid Powell IndustriesST260.52Apr 27 '26232.21-10.9%
Also watching298040:KRX energygrid 267260:KRX energygrid 010120:KRX energygrid 103590:KRX energygrid HPS.A CN
Full summary 455 words

This short flash note (April 27, 2026) updates Citrini's longest-running intersection trade -- power as the meeting point of its two decade themes, Fiscal Primacy and AI. On April 20 the President signed Presidential Determination 2026-10, a Defense Production Act Section 303 determination for grid infrastructure, building on the January 2025 National Energy Emergency executive order. The text formally classifies transformers, transmission lines, conductors, substations, high-voltage circuit breakers, power control electronics, protective relays, capacitor banks and electrical core steel as essential to national defense. Citrini has been long this supply chain since 2023 (expanded in June 2024's 'The Utility of Bubbles'), and notes the backlog keeps growing despite years of upward revisions: in 1Q26 the net addition to GE Vernova's electrification backlog was nearly as large as the annual additions from 2022-2025.

The note explains what the DPA actually does: (1) priority ratings route grid orders ahead of other industrial uses, compressing lead times for grid customers (large power transformer lead times run three to four years, distribution transformer backlogs near a year); (2) federal capital crowds in private investment and protects US manufacturers from Chinese undercutting; (3) a national-security frame replaces climate policy, and that framing survives administration transitions. Only ~$323 million of FY26 DPA Title III money remains, so the immediate firehose is small -- scale comes via the much larger DOE Loan Programs Office, forward purchase commitments, and the priority rating system itself. The transformer bottleneck is acute: the marginal supplier is Korean, with Hyosung's Memphis plant the only US facility making 765 kV ultra-high-voltage transformers, HD Hyundai Electric expanding Montgomery, AL to 150 units/year by 2027, LS Electric opening in Bastrop, TX, and Iljin winning a record $333M US order; the Korean Big Four backlog is $23.9B (five to six years of work).

Positioning: most AI-power names (e.g., POWL, nearly tripled since the Stargate Field Trip) have already re-rated, so asymmetry sits in laggards. Cleveland-Cliffs is the standout -- the sole domestic GOES (grain-oriented electrical steel) producer via Butler, PA and Zanesville, OH, restarting Weirton, WV as a $150 million transformer plant, protected by tariffs reaching 50% on derivative foreign GOES; Citrini says it knows of no other public security where a single national-security determination so directly maps to one company's monopoly. Other names: Quanta Services (record transmission backlog; the DPA can fund factories but not the multi-year linemen pipeline, so EPC contractors should outperform OEMs on a 24-month view), Worthington Steel (ignored toll-processor one step downstream from Cliffs), and Hammond Power Solutions (North America's largest dry-type transformer maker, the fast-deploy default for data centers, with a Monterrey nearshoring angle). The caveat: if the DPA succeeds in adding supply, margins eventually compress -- but likely not for a couple of years.

Key metrics
Key insights
#121 Field Trip Apr 05, 2026

Strait of Hormuz: A Citrini Field Trip

Citrini sent a field analyst to the Strait of Hormuz during the live US-Iran conflict and concluded the market's binary 'open vs. closed' framing is wrong: Iran is running the strait as a toll road, not a blockade, approving vessels through a Qeshm-Larak checkpoint while the ground conflict continues. Hot war and commercial diplomacy are happening simultaneously -- US allies like France, India and Japan are negotiating passage with Tehran, mostly via underreported diplomatic workarounds rather than yuan or crypto payments. Traffic should keep rising (Citrini expects ~50% of pre-conflict volume within 4-6 weeks) even as the conflict escalates, so the trades are ones that win regardless of resolution: tankers (BWET), US petrochemicals (DOW, WLK), long SFRH7 rates, long December 2026 WTI versus front month, relative country pairs, and EU/Japan energy-independence and defense names (EUAD).

commoditiesdefenseenergywar
Positions & performance
-18.6%avg return25% win · 4 tracked · L -18.6%
PositionMentionsEntryLastReturn
LEUAD:NASDAQ defense Europe Aerospace & Defense ETF42.75Apr 06 '2642.97+0.5%
LBWET:NYSE energywar Breakwave Tanker Shipping ETF140.66Apr 06 '26128.0-9.0%
LDOW:NYSE commodities DowPT40.56Apr 06 '2629.84-26.4%
LWLK:NYSE commodities Westlake119.53Apr 06 '2672.33 -39.5%
Full summary 520 words

This April 2026 piece is field reporting: Citrini dispatched 'Analyst #3' -- fluent in Arabic, carrying $15,000 in cash and hidden recording gear -- to Dubai, Fujairah, and Oman's Musandam province to observe the Strait of Hormuz first-hand during the US-Iran war, after concluding that nobody (analysts, correspondents, retired generals) actually knew what was happening and that AIS data was missing roughly half of actual transits. The narrative covers a Dubai poker game with connected Gulf contacts (who correctly predicted strikes on Qeshm), interrogation by Omani CID agents who ordered him to cancel his boat trip, an illicit speedboat run to Kumzar and the open strait with smuggler Hamid, direct observation of Shahed drones and AIS-dark tankers, detention by the Coast Guard, and eventual exit under surveillance.

The findings overturn consensus. Iran has built a functioning 'toll booth': approved traffic routes through the Qeshm-Larak channel after brokers submit ownership, flag, cargo and crew details; payment is made in cash, crypto, or -- far more commonly than reported -- diplomatic workarounds like unfreezing Iranian assets (often settled via Bank of Kunlun), which sidestep OFAC fears. Enforcement is selective but real: no ship with IRGC clearance has been struck, while drones hit non-compliant vessels. Analyst #3 confirmed 15 ships crossing on April 2 (versus 2-5/day two weeks earlier, but far below the >100/day pre-conflict), with contacts reporting 15-18 more on April 4, and saw a Greek Dynacom tanker running full-speed through the center of the strait -- evidence the strait is not mined and that bespoke deals exist. On March 26 Iran granted passage to China, Russia, India, Iraq and Pakistan; within a week Malaysia, Thailand, the Philippines, France and Japan secured access. The Houthis are being deliberately restrained by a still-centralized Iranian command, holding the Bab al-Mandab card in reserve. An Omani official compared Iran's endgame to Turkey's Montreux Convention management of the Bosphorus -- sovereignty and tolls, not blockade. The report estimates the net hit to global commercial oil stocks at 10.6 million barrels/day and warns that if traffic stays at only ~15 ships/day through end-April the situation turns disastrous; if the strait stays effectively closed, global equities could fall ~15-20%.

Positioning follows the 'wins either way' logic. Tankers, via the BWET ETF (up more than 4x since the January call), have not topped; the Iran Conflict Beta basket is +17% since inception. The most asymmetric leg is US petrochemicals -- Dow and Westlake -- because Gulf capacity destruction is underreported, up to 50% of polyethylene supply is offline or constrained per Dow's CEO, who sees 250-275 days to normalize even after reopening, and Dow followed a $0.10 March polyethylene hike with $0.30 in April. Macro trades include long SFRH7 (playing rate cuts being priced back in), long December 2026 WTI (at $71 versus $110 front month, the market wrongly prices a short sharp disruption) with an eventual long CLZ6/short front-month spread, country pairs (long Norway/short Australia, long Japan/short Korea, etc. scored on energy security and willingness to deal with Tehran), and buying dips in EU/Japan energy independence and defense (EUAD), a permanent multipolar-world shift regardless of how Hormuz resolves.

Key metrics
Key insights
#120 Thematic Primer Mar 25, 2026

Agentic Utilities: Always On, Never Prompted

AI agents reached an inflection point with the viral adoption of OpenClaw in late 2025, converting theoretical agentic AI into a real workload that consumes tokens around the clock. Because agents generate up to 25x the network traffic of chatbots, run always-on persistent sessions, and route traffic 'east-west' between servers rather than 'north-south' to humans, the structure of the internet itself must be rebuilt. The winners are 'Agentic Utilities' -- infrastructure names (CDNs, optical, DNS, data centers), business-to-agent ecosystem tollbooths (payments, telephony, e-signature), and governance vendors (observability, identity, security) -- many of which are legacy stocks left for dead that are already seeing revenue inflections. Citrini is long AKAM, FSLY, CRCL and NET in the Citrindex and publishes a broad Agentic Utilities basket.

aineocloudaiopticalaisemicybersecurityfinancecryptofinancefintechsaas
Positions & performance
+35.2%avg return71% win · 24 tracked · L +40.1% · S -77.3%
PositionMentionsEntryLastReturn
LBAND:NASDAQ saas BandwidthI17.1Mar 25 '2659.8+249.7%
LRXT:NASDAQ aineocloud Rackspace1.3Mar 25 '263.94+203.1%
LPANW:NASDAQ cybersecurity Palo Alto NetworksIAPT153.22Mar 25 '26323.79+111.3%
LDDOG:NASDAQ saas DatadogIPT123.29Mar 25 '26246.86+100.2%
LHPE:NYSE aineocloud Hewlett Packard EnterpriseIPT25.78Mar 25 '2647.69+85.0%
LTWLO:NYSE saas TwilioIP125.43Mar 25 '26194.47 +55.0%
LATEN:NYSE saas A10 Networks23.26Mar 25 '2633.47 +43.9%
LCSCO:NASDAQ aisemi CiscoPT81.83Mar 25 '26114.17+39.5%
LDOCN:NYSE aineocloud DigitalOceanIAT87.0Mar 25 '26120.2 +38.2%
LFFIV:NASDAQ saas F5PT297.86Mar 25 '26394.53+32.5%
LSAIL:NASDAQ cybersecurity SailPointIT12.33Mar 25 '2614.95+21.2%
LNET:NYSE saas CloudflareISPT218.0Mar 25 '26262.15+20.3%
LVRSN:NASDAQ saas VeriSignIPT251.7Mar 25 '26280.0+11.2%
LDLR:NYSE aineocloud Digital RealtyPT176.43Mar 25 '26195.76 +11.0%
LDOCU:NASDAQ saas DocuSignIT46.3Mar 25 '2650.44+8.9%
LEQIX:NASDAQ aineocloud EquinixIT965.95Mar 25 '261046.79 +8.4%
LZS:NASDAQ cybersecurity ZscalerT139.44Mar 25 '26142.32+2.1%
LAKAM:NASDAQ saas AkamaiIPT119.15Mar 25 '26115.37-3.2%
LCOIN:NASDAQ financecrypto CoinbaseISPT181.1Mar 25 '26158.29-12.6%
LCIEN:NYSE aioptical CienaIPT437.7Mar 25 '26377.27 -13.8%
LVNET:NASDAQ aineocloud VNET GroupA9.11Mar 25 '267.21-20.9%
LFSLY:NASDAQ saas Fastly29.79Mar 25 '2620.24-32.1%
LCRCL:NYSE financecrypto Circle Internet GroupIS103.86Mar 25 '2665.67 -36.8%
SOKTA:NASDAQ cybersecurity OktaIAT78.12Mar 25 '26138.5-77.3%
Also watchingPYPL:NASDAQ financefintech V:NYSE financefintech MA:NYSE financefintech GPN:NYSE financefintech FIS:NYSE financefintech FISV:NASDAQ financefintech SHOP:NASDAQ saas
Full summary 506 words

This March 2026 report extends Citrini's three-year AI arc into what it calls the Agentic Era. Back in May 2023, Citrini predicted a three-phase AI adoption process ending in agents that carry out tasks without direct prompting; the report argues that phase has now arrived. The catalyst was the November 2025 release of ClawdBot (renamed OpenClaw after Anthropic's lawyers intervened), an open-sourced, self-hosted agentic library whose GitHub adoption and OpenRouter token consumption went vertical in two months. Agents now run overnight from a Mac Mini via iMessage, and Jensen Huang has floated token-based compensation, saying he would be 'deeply alarmed' if a $500,000 engineer consumed less than $250,000 in tokens. Citrini's existing 'AI Losers' short basket began waterfalling as agents made theoretical disruption tangible, and the firm has been adding agentic-utility longs -- AKAM, FSLY, CRCL and NET -- bought when they were viewed as separate from the AI trade.

The framework splits winners into three categories. Infrastructure: Cisco estimates agentic AI generates up to 25x more network traffic than a chatbot, and Nokia forecasts machine-to-machine agentic traffic growing from 66 EB/month in 2025 to 537 EB/month in 2034. Using Austin's missing east-west highways as a metaphor, the report argues agentic traffic moves laterally between servers, benefiting Cisco (SiliconOne G300, AgenticOps), Ciena (optical backbone, capex up ~2.5x historical average), and HPE (networking up 152% YoY post-Juniper, now 30% of revenue and half of operating profits). Chokepoint legacy names include A10 Networks (carrier-grade NAT amid IPv4 scarcity -- only ~4.3 billion addresses exist) and VeriSign (450 billion DNS queries a day, 67% operating margins, agent workflows multiplying lookups per task). CDNs become 'Compute Delivery Networks': Akamai's API-security revenue is growing 100% YoY and it launched the Akamai Inference Cloud with $250 million of capex; Fastly offers the highest convexity; F5's NGINX gateway sees AI API calls running 'meaningfully ahead' of projections. Data center plays include Equinix (500,000 interconnects, 60% of large new contracts from AI), Digital Realty, VNET, DigitalOcean, and higher-risk Rackspace ($2.75 billion of debt, saved by a Palantir partnership). Cloudflare is dubbed the agentic conglomerate -- Workers, NET Dollar stablecoin, x402 co-founder, Firewall for AI.

Ecosystem: agents need payment rails and human interfaces. The report details the x402 standard (Coinbase/Cloudflare), Circle Nanopayments enabling gas-free USDC transfers as small as $0.000001, PayPal's PYUSD (over $4 billion circulation), and Stripe/Visa-backed Tempo, while cautioning it is too early to invest in payments on agentic upside alone. Bandwidth and Twilio own telephony tollbooths -- Twilio already handles 85% of its own inbound sales calls with AI -- and DocuSign's IAM platform ($350 million+ ARR, ~11% of ARR, expected to nearly double in fiscal 2027) carries regulatory moats and Anthropic/OpenAI integrations.

Governance: observability and security converge into 'Agentic Governance', favoring Datadog, Palo Alto (Chronosphere plus the ~$25 billion CyberArk deal), SailPoint, and Zscaler, with Okta watched but unconvincing. The conclusion: merely saying 'agentic' on a slide deck means nothing, but companies that truly enable the structural shift should see meaningful long-term growth, captured in the Agentic Utilities basket on Citrindex.

Key metrics
Key insights
#119 Thematic Update Mar 12, 2026

Let There Be Light: Revisiting the Optics & AI Connectivity Theme

Citrini's contrarian mid-2024 optics calls (Interconnects 101, Can You Hear Me Now?) have tripled the connectivity basket, but the obvious winners (Lumentum, Coherent, AAOI) are now priced for perfection, so the next asymmetry sits deeper in the photonics stack. Both pluggable transceivers and co-packaged optics converge on the same upstream substrates, components and equipment — so regardless of CPO timing, MOCVD tools (Aixtron), bonding equipment (SUSS MicroTec), SOI substrates (Soitec), InP fabs (Nokia) and optical attach hardware (Furukawa, Sumitomo Electric) capture the buildout. The highest-conviction single name is Himax, whose nanoimprint-lithography micro-lens arrays and V-groove baseplates appear (per a Hunterbrook patent investigation) to sit inside TSMC's COUPE fiber-array-unit supply chain for Nvidia CPO, with a second underappreciated kicker in Apple smart-glasses optics.

aimemoryaiopticalaisemimag5
Positions & performance
+31.1%avg return83% win · 6 tracked · L +35.8% · S +7.9%
PositionMentionsEntryLastReturn
LTSEM:NASDAQ aisemi Tower SemiconductorS118.54Mar 12 '26224.21 +89.1%
LSTM:NYSE aisemi STMicroelectronicsSP33.24Mar 12 '2653.45 +60.8%
LHIMX:NASDAQ aisemi HimaxS10.13Mar 12 '2612.62+24.6%
LNOK:NYSE aioptical NokiaSP8.14Mar 12 '269.1+11.8%
SAAOI:NASDAQ aioptical Applied OptoelectronicsS106.19Mar 12 '2697.82 +7.9%
LPOET:NASDAQ aioptical POET TechnologiesS7.44Mar 12 '266.89-7.4%
Non-US / no priceAIXA GR SMHN:XETRA aisemi SOI FP 5801:TSE aioptical 5802 JP 4063:TSE aisemi 3363:TWSE aioptical
Also watchingLITE:NASDAQ aioptical COHR:NYSE aioptical CIEN:NYSE aioptical TSM:NYSE aisemi AVGO:NASDAQ aisemi VECO:NASDAQ aisemi ACLS:NASDAQ aimemory SMTC:NASDAQ aisemi ALAB:NASDAQ aisemi CRDO:NASDAQ aisemi 300308 CH NVDA:NASDAQ aisemi AAPL:NASDAQ mag5
Full summary 598 words

This March 2026 report revisits the optics theme Citrini pioneered in July-August 2024, when 'Interconnects 101' and 'Can You Hear Me Now?' argued — against consensus, with the stocks near 52-week lows — that AI connectivity demand would collide with underinvestment to create an optics shortage. The connectivity basket has since more than tripled and is up 35% YTD led by Lumentum, while hyperscaler capex heads toward an estimated $650-700B in 2026. But with crowd favorites approaching priced-for-perfection, the piece asks where the next asymmetry sits and answers: further down the stack, in photonic components, substrates and capital equipment, especially as CPO becomes a necessity.

A Photonics 101 section explains the physics: compute performance improved 60,000x in two decades while electrical interconnect bandwidth rose only 30x; copper hits a wall, and photonic integrated circuits close the gap. Pluggables still dominate and demand is exploding (the AI-cluster transceiver market should exceed $10B in 2026, roughly doubling from 2024), but power consumption at 6.4Tb/s+ forces co-packaged optics, which cut per-port power from ~30W to as low as 9W — Jensen Huang's math is that a million GPUs at six transceivers each would burn 180 megawatts. Citrini flags AAOI as the crowded, fragile expression: ten customers were 96.6% of 2025 revenue (Microsoft 28.8%), its CPO laser is only at sample stage, and the stock could trade 50% lower — yet AAOI's own call confirms the bottleneck ('a major laser shortage, with lead times of at least one year'). Nvidia's Quantum-X CPO ships in H1 2026, NVIDIA invested $2B each into Lumentum and Coherent, Marvell bought Celestial AI, Ciena bought Nubis — the PIC demand pull is accelerating, and Hock Tan's CPO skepticism doesn't matter because the thesis is architecture-agnostic.

The single-name highlight, produced with Hunterbrook, is Himax (HIMX): a sleepy display-driver company (~50% cyclically depressed automotive sales) whose wafer-level optics arm makes the micro-lens optics block (with 45-degree prisms) and V-groove baseplate inside the fiber array units that partner FOCI assembles for TSMC's COUPE platform. Three patents — two Himax, one TSMC — describe what appears to be the same 22-channel FAU design, and a former Lumentum engineer concluded there is 'a high probability' Himax and FOCI are in the FAU supply chain. Himax's nanoimprint lithography experience dates to iPhone X Face ID dot projectors; management guides 2026 as the first mass-production year with potential $100M+ CPO revenue and acceleration in 2027-28 (Morgan Stanley projects 5,000 Rubin Ultra racks in 2027 and 28,000 in 2028). A second kicker is Apple smart glasses, where Himax's WiseEye sensor and later LCoS microdisplays plus nanoimprint waveguides could rival CPO in size; Citrini sees non-driver sales reaching ~50% of revenue by 2028 and the stock at roughly 3-4x EV/EBITDA on 2028 numbers.

The 'PICs and shovels' basket rounds it out: Aixtron (70-90% MOCVD share; photonics orders guided to more than double, plus 85%+ GaN share ahead of Nvidia's 800V HVDC ramp), SUSS MicroTec (~50% of Samsung/Micron HBM temporary bonding, ~90% of TSMC photomask cleaning, the XBS300 CPO bonding platform, ~6x EBIT on 2030 targets vs BESI at ~40x), Soitec (near-monopoly SOI substrates at ~10x trough EV/EBITDA), Shin-Etsu (licenses Smart Cut rather than competing — proof of the moat), Nokia (the West's only vertically integrated InP fab via Infinera, $1B Nvidia 6G investment, CHIPS-subsidized US buildout), Furukawa (DFB laser capacity +500% by 2028), Sumitomo Electric (info-comm profit +360% YTD; connector capacity up 7x by 2028), STMicro (PIC100 in volume with a multi-billion-dollar AWS contract) and speculative POET. Positioning: overweight Himax, underweight POET, consider shorting AAOI against the basket, and take profits in the original priced-for-perfection winners.

Key metrics
Key insights
#118 Macro Memo Feb 22, 2026

The 2028 Global Intelligence Crisis: A Thought Exercise in Financial History, from the Future

Written as a fictional macro memo from June 2028, the piece models what happens if AI bullishness is right and that is precisely what is bearish: agentic AI triggers a self-reinforcing 'intelligence displacement spiral' in which capability improvements drive white-collar layoffs, savings are redeployed into more AI, displaced high earners cut the discretionary spending that anchors the consumer economy, and the loop has no natural brake because AI is OpEx substitution, not cyclical capex. The disruption spreads from SaaS repricing to agent-led disintermediation of payments, insurance and marketplaces, then to systemic risk via private credit (insurer-funded 'permanent capital' holding defaulting software LBO debt) and finally to the $13 trillion prime mortgage market as 780-FICO borrowers' incomes are structurally impaired. It is a scenario, not a prediction — published in February 2026 so investors can audit which portfolio assumptions won't survive the decade.

aisemiconsumershoppingfinancefintech
Positions & performance
Also watchingDASH:NASDAQ consumershopping MA:NYSE financefintech V:NYSE financefintech AXP:NYSE financefintech SYF:NYSE financefintech COF:NYSE financefintech DFS:NASDAQ financefintech NVDA:NASDAQ aisemi TSM:NYSE aisemi
Full summary 559 words

This is an explicit thought exercise — 'a scenario, not a prediction,' co-conceived with Alap Shah of LOTUS — framed as the Citrini macro memo of June 30, 2028, reconstructing a 'Global Intelligence Crisis.' In the scenario, unemployment prints 10.2%, the S&P is down 38% from October 2026 highs (having touched ~8000, Nasdaq above 30k), and the memo works backward through the sequence. It begins in late 2025 when agentic coding tools take a step-function jump: developers with Claude Code or Codex can replicate mid-market SaaS in weeks, procurement teams renegotiate (one Fortune 500 renewal at a 30% discount), and ServiceNow's fictional Q3 2026 print — net new ACV growth decelerating from 23% to 14% alongside a 15% workforce reduction — reveals the reflexive mechanism: seat-based vendors' AI-driven customer layoffs mechanically destroy their own revenue, and threatened incumbents become AI's most aggressive adopters because they cannot afford not to.

The second phase is disintermediation. Consumer agents become default (the median American consuming 400,000 tokens/day by March 2027, 10x in a quarter), and the economy's 'rent-extraction layer' built on human friction collapses: passive subscription renewals, insurance renewal books (15-20% of premiums from inertia), travel platforms, real estate commissions compressing from 2.5-3% to under 1%, and DoorDash-style habitual-app moats dissolving as agents check every option. Agents then route around 2-3% card interchange into stablecoins, hitting Mastercard, Amex, Synchrony, Capital One and Discover. The third phase is macro: white-collar workers are 50% of employment but drive ~75% of discretionary spending, and the top 10% of earners account for over 50% of consumption, so concentrated upper-decile job losses produce an outsized demand shock with a savings-buffer lag. The 'jobs always come back' counterargument fails because AI improves at the very tasks workers would redeploy into. India's IT services model ($200B+ of exports) collapses; the rupee falls 18% in four months.

The financial cascade runs through private credit: $2.5 trillion by 2026, stuffed with SaaS LBOs whose ARR assumptions died — the fictional Zendesk default marks a $5B direct-lending facility at 58 cents, the largest private credit software default on record. The 'permanent capital' defense unravels because the capital is annuity money at manager-owned life insurers (Athene/Apollo, Global Atlantic/KKR, American Equity/Brookfield) run through opaque offshore Bermuda reinsurance; regulators tighten RBC treatment, Athene goes on negative outlook and Apollo drops 22% in two sessions. The November 2027 crash — 'a daisy chain of correlated bets on white-collar productivity growth,' per fictional Fed Chair Kevin Warsh — precedes the final question: whether $13 trillion of prime mortgages written to 780-FICO borrowers are still money good when the income assumptions beneath them break (Zillow home values -11% YoY in San Francisco in the scenario; a full crack implies a GFC-rivaling 57% drawdown to S&P ~3500). Policy is structurally hamstrung: federal receipts run 12% below baseline because the tax base is human labor, labor share falls from 56% to 46% of GDP, and proposals like a 'Transition Economy Act' funded by an inference-compute tax stall in partisan gridlock while rate cuts cannot fix a real-economy engine driven by a $200/month Claude agent replacing a $180,000 product manager. The piece closes by snapping back to February 2026: none of this has started, the S&P is near highs, and the point is to audit which portfolio assumptions depend on the scarcity of human intelligence — 'the canary is still alive.'

Key metrics
Key insights
#117 Thematic Update Feb 18, 2026

Thematic Update: Modern Warfare

Modern warfare is being reshaped by three headline-driven trends — directed energy weapons finally working, cheap subsea drones threatening multi-billion-dollar naval assets, and a great-power scramble for Greenland and the Arctic — and the winners are smaller 'enablers' rather than the big primes. nLIGHT, up nearly 6x since Citrini's May 2025 entry, is the only public pure-play vertically integrated directed-energy company targeting a megawatt laser, and Iron Beam's operational deployment plus Golden Dome funding validate a spending wave barely in consensus estimates. Subsea drone offense and defense (Exail, Kraken, Oceaneering and others) and Arctic exposure (miners like Critical Metals and Energy Transition Minerals, icebreaker supply chains, Iridium's polar satcom moat) round out three new baskets built to capture accelerating defense budgets with structural tailwinds beyond headline beta.

airare-earthairobotconsumertraveldefensecomponentsdefensedefensedirected-energydefensedronedefenseprimeenergynuclearenergywarspace
Positions & performance
+28.9%avg return80% win · 5 tracked · L +28.9%
PositionMentionsEntryLastReturn
LIRDM:NASDAQ space IridiumIAT23.07Feb 18 '2645.96 +99.2%
LOII:NYSE defensedrone Oceaneering33.09Feb 18 '2652.17 +57.7%
LLASR:NASDAQ defensedirected-energy nLIGHTIS54.35Feb 18 '2670.02+28.8%
LESLT:NASDAQ defense Elbit SystemsP709.15Feb 18 '26715.72+0.9%
LAVAV:NASDAQ defensedrone AeroVironmentISP265.46Feb 18 '26154.24 -41.9%
Non-US / no priceEXA:EURONEXT defensedrone PNG:TSX defensedrone NORBT:OSL defensecomponents KOG:OSL defense MDA:TSX space ABBN:SIX airobot VSSABB:OMX energywar LIND:NASDAQ consumertravel
Also watchingDRS:NASDAQ defense HO:EURONEXT defense TKMS:XETRA defense BA:NYSE defense HII:NYSE defense NOC:NYSE defenseprime GD:NYSE defense 272210:KRX defense CRML:NASDAQ airare-earth ETM:ASX airare-earth AMRQ:LSE airare-earth PELI 600392:SSE airare-earth 601985:SSE energynuclear USAR:NASDAQ airare-earth
Full summary 563 words

This thematic defense update builds on Citrini's Drones basket from 25 Trades for 2025 — one of its best trades of that year — and The New WFH (War From Home), organizing recent headlines (El Paso airspace closure, dark-fleet tanker seizures and Maduro's extraction, Ukrainian sea drones destroying Russian submarines, Trump's Greenland demands) into three buckets: directed energy weapons, subsea drones, and Greenland/Arctic investment.

The centerpiece is nLIGHT (LASR), bought in the EW basket in May 2025 at $8.47 and up nearly 6x, which Citrini argues is 'just the start.' A Citrini analyst attended the Riyadh World Defense Show, where the 800-employee Camas, Washington company displayed a fully integrated 70kW laser weapon system (with 30kW and 10kW variants) — the only DEW booth at the conference. The report chronicles the field's inflection: the Navy's Vice Admiral McLane committing to 'a laser on every ship,' the UK's DragonFire deploying on Type 45 destroyers by 2027 (half a decade early), and Israel's Iron Beam formally entering IDF service on December 28, 2025 — the first operational high-power laser air defense system, flipping interception economics from $50,000 Iron Dome missiles against $500 rockets to single-digit-dollar marginal cost. CRS thresholds frame the roadmap: ~100kW kills drones and mortars, 300kW engages cruise missiles, 1MW can threaten ballistic missiles and hypersonics. nLIGHT is the only contractor publicly under contract (the $171M HELSI award, expanded from $86M) to scale to a full megawatt, controls the entire stack from diodes to beam directors (thanks largely to the 2019 $33M Nutronics acquisition), supplies Iron Beam, counts the US government and Raytheon as >10% customers, and just raised ~$200M to build capacity ahead of a program of record. Numbers: Q3 2025 revenue $66.7M (+19%) with A&D up ~50% to a record $46M; Q4 preliminary revenue $78-80M; product gross margin a record 41%. A double requires two of three: sustained 40%+ A&D growth toward $450M FY2027 revenue, a HELSI/Golden Dome validation ($24.4B of Golden Dome funding, $13B in FY2026), and an EBITDA inflection toward $75-100M; the bear case is ~30% downside.

The subsea drone section keys off Ukraine's December 16, 2025 underwater-drone strike on a KILO-class submarine inside Novorossiysk harbor — a step-change proving cheap UUVs can penetrate defended ports (and noting Norfolk's port security barriers have far larger gaps). Plays span XLUUV primes (Boeing/HII Orca, Northrop Manta Ray, Anduril Ghost Shark), with preference for pure-plays: Exail Technologies (the most levered integrator, <$2B cap, rapidly growing backlog), Kraken Robotics (synthetic aperture sonar, KATFISH, SeaPower batteries), Norbit, and favorite Oceaneering (OII) — 60 years of subsea robotics, its largest-ever DoW contract ramping 2026/27, the SIIPS 'guard dog' infrastructure-protection system, at 12x forward P/E. The Greenland/Arctic section frames Trump's pressure as a decade-long US-China contest: rare earth plays Critical Metals (Tanbreez, EXIM-funded), Energy Transition Minerals (Kvanefjeld, cutting Chinese ties and pursuing a Nasdaq listing) and Amaroq, all labeled speculative meme-beta; icebreaker exposure via ABB (Azipod propulsion, minority Aker stake) and Viking Supply Ships as Russia runs 40 icebreakers versus one US heavy polar vessel; Iridium's pole-to-pole LEO constellation (a 25-year DoW relationship, the $738.5M EMSS contract up for rebid, with a December 2025 Space Force modernization award suggesting the risk premium unwinds); MDA Space on Canada's ESCP-P polar satcom program; and Kongsberg for Nordic rearmament. A Greenland & Arctic basket is published with acknowledged headline beta but underlying trends that work regardless of any US-Denmark deal.

Key metrics
Key insights
#116 Thematic Primer Feb 11, 2026

Atoms vs Bits: What Can't You Prompt Your Way Out Of?

Agentic AI has forced the market to apply an 'AI Disruption Discount' to software, rotating capital from bits into atoms — the physical materials, metals and chemicals that AI, defense, aerospace and electrification all need but that no prompt can conjure. The obvious physical winners (power equipment, copper, nuclear, optics) are crowded, so the next leg is in overlooked upstream materials with oligopoly or monopoly supply, multi-year qualification moats, and converging cyclical-plus-structural demand: uranium conversion (Solstice), beryllium (Materion), titanium sponge (Osaka/Toho), aerospace aluminum, tungsten (Kennametal), superalloys, carbon fiber (Hexcel), grain-oriented electrical steel, mining capex (Komatsu), and AI electronic chemicals (Nittobo, Asahi Kasei, Entegris). These names are still priced as commodity producers even as they become critical enablers, and the re-rating 'won't be gentle.'

airare-earthaisemicommoditiesdefensecomponentsdefenseenergygridenergynuclear
Positions & performance
+4.0%avg return46% win · 13 tracked · L +4.0%
PositionMentionsEntryLastReturn
LMTRN:NYSE airare-earth MaterionIST157.11Feb 11 '26241.82 +53.9%
LPKE:NYSE defensecomponents Park AerospaceS24.09Feb 11 '2634.24+42.1%
LATI:NYSE defensecomponents ATI IncI138.72Feb 11 '26192.64 +38.9%
LHXL:NYSE defensecomponents HexcelI87.85Feb 11 '26110.28+25.5%
LCSTM:NYSE commodities ConstelliumI24.7Feb 11 '2629.05+17.6%
LKALU:NASDAQ commodities Kaiser AluminumT144.71Feb 11 '26161.89 +11.9%
LENTG:NASDAQ aisemi EntegrisISPT137.79Feb 11 '26126.37 -8.3%
LOLN:NYSE commodities OlinI26.32Feb 11 '2623.2-11.9%
LKMT:NYSE defensecomponents Kennametal40.26Feb 11 '2635.23-12.5%
LCENX:NASDAQ commodities Century AluminumIA53.44Feb 11 '2644.87 -16.0%
LSOLS:NASDAQ commodities Solstice Advanced MaterialsPT74.95Feb 11 '2660.54-19.2%
LAA:NYSE commodities AlcoaIP63.15Feb 11 '2644.08 -30.2%
LIPX:NASDAQ defensecomponents IperionXA44.07Feb 11 '2626.5-39.9%
Non-US / no price5726:TSE defensecomponents 5727:TSE defensecomponents AMAG:VIENNA commodities ACX:BME commodities 5411:TSE commodities 005490:KRX commodities 5401:TSE commodities 6301:TSE defense 3110 JP 4004:TSE aisemi 3407:TSE commodities 7741:TSE aisemi 5201:TSE aisemi 4005:TSE commodities AKE:EURONEXT commodities ORBIA:BMV commodities
Also watchingLEU:NYSE energynuclear CCJ:NYSE energynuclear 3402:TSE defensecomponents 3401:TSE defensecomponents SGL:NASDAQ aisemi CLF TKA:XETRA commodities CAT:NYSE energygrid 4062 JP 4063:TSE aisemi 300395:SZSE aisemi 7911:TSE aisemi GEV:NYSE energygrid ENR:XETRA energygrid HWM:NYSE defensecomponents CRS:NYSE defensecomponents
Full summary 590 words

Published February 11, 2026 into the software selloff, 'Atoms vs Bits' argues the market is ruthlessly and correctly repricing anything with an unclear AI-era moat — vertical SaaS, digital ads, fintech — and that investors will converge on a simpler question: 'what can't you prompt your way out of?' The answer is atoms. Every real bottleneck in the AI trade has been physical, and the next evolution is where new demand (a proposed $1.5T US defense budget, NATO and Japanese rearmament, a record aerospace backlog, data center gas turbines sharing input materials with jet engines) collides with the buildout to strain supply chains. The screen: companies with pricing power across a capital cycle, concentrated qualified supply, 2-5 year qualification moats, and protection from Chinese flooding via physics, defense procurement rules or quality requirements.

The anchor idea is Solstice Advanced Materials (SOLS), the October 2025 Honeywell spin-off that owns Metropolis Works — the only US uranium hexafluoride conversion facility, ~15,000 MTU nameplate, roughly 20% of global conversion capacity. Legacy contracts struck at ~$20/kgU during the 2017-2023 idle are rolling off (~25% per year) into a ~$64/kgU spot market with identical production costs (~$13-16/kgU variable plus $150-170M fixed), so repricing flows straight to EBITDA; Citrini bridges the AES segment to ~$673M of 2028 EBITDA (haircut to $500M EBIT), sees 60% segment margins, a $2B backlog, and argues a 12-14x multiple implies $95-105 per share with a bull case near a triple, versus Centrus at 33x. Subsequent sections tour the other 'atom' monopolies: Materion (over 40% of global beryllium, 70%+ of freshly mined supply, defense bookings +40%, a Commonwealth Fusion agreement), the Japanese titanium sponge duopoly Osaka Titanium and Toho Titanium (~80% Western share with the Saudi JV, single-digit EV/EBITDA, a $210M expansion to 50,000 tonnes by 2028, IperionX the US dark horse), aerospace/high-purity aluminum (Constellium the highest conviction, plus Kaiser, Century, AMAG, Alcoa; copper/aluminum cost ratio at 4.2x versus the 3.5x switching threshold; no new US smelter since 1980), tungsten (prices tripled on Chinese export controls; Kennametal at ~8.5x EV/EBITDA is the vertically integrated Western play with Metal Cutting margins up from 6.0% to 9.6%), superalloys (ATI the best US story; Acerinox with Haynes as the cheap European route), and carbon fiber (Hexcel: ~93% aero/defense mix, guided 2026 revenue of $2.0-2.1B with EPS $2.10-2.30, ~$500M of incremental revenue when OEM production rates normalize, plus underappreciated space exposure as launch cadence grows 20-25% a year).

Electrical steel gets its own section: transformer lead times have blown out from 20 to 128 weeks (144 for GSUs), prices are up 4-6x since 2022, GOES cores are 25-30% of transformer cost, and the plays are JFE (monopoly on 6.5% silicon steel, ~5x EV/EBITDA), POSCO and Nippon Steel, with Cleveland-Cliffs (sole US GOES producer, $400M five-year government contract) a contrarian turnaround. Mining capex favors Komatsu at ~15x forward earnings versus Caterpillar's 31x — CAT itself projects mining capex +50% by 2030, and the collapsed Rio-Glencore merger means two giant standalone checkbooks. Finally, the 'AI materials' update: the upstream molecules-and-powders basket from December is catching up as predicted — WSJ confirmed the Nitto Boseki T-glass bottleneck (stock +75% YTD, dividend nearly tripled), Resonac +40% YTD — with new ideas in Asahi Kasei (PIMEL photosensitive polyimide, doubling capacity after a ¥16B investment; Q Glass for M9-grade CCLs), photomask blanks (Hoya/AGC duopoly), Sumitomo Chemical, Entegris (60%+ of revenue now advanced nodes; the tungsten-to-molybdenum NAND transition), and qualification-moat chemicals Arkema, Olin and Orbia. Conclusion: with AI now writing its own successor models, the premium on un-promptable physical chokepoints should keep expanding.

Key metrics
Key insights
#115 Semis Memo Jan 26, 2026

Semis Memo: Muscle Memory

As returns from mainstream AI 'layups' (Nvidia, Micron, SK Hynix, Broadcom) moderate, alpha migrates to less-followed layers of the semiconductor supply chain, and Citrini has hired dedicated semis analysts to hunt there. The memory supercycle structurally lifts demand for memory testing (a 16-name basket spanning testers, probe cards, handlers and sockets) because HBM must be tested at every assembly layer and the HBM4E hybrid-bonding transition raises complexity further, while semicap subsystems ('picks and shovels for the picks and shovels') capture disproportionate growth as process steps per wafer multiply. Silicon photonics re-rates legacy foundries GlobalFoundries and UMC, and a watchlist adds legacy memory squeeze names, oversold cybersecurity, SpaceX's Taiwanese supply chain, and a bullish Nvidia earnings setup now that the king is under-owned.

aimemoryaisemicybersecuritysaas
Positions & performance
+68.8%avg return91% win · 11 tracked · L +68.8%
PositionMentionsEntryLastReturn
LICHR:NASDAQ aisemi Ichor HoldingsPT30.59Jan 26 '2694.0+207.3%
LAEHR:NASDAQ aisemi Aehr Test SystemsS26.78Jan 26 '2677.48 +189.3%
LUCTT:NASDAQ aisemi Ultra Clean HoldingsT44.05Jan 26 '2686.97 +97.4%
LCOHU:NASDAQ aisemi CohuT28.97Jan 26 '2650.7+75.0%
LUMC:NYSE aisemi United Microelectronics11.33Jan 26 '2619.08 +68.4%
LAMAT:NASDAQ aisemi Applied MaterialsISPT319.46Jan 26 '26516.89 +61.8%
LTER:NASDAQ aisemi TeradyneISPT231.75Jan 26 '26349.92+51.0%
LFORM:NASDAQ aimemory FormFactorST74.0Jan 26 '26104.04+40.6%
LONTO:NYSE aisemi Onto InnovationIS206.74Jan 26 '26272.62+31.9%
LGFS:NASDAQ aisemi GlobalFoundriesS44.22Jan 26 '2653.18 +20.3%
LKLAC:NASDAQ aisemi KLA CorpISPT1543.03Jan 26 '26210.52-86.4%
Non-US / no price6871:TSE aisemi BESI NA ASM:EURONEXT aisemi 6525:TSE aisemi 6857 JP 8035 JP 522:HKEX aisemi
Also watchingMU:NASDAQ aimemory SKHYNIX:KRX aimemory 005930 KS AVGO:NASDAQ aisemi NVDA:NASDAQ aisemi 2408:TWSE aimemory 2344 TT 3006:TWSE aimemory 2337 TT 6239:TWSE aimemory 3491:TWSE aisemi 2314:TWSE aisemi 6285:TWSE aisemi 2313 TT 3481:TWSE aisemi CRWD:NASDAQ saas NET:NYSE saas RBRK:NYSE cybersecurity PANW:NASDAQ cybersecurity ZS:NASDAQ cybersecurity PDFS:NASDAQ aisemi 042700:KRX aimemory 6515:TWSE aisemi
Full summary 574 words

The first 'Semis Memo' introduces Citrini's new semiconductor analysts (Zephyr and Jukan) and argues the easy AI trades are over: generalists must go a layer deeper, as the firm did when underwriting Teradyne via memory testing, Amkor via chiplet/OSAT demand, and the January 2024 call that SK Hynix and Micron could double. The memory supercycle frames everything: HBM content per accelerator is rising fast (Nvidia's GB300 carries ~$4k of HBM3E), and long-context, agentic AI pushes KV cache into DRAM and SSDs, structurally lifting demand across the stack.

The deepest section covers memory testing — 'a $40k GPU isn't worth much if its memory doesn't work.' Existing holdings FormFactor, Onto Innovation and Teradyne have outperformed, and the memo maps the whole obstacle course: wafer sort with Tokyo Electron/Accretech probers and Advantest/Teradyne testers, laser repair, burn-in (Aehr), and final test with Cohu/Advantest handlers and a socket 'knife fight' among WinWay, LEENO, ISC and Enplas. HBM raises the stakes: known-good-die screening before stacking, full package testing (Nvidia has reportedly tightened standards further), and probing thousands of 40µm-pitch microbumps — MEMS probe tech supplied almost exclusively by FormFactor and Micronics Japan. The HBM4E transition (2026/27) to hybrid bonding is the next dislocation: Samsung has effectively confirmed adoption with mature yields, and BESI is a favorite — likely capped near 30% share at Samsung (Semes takes the rest) but potentially 50-60% at SK Hynix and over 80% at Micron. A 16-name Memory Testing basket spans capital equipment and consumables.

Semicap and subsystems come next: TSMC is expected to spend $190-200B of capex over three years and Intel could ramp to 100k wafers/month of 18A-P plus 14A capacity by 2029-30. Within wafer fab equipment, Citrini highlights deposition — especially ASM International's atomic layer deposition exposure as GAAFET makes conformal films critical — alongside existing longs AMAT, ONTO and KLAC. Subsystem vendors (called out in July: ICHR, UCTT) are the 'picks and shovels for the picks and shovels': HBM wafer starts growing ~50% annually mean 100-200% more process steps, 3nm-and-below flows exceed 1,500 steps per wafer, and each node raises fab cost ~30%. In silicon photonics and legacy fabs, GlobalFoundries (GF Fotonix at 200G/lane, the Advanced Micro Foundry Singapore acquisition, Cisco partnership, TSMC GaN license with Navitas and ON Semi as 2026 customers, MIPS and Synopsys ARC IP deals) and UMC (imec iSiPP300 partnership targeting 800G/1.6T PICs with risk production 2026-27, 3Q25 utilization at 78%) are commodity-priced foundries building specialty platforms.

The watchlist covers four trends: a legacy memory squeeze (DDR4 EOL panic buying spilling into DDR3 and NOR — Macronix hiked NOR ~30% in 1Q26; MLC NAND capacity projected down 41.7% in 2026), the 'SaaS-pocalypse' unfairly hitting cybersecurity (CrowdStrike, Cloudflare, Rubrik, Zscaler are AI-security beneficiaries, not victims), SpaceX's Taiwanese supply chain ahead of a potential IPO, and a bullish Nvidia earnings setup — after six months sideways, China sales resuming and Claude Code-driven compute demand set up an underpriced guidance surprise, played via longer-dated options. Single names: Cohu (Neon HBM inspection, ~$10-11M 2025 revenue; Eclipse handler selected for a likely-Intel AI processor at ~3,000W), Powertech (PiFO as a CoWoS-L alternative, NT$40B+ 2026 capex, reported Meta interest), ASMPT (TC bonders to SK Hynix; hybrid bonding threat to Hanmi's ~90% HBM4 TCB share), and PDF Solutions (Exensio analytics tied to Intel 18A). The Dynamic AI basket is up ~16% YTD and +278.6% since inception; adds include ASM NA, Kokusai and GFS, with shorts on consumer electronics as the memory squeeze passes through.

Key metrics
Key insights
#114 Macro Memo Jan 14, 2026

Macro Memo: Running Hot

The US economy is re-accelerating despite a stagnant labor market because AI-driven productivity gains are increasingly showing up in output, while pro-growth pre-midterm policy (MBS purchases to lower mortgage rates, teased stimulus) and the Fed's pivot from QT to ~$40B/month of balance sheet expansion add fuel. That mix supports risk assets, argues rates are too low (hence a contrarian 2s30s flattener), and favors housing-sensitive longs like Rocket. Abroad, the 'Don-roe Doctrine' — a transactional US retrenchment into its hemisphere after the Venezuela intervention — makes LatAm (especially Chile), Southeast Asia (long Vietnam/Indonesia/Malaysia/Philippines), and a reflating China the places to be, while Iran tension plus structural fleet tightness supports long oil and especially tankers.

airare-earthaisemiconsumerreal-estateconsumershoppingenergygridfinancecryptofinancefintechindexclindexcnindexmy
Positions & performance
-14.6%avg return10% win · 10 tracked · L -14.6%
PositionMentionsEntryLastReturn
LUHAL:NYSE consumerreal-estate U-HaulT56.54Jan 14 '2672.96 +29.0%
LEWM:NYSE indexmy iShares MSCI Malaysia ETF28.2Jan 14 '2627.88 -1.1%
LHD:NYSE consumershopping Home DepotIPT375.95Jan 14 '26336.09 -10.6%
LECH:NASDAQ indexcl iShares MSCI Chile ETF44.51Jan 14 '2638.61-13.3%
LFXI:NYSE indexcn iShares China Large-Cap ETF40.04Jan 14 '2634.58-13.6%
LSQM:NYSE airare-earth Sociedad Quimica y Minera83.18Jan 14 '2668.73-17.4%
LRH:NYSE consumershopping Restoration HardwareIAP217.24Jan 14 '26174.51-19.7%
LLOW:NYSE consumershopping Lowe'sPT274.95Jan 14 '26207.64-24.5%
LIBIT:NASDAQ financecrypto iShares Bitcoin TrustP55.44Jan 14 '2636.35-34.4%
LRKT:NYSE financefintech Rocket CompaniesIT22.67Jan 14 '2613.49 -40.5%
Also watchingBE:NYSE energygrid 688795:SSE aisemi 688802:SSE aisemi XLU:NYSEARCA energygrid
Full summary 531 words

This January 2026 macro memo lays out a 'running hot' view of the US economy. The two big 2025 worries — tariffs and job creation — never produced a slowdown: real GDP grew 3.8% annualized in Q2 and 4.3% in Q3, with the Atlanta Fed GDPNow tracking 5.1% for Q4, even as net job creation stalled, hire and quit rates settled below pre-COVID norms and wage growth slowed across the income spectrum. Citrini's contrarian resolution of the labor/GDP divergence is productivity: the hundreds of billions invested in AI for three years is actually enhancing output per hour, visible first in software engineering and spreading with agentic AI. They expect 2026 could pair steady-or-rising unemployment with solid GDP and a rising market — a dynamic seen in 1992, 1975, 1958 and the post-WW2 years — with productivity spillover buoying corporate earnings.

The 'Big MAC' (Midterms Are Coming) section argues the administration is greasing voters: proposed credit card rate caps, 'tariff stimmy' checks, and above all housing. Citrini's September 2025 prediction that the White House would compress mortgage rates is playing out via $200 billion of announced MBS purchases, with removal of the GSE MBS purchase cap still on the table. Favored expressions: Rocket Mortgage (which acquired Redfin and Mr. Cooper), U-Haul (less lock-in), RH (jumbo mortgage availability, higher-end demographic) and Home Depot/Lowe's. On liquidity, late-2025 repo stress — SOFR above policy floors and a record $29.4 billion single-day Standing Repo Facility draw on October 31 — killed QT and birthed 'Reserve Management Purchases' expanding the balance sheet ~$40 billion per month, a directional positive for risk assets. The Powell/Trump feud (DOJ subpoenas over the Fed renovation, Trump calling Powell 'a jerk') underpins a contrarian 2s30s flattener: Powell can stay on as governor two more years, hobbling a loyalist replacement, the steepener is crowded, and with the 2-year at 3.5% Citrini thinks the two cuts priced by end-2026 get removed.

Geopolitically, the memo goes long oil (WTI bought at ~$59.15 on January 12 with a stop at entry) and, more interestingly, tankers: record Iranian crude on the water, an aging fleet, sanctions on the shadow fleet and multi-year-high VLCC rates give independent catalysts beyond a Strait of Hormuz event. The 'Don-roe Doctrine' frames the Venezuela intervention (VENZ 9.25% 9/15/27 bonds +37% after Maduro's capture) as a watershed: the US will 'clean house' in LatAm and push out China. Chile is the favorite (25% of world copper, major lithium, pro-market Kast taking office March 11, 2026); Korea, Japan and Southeast Asia benefit from supply chain redesign, with the earlier long-Indonesia/short-Vietnam idea replaced by long VIMP (Vietnam, Indonesia, Malaysia, Philippines) and Malaysia the favorite. China is seen inching toward corporate-sector recovery via anti-involution and reflation — Moore Threads and MetaX traded up 6x on debut — keeping Citrini bullish FXI and specific names. Trade updates: NGZ5 profits taken near the peak and long re-established in NGF27 at 4.42; the HGZ6 copper roll gained another 20%; QQQ/IBIT worked (~8%) and was flipped to outright long IBIT targeting a move back above 100K; the XLU/SPY pair was stopped out. New trades: long Bitcoin, long oil, long FXI calls, EWM and ECH, the 2s30s flattener, and long tankers.

Key metrics
Key insights
#113 State of the Themes Dec 17, 2025

26 Trades for 2026: A Thematic Watchlist for the New Year

Citrini's annual 'Twenty-Something Trades' exercise drops the pretense of a precise year-ahead outlook and instead publishes 26 thematic trade ideas for 2026 as a watchlist designed to minimize intellectual blind spots. The 2025 edition validated the format — over half the ideas beat the S&P 500 and single-stock picks averaged +26.5% — so the 2026 list continues it, delivered as a long PDF with accompanying thematic basket spreadsheets.

airobothealth
Positions & performance
+33.5%avg return50% win · 2 tracked · L +33.5%
PositionMentionsEntryLastReturn
LALNT:NASDAQ airobot AllientI51.41Dec 17 '2586.78+68.8%
LARQT:NASDAQ health Arcutis BiotherapeuticsP28.34Dec 17 '2527.84 -1.8%
Full summary 183 words

This is a short wrapper post introducing '26 Trades for 2026,' Citrini's annual thematic watchlist published December 17, 2025. The introduction argues that conventional year-ahead outlooks are a 'ridiculous premise' and that once a year Citrini deliberately drops the pressure of being right at the right time, generating a long list of ideas — some potential winners, some scenario preparation, some just names to keep on screen — to minimize intellectual blind spots. A 2025 scorecard recaps last year's edition: a bit more than half of the ideas outperformed the S&P 500 and more than 80% had positive returns; winners included drone names (most doubled), Ukraine normalization picks, and South Africa over Turkey riding the gold rally, while the remittances idea failed amid ramped deportations. Single-stock picks averaged +26.50% equally weighted, beating the S&P 500 by more than 10 percentage points, with Allient doubling and ARQT's Zoryve success correctly anticipated. The actual 26 trades — each roughly six pages — live in a downloadable PDF, with thematic basket holdings in a linked spreadsheet; this post itself contains no detail on the new ideas.

Key metrics
Key insights
#112 Thematic Update Nov 27, 2025

Carving Up the TPU: Leftovers for Jensen or Just Gravy on the AI Trade?

Gemini 3's success and reported TPU adoption by Anthropic and Meta have vindicated Citrini's August 'Long GOOGL' call, but the market's read that this is simply bearish Nvidia is too crude. A TPU scale-up is more bullish for Google and for the shared supply chain than it is bearish for Nvidia, because both giants will compete for the same TSMC CoWoS capacity, HBM, advanced packaging, PCBs and optics, boosting suppliers' pricing power. Citrini believes the market's reaction will effectively force Google to sell TPUs as a merchant vendor, which turns a walled-garden asset into revenue and optionality. The trade is therefore a basket of first-order TPU suppliers (packaging, memory, dense PCBs, optical circuit switch players) plus second-order winners like Apple (as a prospective Google TPU/Gemini customer), SiTime and MACOM riding the 800G-to-1.6T optical transition.

aimemoryaineocloudaiopticalaisemienergygridmag5
Positions & performance
+73.1%avg return91% win · 11 tracked · L +73.1%
PositionMentionsEntryLastReturn
LMU:NASDAQ aimemory MicronISAPT236.48Nov 28 '25920.95+289.4%
LLITE:NASDAQ aioptical LumentumISPT325.16Nov 28 '25711.96 +119.0%
LSITM:NASDAQ aisemi SiTimeAT297.7Nov 28 '25554.46+86.2%
LTTMI:NASDAQ aioptical TTM TechnologiesST70.18Nov 28 '25123.71 +76.3%
LAMKR:NASDAQ aisemi AmkorSAPT36.39Nov 28 '2560.71 +66.8%
LMTSI:NASDAQ aioptical MACOMISP174.99Nov 28 '25263.08 +50.3%
LMPWR:NASDAQ aisemi Monolithic Power SystemsISPT928.17Nov 28 '251339.08 +44.3%
LTSM:NYSE aisemi TSMCISAP291.51Nov 28 '25399.09 +36.9%
LAAPL:NASDAQ mag5 AppleISPT278.85Nov 28 '25333.02+19.4%
LETN:NYSE energygrid EatonISAPT345.89Nov 28 '25398.64 +15.3%
LGOOGL:NASDAQ mag5 AlphabetSPT320.18Nov 28 '25319.74-0.1%
Non-US / no price3711:TWSE aisemi SKHYNIX:KRX aimemory 005930 KS 2454 TT 007660:KRX aisemi 3037 TT 300456:SZSE aisemi HUBN:SIX aioptical
Also watchingNVDA:NASDAQ aisemi CRWV:NASDAQ aineocloud WULF:NASDAQ aineocloud META:NASDAQ mag5 3661:TWSE aisemi 3443:TWSE aisemi JBL:NYSE aioptical FLEX:NASDAQ aineocloud 6752:TSE aisemi 5801:TSE aioptical CIEN:NYSE aioptical COHR:NYSE aioptical
Full summary 491 words

The report opens by recapping Citrini's August State of the Themes call — 'Long GOOGL' — grounded in Google's vertical integration, cheap TPU-based training, best-in-class first-party data and low customer acquisition costs, versus a compute-constrained OpenAI. Since then sentiment has flipped violently: Gemini 3 put Google at the frontier on its own silicon, and reports that Anthropic and Meta plan to adopt TPUs (Meta reportedly for training, not just inference) triggered a 'passing of the public torch.' Google remains the largest allocation in Citrini's Dynamic AI basket, but the author warns against recency bias and consensus crowding, citing Oracle's trip from a 40% gap-up to CDS-watching in weeks.

A 'TPUs for Idiots' section explains the architecture: neural nets reduce to matrix multiplication, and TPUs dedicate nearly all silicon to matmuls via systolic arrays of MAC cells that take data rather than instructions, yielding superior performance per watt and per dollar on ML at the cost of flexibility. On Nvidia, Citrini is deliberately non-sensationalist: switching from CUDA/PyTorch to JAX is expensive and disruptive, Google spent ten years optimizing around TPUs, Google itself remains one of Nvidia's largest customers, and Gemini's success should push NVDA-locked labs to buy more next-gen chips. The kneejerk NVDA selloff reflects future margin risk (27/28), not volume risk; supply and infrastructure, not demand, are the bottleneck. Citrini would even consider dipping back into NVDA if bearish sentiment overshoots.

On distribution, the report argues the decision to sell TPUs has effectively been made: chip deals with Anthropic, Meta and Fluidstack contradict a pure walled-garden approach, and the Fluidstack arrangement (TPUs deployed in a Terawulf-leased NYC data center with a $3.2 billion Google backstop and 14% equity) shows a 'franchise' model. Selling TPUs is a pure-margin, variable-production hedge against long-duration data center capex risk, and not selling would invite a new merchant silicon competitor (possibly Chinese) within 4-7 years.

Positioning centers on a 25-name, equally weighted TPU Supply Chain basket — the best performing group in Citrini's AI coverage YTD, yet still cheaper than the broader 125-name Phase 1 AI Infrastructure basket. Favored areas: advanced packaging (TSMC, ASE, Amkor), HBM (SK Hynix, Samsung, Micron), a Mediatek catch-up, dense TPU boards benefiting Isu Petasys, TTM and Unimicron, and Google's MEMS-based Optical Circuit Switches benefiting Lumentum (R300/R64), Silex owner Sai MicroElectronics, and Huber+Suhner. Second-order ideas: Apple as a natural TPU/Gemini cloud-inference customer for a better Siri; SiTime, whose MEMS oscillator content roughly doubles to ~$2 per 1.6T module as 1.6T optical modules jump from ~3 million (2025) to ~20 million (2026) on Google's TPU forecast doubling from ~2 to ~4 million units, plus an exclusive Apple 5G-modem win worth ~$240M of 2027 revenue; and MACOM with >60% share in 200G photodiodes. The report closes cautious — net long cut from +100% to +80% and hedged — flagging shrinking big-tech buybacks, a $200 billion-plus gap between hyperscaler capex and D&A overstating earnings, and Nvidia's oddly defensive public posture as a signal worth watching.

Key metrics
Key insights
#111 Macro Memo Nov 17, 2025

Macro Memo: Mo-vember

With the shutdown ending and a deluge of delayed data incoming, Citrini expects continued labor deterioration on private data, a cautious Fed that skips the December cut, risk-off pressure on speculative assets (crypto, quantum, miners) into mid-December, and then a Santa rally as 2026's fiscal impulse ($380-545B of OBBBA tax savings plus possible tariff dividends) gets priced. The durable structural call is that AI datacenter load exhausts every 'spare grid capacity' workaround — storage, demand response, BYOG microgrids — forcing real generation buildout that transforms utilities' earnings runway; hence a new long XLU/short SPY pair, alongside long QQQ/short IBIT (reflexive Bitcoin to ~75K), profit-taking in natural gas (+15%) and gold puts (+100% on half), rolling copper long on undermodeled datacenter demand, and re-entering the SOFR H6H7 flattener on aggressive cuts under Powell's successor.

airare-earthcommoditiesenergygridenergywarfinancecryptoindexbondsindexjpindexus
Positions & performance
-4.5%avg return40% win · 5 tracked · L -14.0% · S +9.6%
PositionMentionsEntryLastReturn
SIBIT:NASDAQ financecrypto iShares Bitcoin TrustP52.1Nov 17 '2536.35+30.2%
LQQQ:NASDAQ indexus Invesco QQQS603.66Nov 17 '25682.12 +13.0%
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF89.09Nov 17 '2583.25-6.6%
SSPY:NYSEARCA indexus SPDR S&P 500 ETFIS665.67Nov 17 '25739.09 -11.0%
LXLU:NYSEARCA energygrid Utilities Select Sector SPDRSP89.56Nov 17 '2546.29-48.3%
Also watchingEQT:NYSE energywar EXE:NASDAQ energywar FCX:NYSE airare-earth FLNC:NASDAQ energygrid EOSE:NASDAQ energygrid 6674:TSE energygrid GLD:NYSE commodities NKY:NASDAQ indexjp
Full summary 594 words

This November 17, 2025 Macro Memo scores last month's calls (slowing-without-breaking, deepening K-shape, China tensions peaking then easing, a 5-10% pullback within a continuing bull) and sets four-week expectations: further private-data labor deterioration, volatility from the post-shutdown data deluge, improved funding liquidity as the shutdown and QT end, a December Fed hold (market prices 43% cut odds; Citrini's FOMC tally suggests lower), continued risk-off in speculative corners (crypto, quantum, bitcoin miners) into mid-December, then a Santa rally as 2026 fiscal expansion is priced. The economy section marshals private data — ADP payrolls steadily slowing, Indeed job postings falling, hire/quit rates at lows, construction payroll growth declining, consumer confidence sliding — against a paradoxical Atlanta Fed Q3 GDP nowcast of 3.7%, with earnings from McDonald's, Chipotle, Cava and Tyson confirming low-income strain while auto-loan and student-loan delinquencies climb (mortgages remain historically healthy thanks to household deleveraging).

Three macro subplots get attention. Funding-market stress: SOFR has traded above IORB at spreads last seen in 2019, indicating reserve scarcity from QT and the shutdown's Treasury General Account freeze — a reason the Fed is ending QT and a hidden-leverage warning worth monitoring rather than trading. The fiscal impulse: 2026 OBBBA tax savings of roughly $380-545B (mostly TCJA extension, ~$75B incremental) plus potential 'tariff dividend' checks mean the wall of worry likely resolves bullishly in Q1 2026, while tariffs collect ~$30B/month (~$360B/year, ~20% of the FY2025 deficit) with SCOTUS odds of upholding them priced at just 25% — an overturn would pressure UST yields. Sentiment: AAII bulls at only 39%, VIX ~16 at the recent high versus 25+ at late-90s peaks, breadth at 62% above 200-day averages — consistent with Citrini's 1998 analog of a bull that advances with rising two-way volatility; ES's 50-day EMA (6722) is the tactical line in the sand.

The trade block is extensive. Natural gas: three-quarters of the NGZ5 long (from ~$3.90) is booked for +15%, with intent to re-add further out the curve; the structural equity thesis strengthens as behind-the-meter power-gen demand already shows up as +1 Bcf/d YoY of summer res/comm demand, large caps like EXE buy resource despite higher costs, and LNG FIDs continue. Copper: rolled from HGZ5 to HGZ6 booking +7% — datacenter additions going from 5GW to 25GW/year imply ~500kt of incremental annual copper demand at a conservative 25kt/GW, 'a year of China entering the WTO,' with scrap export restrictions adding a resource-nationalism bid. Gold: the contrarian GLD 350 December puts bought October 15 caught the momentum unwind; half closed for ~+100%. Rates: re-entering the SOFR H6H7 flattener at half size — the curve prices ~50bps between March 2026 and March 2027 versus Citrini's 75bps base case with a fat 100bps tail under Powell's successor; a December hold should push more cuts into the spread.

Two new trades anchor the piece. Long XLU/short SPY is the macro/AI crossover: every substitute for new generation — reserve margins, storage ('fixes shape, not supply'), demand response, sweating assets — is temporary, and BYOG microgrids are prohibitively expensive (SLAs require ~1.5-2x load in firm capacity; Stargate plans 1.2GW of load against only ~360MW of generation), so operators will ultimately partner with utilities, converting massive investment-grade load growth into rate-base and earnings-runway expansion, with defensive beta as the free hedge. Long QQQ/short IBIT exploits Bitcoin's pure reflexivity now that MicroStrategy can no longer be the buyer of last resort: target ~75K on BTC, stop on a close above 100K. A Nikkei short sits on the watchlist (trigger: close below 50K JPY, target -5%, stop 51.5K) on Takaichi's wage-focused rhetoric and Japan's GDP contraction.

Key metrics
Key insights
#110 Thematic Update Nov 03, 2025

I Can See Clearly Now... The Rain Is Gone?

Fifteen months into the Healthcare Innovation basket, the feared Trump-era policy damage never materialized — funding cuts were walked back, landmark approvals landed, diagnostics reimbursement improved — yet healthcare positioning sits at 20-year lows with post-COVID-high short interest and depressed multiples, while guidance beats run near record highs and 2025 M&A tracks ahead of any year on record. Citrini argues this is the start of a multi-year upswing led by small-cap medtech crossing into profitability (the IRTC/ATEC re-rating template applies to the STAX names), insurers' medical-cost crisis funneling business to value-based care (TOI, ALHC, new add ASTH), GLP-1 second-order winners (AIRS, WW, NGVC, LLY vs shorts in low-end food), and a diversified life-sciences upcycle sleeve (TKNO, NOTV, AVTR, plus new FTRE and CYRX).

airobotaisemiconsumerhealthconsumershoppinghealthGLPhealthhealthtesting
Positions & performance
-10.0%avg return47% win · 19 tracked · L -8.7% · S -14.6%
PositionMentionsEntryLastReturn
LFTRE:NASDAQ health FortreaI10.12Nov 03 '2519.2 +89.7%
LCYRX:NASDAQ health Cryoport9.04Nov 03 '2515.15 +67.6%
SSHAK:NYSE consumershopping Shake ShackAPT93.53Nov 03 '2561.57 +34.2%
LLLY:NYSE healthGLP Eli LillyIPT896.53Nov 03 '251196.03+33.4%
LTOI:NASDAQ health The Oncology InstituteA4.49Nov 03 '255.39+20.0%
LASTH:NASDAQ health Astrana HealthT32.99Nov 03 '2538.19 +15.8%
LALHC:NASDAQ health Alignment HealthcareT16.84Nov 03 '2519.43+15.4%
SDPZ:NASDAQ consumershopping Domino's PizzaIPT403.63Nov 03 '25343.53 +14.9%
LAVTR:NYSE health AvantorIAT11.68Nov 03 '2511.76 +0.7%
LTKNO:NASDAQ health Alpha Teknova5.08Nov 03 '254.85 -4.5%
LNGVC:NYSE consumerhealth Natural Grocers32.96Nov 03 '2530.01-9.0%
SHRL:NYSE consumershopping HormelIT21.48Nov 03 '2526.05 -21.3%
LSTIM:NASDAQ health NeuroneticsA2.77Nov 03 '251.81 -34.7%
LCVRX:NASDAQ health CVRxA10.36Nov 03 '254.74-54.2%
LAIRS:NASDAQ health AirSculptA10.39Nov 03 '254.61-55.6%
LWW:NASDAQ health WW InternationalA34.06Nov 03 '2513.85 -59.3%
LXGN:NASDAQ health Exagen11.83Nov 03 '254.4 -62.8%
SEAT:NYSE consumershopping Brinker InternationalIT105.05Nov 03 '25195.44 -86.0%
LNOTV:NASDAQ healthtesting Inotiv1.24Nov 03 '250.08-93.6%
Also watchingIRTC:NASDAQ health ATEC:NASDAQ health BWAY:NASDAQ health PRVA:NASDAQ health LH:NYSE health ISRG:NASDAQ airobot BSX:NYSE health ICLR:NASDAQ health TMO:NYSE health DHR:NYSE health SFM:NASDAQ consumerhealth NVDA:NASDAQ aisemi BN:EURONEXT consumershopping XBI health
Full summary 598 words

This November 3, 2025 Healthcare Innovation update marks fifteen months since basket inception and declares the policy storm over — for now. The predicted MAGA-era catastrophes largely failed to materialize: funding-cut threats were walked back, pharma struck domestic-manufacturing deals reducing pricing risk, landmark approvals arrived, and diagnostics reimbursement enjoys unprecedented support. Companies guiding above expectations are near record highs — yet healthcare long positioning sits around 20-year lows, short interest tests post-COVID highs, and the Russell 2000 healthcare growth sub-index trades well below historical revenue multiples. That disconnect is attracting strategic buyers: 2025 healthcare M&A deal count is tracking substantially ahead of any prior year on record, and Citrini thinks several basket names are targets.

The core of the report is the 'STAX' medtech quartet (STIM, TOI, AIRS, XGN) and the profitability-inflection playbook: when loss-making medtechs cross into profits, the market re-rates them from peer discounts to premiums — as former basket members iRhythm (IRTC) and Alphatec (ATEC) demonstrated — and all four STAX names are guided to cross that threshold within quarters. TOI anchors the value-based-care (VBC) theme: with insurers reporting elevated medical loss ratios, Cigna, Centene, CVS and Elevance all explicitly named VBC as strategy, and Molina called out oncology drug costs specifically — playing straight into TOI's vertically integrated oncology VBC model. TOI just beat its first-ever active sellside estimates before large new contracts even contribute, guided to sustainable profitability before end-2025, and trades at a 50%+ discount to peers like Privia. The VBC sleeve deepens: CVRx (BAROSTIM saves at least $9,000 per patient versus standard of care; largest shareholder JNJ is hunting high-growth medtech), ALHC (exceeded its entire annual EBITDA guidance in a single quarter in Q2, then tripled Q3 consensus), and new addition Astrana Health (ASTH) — 20+ payers across thirteen markets, ~10% FCF yield, a path to 25%+ revenue growth, and the lowest revenue multiple among VBC players.

XGN and STIM ride industry tailwinds: diagnostics peers re-rated from ~4x to >9x trailing revenue since July while XGN still sits just above 4x despite accelerating growth, AI-enabled data moats and Labcorp naming autoimmune diagnostics a strategic acquisition area; TMS search interest ended Q3 at multi-year highs, and STIM's multiple contracted while inferior peer Brainsway re-rated — a gap Citrini attributes to accounting optics (STIM consolidates its Greenbrook clinics and has invested nearly twice BWAY's R&D over five years) that resolves as STIM reaches profitability. AIRS extends into the GLP-1 'Second Serving' thesis: the cosmetic-surgery headwind is flipping to tailwind (WSJ, NY Post and McKinsey document the GLP-1-driven aesthetics boom; a Needham survey of 250+ patients shows rising procedure intent), and returning to 2024 utilization would produce over $60M of free cash flow in three years. The GLP-1 shorts (SHAK, DPZ, EAT, HRL) keep working, while Natural Grocers (NGVC) is upgraded — its ~$100k-median-income customer is thriving, a third of its SKUs are supplements benefiting from GLP-1 behavior change, and the Sprouts readthrough is misplaced. WW (effectively 'a value-based care provider specializing in GLP-1s') and NGVC weights rise, funded by exiting Danone; LLY's orforglipron oral GLP-1 launches in 2026.

The life-sciences upcycle remains 'waiting for Godot' but the three supports strengthen: improved biotech valuations (XBI rebound, ICON's backlog stabilizing three quarters running), reshoring policy tailwinds (TMO and DHR both guiding above consensus with bullish supply-chain commentary), and AI in drug development (new NVDA partnerships with LLY and Verily). Citrini diversifies this sleeve for beta — trimming overweights, raising Avantor to equal weight after its sell-off, and adding Fortrea (FTRE) and Cryoport (CYRX) alongside TKNO and NOTV — with full basket weights published on Citrindex.

Key metrics
Key insights
#109 Thematic Primer Oct 17, 2025

Power Struggle: Natural Gas

The US natural gas market is flipping from fifteen years of price-insensitive supply-push to demand-pull: ~35 Bcf/d of high-confidence demand growth from LNG exports and AI/electrification power generation over the next decade collides with only 15-20 Bcf/d of supply growth at current strip prices, because the Permian's 'free' associated gas is oversubscribed (~7-10 Bcf/d left) and dry-gas producers need $4-5+/MMBtu to dispatch growth from deteriorating rock. With early-2030s NYMEX futures at ~$3.20 in steep backwardation, the curve is mispriced and the repricing gets more violent the longer it waits; Citrini positions in a broadened basket of deep-inventory upstream E&Ps (US and Canadian), midstream, utilities, compression, power-generation equipment and E&C, most trading at 8-12x earnings.

aineocloudenergyaienergygridenergywar
Positions & performance
+29.9%avg return67% win · 9 tracked · L +29.9%
PositionMentionsEntryLastReturn
LAGX:NYSE energygrid ArganT283.94Oct 17 '25568.92+100.4%
LGEV:NYSE energygrid GE VernovaIPT600.0Oct 17 '251014.75+69.1%
LBE:NYSE energygrid Bloom EnergyISPT111.5Oct 17 '25188.18 +68.8%
LLNG:NYSE energywar Cheniere EnergyIPT218.96Oct 17 '25269.72+23.2%
LKMI:NYSE energywar Kinder MorganIPT27.38Oct 17 '2532.86+20.0%
LWMB:NYSE energywar Williams CompaniesIPT62.46Oct 17 '2570.79 +13.3%
LSRE:NYSE energygrid SempraAT91.29Oct 17 '2591.25 -0.0%
LEQT:NYSE energywar EQTPT54.08Oct 17 '2553.03-1.9%
LCRK:NYSE energywar Comstock ResourcesT17.0Oct 17 '2513.0 -23.5%
Non-US / no priceENR:XETRA energygrid
Also watchingFANG:NASDAQ energywar D:NYSE energygrid ETR:NYSE energygrid TRP:TSX energywar XOM:NYSE energywar 1605:TSE energywar IREN:NASDAQ aineocloud SEI:NYSE energyai
Full summary 599 words

Published October 17, 2025 as a part-primer/part-thesis sequel to the Stargate field trip, this report argues 'AI eats electrons, electrons eat gas' — and the natural gas market is at a structural inflection. For fifteen years, shale drillers and Permian associated gas overwhelmed the market with price-insensitive supply, training investors to assume cheap gas forever. Now Appalachia has plateaued, dry-gas producers demand economic returns, and the Permian's associated-gas deluge is in its final innings — just as two demand walls rise: the largest LNG export buildout in history and power generation for data centers, onshoring and electrification. Citrini quantifies ~35 Bcf/d of high-confidence demand growth over the next decade (a fuller view approaches 70 Bcf/d, a 70% increase on current production) versus just 15-20 Bcf/d of supply growth at current NYMEX forwards, with early-2030s futures at ~$3.20/MMBtu in steep backwardation — a curve deemed self-defeating, since cheap-forever strip pricing keeps new gas-demand projects penciling.

The demand section details both engines. Data centers consumed ~17GW of US electricity in 2022 and could need 130GW (~12% of US demand) by 2030; PJM credits gas at ~90% of nameplate versus far less for solar-plus-storage, and Transco Zone 6 hit $97/MMBtu in a January 2025 cold snap. GE Vernova signed 9GW of Q2 2025 turbine orders with a 29GW backlog plus 25GW of slot reservations — ~55GW, enough to burn 6-9 Bcf/d — and reconstructed turbine delivery schedules imply ~1 Bcf/d per year of new gas demand for a decade (Sam Altman's '1GW of compute per week' would mean up to 7 Bcf/d annually). Examples span Stargate's simple-cycle plant, Meta's 5GW Hyperion (sited at the crossroads of four pipelines, with ~0.3 Bcf/d of Entergy generation being permitted), Williams' Project Socrates, EQT's agreement to supply nearly 1.5 Bcf/d to two planned Pennsylvania power plants, and Bloom Energy fuel cells running on gas. On LNG: ~14 Bcf/d of operating export capacity will more than double; the Trump administration approved ~8 Bcf/d of new FIDs this year (with ~3.5 more expected) — more than in Biden's entire term — and large developers aspire to another ~40 Bcf/d (~300 MTPA), implying $260-340B of liquefaction capex.

The supply section attacks the consensus crutch that 'the Permian will take care of it.' Permian gas is a byproduct of oil drilling: with US onshore oil likely peaking (Diamondback's CEO says production has peaked; frac crews down ~15-20%), only ~7-10 Bcf/d of associated growth remains, gas is just ~5-7% of Permian operators' cash flow, and incenting gas-directed Permian drilling would take >$6/MMBtu. Dry-gas plays are the only on-demand growth source, but trigger prices have risen: ~$4.00/MMBtu for maintenance and $5+ for growth, per executive quotes from Aethon ('probably starts with a $5-handle'), Expand Energy ($3.50 marginal breakeven) and Comstock (~3 years from legacy Haynesville inventory exhaustion; can't reach 20 Bcf/d 'even at $6'). Enverus shows the Haynesville with ~6 years and the Marcellus <10 years of 'good' inventory by 2030, full-cycle Appalachian costs exceed $3/MMBtu with Mountain Valley Pipeline transport, and recurring Transco basis blowouts show regional molecule competition already emerging.

Positioning: the January natural gas basket (construction-tilted; top weight AGX doubled YTD) is broadened up the supply chain now that Citrini has conviction on the commodity itself — adding US and Canadian E&Ps with deep inventory, midstream, regulated utilities, compression, power-gen equipment and E&C, most trading at 8-12x earnings versus large-cap tech at 8-12x sales. The invalidator is explicit: if strip prices near $3.35 could really summon the needed supply, the thesis fails — but geology, inventory exhaustion and producer discipline argue the repricing only grows more violent with delay.

Key metrics
Key insights
#108 Macro Memo Oct 12, 2025

Macro Memo: Red October

October's tariff flare-up (China's rare-earth export controls, Trump's 100% tariff threat) is escalation-to-negotiate, not the end of the bull market: both sides will repeatedly go to the brink and seek off-ramps, constrained by debt, demographics, recession risk, midterms and defense. Meanwhile the K-shaped economy keeps 'slowing without breaking' — private data show deteriorating jobs during the shutdown data blackout — which supports continued Fed cuts, while the AI bull market at 77% above its 10-year moving average is still well short of the 100-120%+ extremes that marked 1929, 1987, 2000 and Japan 1989. Citrini holds course: rare earths as a fiscal-subsidy watchlist trade (+193% in 5 months), tactical index puts as October insurance, and vigilance on emerging credit cracks (Tricolor, First Brands, subprime auto).

airare-earthaisemiindexbondsindexus
Positions & performance
-36.6%avg return0% win · 2 tracked · L -8.1% · S -65.2%
PositionMentionsEntryLastReturn
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF90.57Oct 13 '2583.25-8.1%
SSMH:NASDAQ aisemi VanEck Semiconductor ETF339.75Oct 13 '25561.19-65.2%
Non-US / no priceSPX:NASDAQ indexus
Also watchingNEO CN SOLB:EURONEXT airare-earth UURAF:NASDAQ airare-earth MP:NYSE airare-earth
Full summary 567 words

This October 12, 2025 Macro Memo, published into the sell-off triggered by China's October 9 rare-earth export controls and Trump's retaliatory threat of 100% tariffs, opens by restating Citrini's macro priors: a K-shaped economy where the lower-income cohort struggles, a secular AI capex cycle roughly halfway done driving index returns (the 'Macroeconomic Ouroboros' of wealth-effect-driven spending), Fiscal Primacy/Dominance meaning the administration will do whatever it takes to support asset prices into the midterms (tariff-refund checks, lifting GSE MBS caps), and a tariff view distinct from 'TACO': Trump will repeatedly bring markets to the brink, and each episode carries real risk weighed against constraints of Debt, Demographics, Recession-Risk, Midterms and Defense.

With the government shutdown blacking out official data, private sources still show 'slowing without breaking': ADP job growth has printed two negative months (the latest the biggest in two years), the Dallas Fed estimates breakeven job growth has fallen to ~30k/month (others say ~10k) due to a smaller labor force, hire/quit rates are at decade lows, Indeed job postings keep falling below Waller's 4.5% threshold, and wage growth for job switchers and new hires has turned negative in real terms. Inflation-wise, the 'integer problem' of rent (wages, not wealth, pay most rents) anchors services inflation while goods prices rebound; 1-year and 5-year inflation swaps have declined and the bond market prices at least two more 25bp cuts. On China, Citrini rejects theories that Beijing timed controls to 'pop the AI bubble,' seeing instead formalized tit-for-tat strangleholds ahead of the expected Trump–Xi APEC meeting, with resolution likely after China's October 20-23 plenum.

The rare-earths section is both victory lap and warning. The May watchlist is up +193% in roughly five months; highlighted names include Neo Performance Materials (2k tonnes scaling to 5k, plans for 20k; 2k tonnes ≈ $20M EBITDA), Solvay (claims the only ex-China capacity to distill all 17 REEs from any ore, potentially 30% of European demand) and Ucore (Rapid5X tech claiming 3-10x processing speed in a third of the space). But Citrini stresses these are macro/fiscal-subsidy trades, not fundamental ones — rare earths are abundant, low-margin and polluting; the US imported only $170M of REEs last year; the defense angle is overstated (110 F-35s consume ~50 tonnes versus 10,000 tonnes of annual US demand, mostly EVs); Japan already cut China reliance from 90% to 60%. The basket becomes a broader watchlist since government picking of winners means many projects never materialize (MP's limited heavy-REE refining is flagged).

On the 'AI bubble' question, Citrini's yardstick — % above the 10-year moving average — shows the four great tops (1929, 1987, 2000, Japan 1989) all occurred >100% above trend with 120% the lowest common threshold; the S&P 500 sits at 77% (8150 would mark 120%), so mania comparisons are premature. New risks get flagged: the Tricolor (Sept 10) and First Brands (Sept 29, ~$2B vanished) collapses, subprime auto ABS spreads +30bps, repossessions at 2009 levels, Carvana's 2023-vintage ABS losing at twice rating-agency expectations, opaque private credit, and a crypto liquidation cascade with an estimated $20-40B of mostly-retail losses. Trades barely change: sized-up SMH January 2026 puts and new SPX November puts as insurance ('October is a minefield... would rather burn put premiums'), the SOFR H6H7 flattener, remaining long TLT December 95 calls (half sold in September), and abandoning the USDJPY short given Takaichi's pro-growth agenda — while reiterating this is a correction within a continuing bull market.

Key metrics
Key insights
#107 Field Trip Sep 28, 2025

Stargate: A Citrini Field Trip

Citrini sent a drone (with Hunterbrook Media) to OpenAI's Stargate site in Abilene, Texas to physically verify the AI datacenter buildout, and concluded the scale — eight 'ludicrous buildings' totaling ~4M sq ft and 1.2GW, a footprint the size of lower Manhattan, one of tens-to-hundreds of similar megaprojects — makes the industrial supply chain around the data hall the next leg of the trade. Because reliability trumps everything, these sites run on natural gas (simple-cycle turbines available in 12-18 months vs 5+ years for combined cycle and 10+ for nuclear), and with >30 Bcf/d of demand chasing ~10 Bcf/d of 'free' Permian gas growth, gas prices must move structurally higher. The actionable takeaway is 'more power, more natural gas, more thermal management and more construction': a 50-name high-confidence (plus 200 low-medium) beneficiary list across power, cooling, MEP, building envelope, fiber and construction services, with EQT added to the portfolio.

aiopticalairobotaisemiconsumertrainingenergyaienergygridenergywar
Positions & performance
-2.6%avg return0% win · 1 tracked · L -2.6%
PositionMentionsEntryLastReturn
LEQT:NYSE energywar EQTPT54.46Sep 29 '2553.03-2.6%
Also watchingVRT:NYSE energyai ETN:NYSE energygrid SU:EURONEXT energygrid ABBN:SIX airobot SIE:XETRA energygrid GEV:NYSE energygrid CAT:NYSE energygrid POWL:NASDAQ energygrid PRY:BIT energygrid COMM:NASDAQ aisemi GLW:NYSE aioptical BDC:NYSE aisemi DY:NYSE energygrid CIEN:NYSE aioptical LITE:NASDAQ aioptical COHR:NYSE aioptical ANET:NYSE aisemi MOD:NYSE energyai MTRS:OMX energyai TT:NYSE energyai CARR:NYSE energyai SPXC:NYSE energyai 6371:TSE energyai DOV:NYSE energyai XYL:NYSE energygrid PNR:NYSE energygrid VIE:EURONEXT energygrid KMI:NYSE energywar ATO:NYSE energygrid WMB:NYSE energywar TRP:TSX energywar MTRX:NASDAQ energygrid GTLS:NYSE energygrid WRT1V:OMX energygrid PRIM:NYSE energygrid PWR:NYSE energygrid EME:NYSE energygrid ACM:NYSE energygrid URI:NYSE energygrid AHT:LSE energygrid HRI:NYSE energygrid WSC:NASDAQ energygrid DE:NYSE airobot 6031 JP UTI:NYSE consumertraining TIC:NYSE energygrid
Full summary 570 words

Published September 28, 2025, this 'field trip' report is Citrini's ground-truth verification of the AI datacenter thesis it first laid out in May 2023. Partnering with investigative outlet Hunterbrook Media, the firm flew drones over the Stargate site in Abilene, Texas, documenting how bare dirt a year earlier had become eight buildings under construction — ~4 million square feet and 1.2GW of capacity by mid-2026, '600 football fields' of cables, transformers, chillers, switchgear and 200,000 tons of equipment consuming Seattle-scale electricity, with waste-heat plumes visible on weather radar. The complex's footprint approximates lower Manhattan, and Meta's Louisiana Hyperion is even larger; five more Stargate sites are already permitted or under construction, alongside xAI's Colossus 2, Microsoft's Fairwater, Amazon's Pennsylvania project and Google/Anthropic's Project Rainier. The framing: 'tech' has become capital-intensive again for the first time in a quarter century — the largest US industrial investment cycle since World War Two.

The biggest insight is energy. Stargate's behind-the-meter plant uses ten simple-cycle gas turbines (5x 38MW Solar Titan 350 from Caterpillar, 5x 34MW GE LM2500) licensed for 361MW of continuous 24/7 output — because combined-cycle turbines have 5+ year lead times, nuclear is 10+ years away, and simple-cycle units ship in 12-18 months; efficiency doesn't matter when you take what you can get. xAI's Memphis site runs 30+ turbines. Citrini builds a gas-demand forecast from turbine delivery schedules and FERC filings showing >30 Bcf/d of committed demand lined up against only ~10 Bcf/d of 'free' Permian associated-gas growth — the consensus 'the Permian will take care of it' is wrong, and captured flared gas would power only ~5% of the full ~5GW Stargate complex. EQT is reportedly negotiating fixed-price supply deals at ~$5/MMBtu, ~70% above Henry Hub spot — hyperscalers paying up for flow surety, the first time in shale history producers are compensated for dispatching growth. Meta's moves corroborate: legendary gas trader John Arnold joined its board, it is funding >2GW of Louisiana gas generation, and it formed power-trading arm Atem Energy ('Meta' backwards).

The report then walks each physical layer with named suppliers: transmission (a 200MW/138kV substation expanding to 1.2GW with a 345kV yard; ABB, Siemens, GE, Schneider as Tier 1, with Powell Industries' custom power control rooms and Prysmian's $118M medium-voltage cable contract; UPS lead times stretched to 18-24 months, pulling Tier 2 names like Mitsubishi Electric and Saft into orders); thermal management (39 cooling towers flanking each side of each building — 624 across eight buildings; Vertiv the clear leader, Schneider second, with Modine, Munters, Trane, Carrier, SPX, Daikin and water-treatment names Xylem/Evoqua, Pentair, Veolia); MEP systems; civil/structural (5-10 million sq ft of specialized insulated metal panels per major project); fiber/networking (Arista fabric, Ciena 400G/800G with Lumentum and Coherent lasers, Prysmian/CommScope/Corning/Belden cable, Dycom installation) for the moonshot of operating six campuses as a single logical data center; and construction services (CAT, Komatsu, Deere, United Rentals, Ashtead, Herc, WillScot, Primoris, Quanta, EMCOR, AECOM — plus commissioning by Acuren (TIC), Citrini's latest single-stock long, and Mistras).

Positioning: Citrini added EQT and will add more natural gas and gas-infrastructure exposure, publishing a spreadsheet of 50 high-confidence and 200 low-to-medium-confidence public beneficiaries, organized into six trackable Citrindex baskets (Power & Energy, Thermal, MEP, Civil/Structural, Fiber, Construction Services). The conviction: whether or not capacity is being overbuilt, 'it's going to get built' — and the power/infrastructure leg of the AI trade persists as long as these monuments to compute keep being funded.

Key metrics
Key insights
#106 Single Stock Sep 18, 2025

Single Stock Long Thesis: Acuren (TIC)

Acuren (TIC US) is a mispriced, multi-thematic toll road on the AI/infrastructure buildout: its core non-destructive testing business converts stressed, can't-go-offline infrastructure (data centers, grids, pipelines, aging power plants) into >90% recurring, mandated inspection revenue, and its opportunistic $1.7B acquisition of NV5 adds hyperscaler data-center MEP design, grid engineering, geospatial data and digital twins just as those businesses inflect. Because of SPAC stigma, misperceived cyclicality and merger complexity, the combined entity trades under 8x EBITDA versus peers at 11-30x; with Sir Martin Franklin running the proven APG playbook (guidance update, investor day, re-rating), Citrini sees 100-200% base-case upside and a path for shares to double or triple in 18-36 months.

aisemienergygridhealthtestingsaas
Positions & performance
-47.0%avg return0% win · 1 tracked · L -47.0%
PositionMentionsEntryLastReturn
LTIC:NYSE energygrid Acuren13.45Sep 18 '257.13-47.0%
Also watchingAPG:NYSE energygrid MG:NYSE energygrid TISI:NYSE energygrid SGSN:SIX healthtesting INTRK:LSE healthtesting ULS:NYSE aisemi LGN:NASDAQ energygrid WLDN:NASDAQ energygrid STN:NYSE energygrid ACM:NYSE energygrid TRMB:NASDAQ saas
Full summary 563 words

Citrini's first Single Stock Long Thesis in nearly a year (September 18, 2025) emerges from its AI-power research: as the buildout moves to greenfield data centers, the firm asks who benefits from the maintenance, testing and design layer, and lands on Acuren Corporation (TIC US) — an obscure name that came public via a UK-listed SPAC transferred to the NYSE, backed by Sir Martin Franklin, which in August completed a transformational 'merger of equals' with NV5 Global that doubled EBITDA. The report (with a companion slide deck) argues obscurity plus 'weirdness' — the same overhangs that once hid Vertiv, Celestica and AMSC — is masking an exceptionally high-quality, multi-thematic business.

Core Acuren is North America's second-largest non-destructive testing (NDT) provider: mandated, mission-critical inspection of pipelines, refineries, power plants and transport infrastructure using radiography, ultrasonics and phased array, performed without taking assets offline. Over 90% of revenue is recurring, the service costs customers under 2% of opex, the safety record shows 75% fewer incidents than industry average, and organic growth runs high-single-digit versus ~5% for the industry and low-single-digits for subscale peers Mistras and Team Inc, at high-teens margins versus their 6-12%. The demand kicker is the ASCE's estimate that the US needs $9.1 trillion of infrastructure maintenance against $5.4 trillion of funding — a $3.7 trillion gap — while AI load forces utilities to run aging plants harder and defer retirements, converting one-time decommissioning into years of premium recurring inspection. Yet TIC has traded at 4-8x consensus EBITDA versus peers SGS, Intertek and UL Solutions at 11-18x, held back by SPAC stigma and a misread of cyclicality (revenue barely declined in 2008, 2015-16 and 2020; the recent softness was deliberate exits of low-margin contracts while EBITDA margins expanded 100bps+ to 17%).

NV5, acquired for just $1.7B (<10x EBITDA) while peers Willdan, Stantec, AECOM and Trimble trade at 15-30x, brings three engines: infrastructure engineering for electric/water utilities (~50% of revenue), geospatial data (~30%), and mission-critical building consulting (~20%). NV5 works with every major hyperscaler on liquid cooling and power distribution, has surpassed 1GW of global data-center design/commissioning, unlocked ~300MW of additional computing capacity for clients in 2024, and management targets growing the sub-$50M data-center unit to $400M+ annually. Its geospatial moat (100,000+ miles of transmission scanned yearly) underpins digital twins and future industrial robotics — maps and predictive maintenance that convert TIC's model from selling 'testing' to selling 'outcomes.' Notably, MEP peer Legence, with roughly NV5's 2024 EBITDA, just IPO'd near $5B — versus the entire combined TIC at just over $3B and under 8x EBITDA.

The combination math: if NV5 hits its pre-deal $1.6B 2028 revenue target and legacy TIC grows 8% annually with 20% margins (co-chairman Robert Franklin: 'no reason' combined margins can't exceed 20%), TIC generates $600M+ of 2028 EBITDA — ~30% annualized growth and 20%+ above consensus, which implausibly embeds legacy TIC revenue declining 20%+ through 2028. The APG analog (another Franklin SPAC that returned 250% in three years post its Chubb acquisition and popped 40%+ after its investor day; TIC's CFO came from APG) frames the catalyst path: November guidance update, an investor day, new analyst coverage and deleveraging. Base case is a re-rate to peers' mid-to-high-teens multiples for 100-200% upside; the bull case with revenue synergies makes shares worth multiples of current levels. TIC joins the Citrindex as a standalone long with a projected double-to-triple over 18-36 months.

Key metrics
Key insights
#105 Macro Memo Sep 03, 2025

Macro Memo: Summer is Over

The US economy is slowing without breaking — labor demand is sagging (more unemployed than job openings for the first time since August 2021) while tariff revenue (~$360B annualized) is quietly halving the primary deficit and supporting bonds. Citrini's key insight is that the Trump administration cares less about Treasury yields than mortgage rates ahead of the 2026 midterms, and will likely lift post-GFC caps on GSE MBS holdings — unleashing up to $1 trillion of quasi-QE MBS demand that compresses mortgage spreads without touching the Treasury market. That favors mortgage originators like RKT and long-duration bonds, while seasonal September/October fragility argues for a tactical equity short and long natural gas on electricity-price inflation.

financefintechindexbonds
Positions & performance
-14.2%avg return0% win · 2 tracked · L -14.2%
PositionMentionsEntryLastReturn
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF86.57Sep 03 '2583.25-3.8%
LRKT:NYSE financefintech Rocket CompaniesIT17.88Sep 03 '2513.49 -24.6%
Full summary 486 words

This September 3, 2025 Macro Memo opens by scoring the prior memo's predictions (slowing-not-breaking economy: yes; flat inflation: half right; Fed openness to cuts: yes) and sets expectations for a cyclical slowdown, a September Fed cut, seasonal equity turbulence, and a Trump administration push to lower mortgage rates via GSE privatization and deregulation. The labor-market check-in shows big downward BLS payroll revisions converging on the ADP series (which Citrini now treats as the more reliable gauge), a job-opening rate back under the 4.5% threshold that historically precedes rising unemployment, more unemployed people than job openings for the first time since August 2021, and Fed Governor Waller — Citrini's and the betting markets' favorite to succeed Powell — publicly emphasizing labor weakness ahead of September 8 benchmark revisions. Continued claims running well above prior years signal 'nobody fired, nobody hired' turning into longer joblessness spells.

On fiscal and bonds, the memo argues tariffs function as a de facto consumption/VAT tax bringing in ~$360B annualized against a likely ~$1.7T FY2025 deficit; the primary deficit is roughly 2% of GDP (not the '8% recession-level deficit' doomers cite) and tariffs cut that underlying gap in half — so a Supreme Court overturn of IEEPA tariffs would ultimately be bond-negative. Secularly, the 'four Ds' (Demographics, De-globalization, Defense, Debt) put a floor under inflation and long rates, explaining blowing-out ultra-long global yields even as the 10Y stays anchored near 4.2%.

The centerpiece is the 'housing unlock' thesis: with affordability the administration's midterm cornerstone and Bessent floating a national housing emergency, Citrini believes Treasury/FHFA plan to remove post-GFC caps on GSE MBS purchases — at the extreme freeing up to $1 trillion of incremental MBS demand, compressing mortgage spreads with 5x GSE balance-sheet leverage while boosting GSE ROEs, all within existing Treasury/FHFA authority. This is 'quasi-QE' delivered through housing credit that bypasses the Treasury market entirely, timed to stimulate exactly one year before the midterms. Housing data support the need: new single-family sales contracting YoY, permits at post-lockdown lows, inventory back at pre-pandemic levels, and Case-Shiller ticking down — hence a preference for mortgage originators (RKT) over homebuilders.

The memo closes with trades built on this backdrop plus an extended riff on March/September/October seasonality (September is the only month with a negative long-run average US equity return; a 'market paranoia index' of top-20 SPX declines and scored crises clusters in those months, driven by fiscal-year-end policy brinkmanship and thin post-summer liquidity). Positions: long natural gas NGZ5 at 3.945 (stop 3.545, target 5) on electricity-price inflation from LNG exports and AI compute; replace the U5H6H7 STIR fly with an H6H7 flattener (short at -55bps, target -90bps) betting Powell's successor cuts more; stay long TLT December 95 calls (cost 0.40) since compressed bond vol resolves violently when yields fall; and short ES at 6450 (stop 6525, target 6240, ~3:1) for a tactical September–October correction — explicitly not a call that the bull market is over.

Key metrics
Key insights
#104 State of the Themes Aug 18, 2025

State of the Themes: Long GOOGL, Asian Outperformance and the Age of Virality

Citrini's quarterly State of the Themes argues that 2025's thematically dispersed market rewards selectivity: GPT-5's incremental improvement confirms AI is shifting from infrastructure builders to implementers, which favors Google (research depth, TPUs, ad monetization at 20x forward P/E) and data-and-distribution owners like fintech super-apps, while the remaining infrastructure upside sits in specific bottlenecks (interconnects, memory, AMD) and cheap Taiwanese suppliers. Simultaneously, fiscal policy is the other dominant driver — the AI Action Plan and OBBB tax provisions subsidize the US buildout, Korea's 'KOSPI 5000' governance push warrants broad long exposure, and beaten-down solar offers asymmetric recovery. With rate cuts imminent and SMID caps deeply underowned, Citrini re-launches its Small Themes basket around rate-sensitive names and 'virality'-driven retail winners, while pressing high-conviction healthcare (STAX) and GLP-1 second-order positions.

aimemoryaiopticalairobotaisemiconsumerautoconsumerhealthconsumershoppingdefensedroneenergygridenergynuclearfinancefintechhealthGLPhealthhealthsenior-homemag5saasspace
Positions & performance
+33.9%avg return59% win · 41 tracked · L +34.5% · S +21.1%
PositionMentionsEntryLastReturn
LMU:NASDAQ aimemory MicronISAPT123.55Aug 18 '25920.95+645.4%
LTER:NASDAQ aisemi TeradyneISPT110.41Aug 18 '25349.92+216.9%
LAMD:NASDAQ aisemi AMDISPT176.14Aug 18 '25521.95+196.3%
LEWY:NYSEARCA aimemory iShares MSCI South Korea ETFIS72.8Aug 18 '25162.96+123.8%
LALNT:NASDAQ airobot AllientI44.56Aug 18 '2586.78+94.7%
LCRDO:NASDAQ aisemi CredoISPT118.74Aug 18 '25213.15+79.5%
LLLY:NYSE healthGLP Eli LillyIPT698.05Aug 18 '251196.03+71.3%
LBVS:NASDAQ health Bioventus7.18Aug 18 '2511.8+64.3%
LGOOGL:NASDAQ mag5 AlphabetSPT203.5Aug 18 '25319.74+57.1%
LALAB:NASDAQ aisemi Astera LabsIST186.43Aug 18 '25291.58+56.4%
LNXT:NASDAQ energygrid NextrackerT67.7Aug 18 '25103.73 +53.2%
LCGNX:NASDAQ airobot CognexI43.01Aug 18 '2562.05+44.3%
LRRX:NYSE airobot Regal Rexnord146.66Aug 18 '25210.87 +43.8%
LAPH:NYSE aisemi AmphenolISAPT111.06Aug 18 '25149.28 +34.4%
LTOI:NASDAQ health The Oncology InstituteA4.04Aug 18 '255.39+33.4%
SHIMS:NYSE health Hims & HersISA45.1Aug 18 '2530.24 +32.9%
LMOB:NASDAQ defensedrone Mobilicom4.12Aug 18 '254.89+18.7%
LINSG:NASDAQ aisemi Inseego8.81Aug 18 '259.79+11.1%
SNVO:NYSE healthGLP Novo NordiskISP53.75Aug 18 '2548.77+9.3%
LNU:NYSE financefintech Nu HoldingsI13.33Aug 18 '2514.53 +9.0%
LZETA:NYSE saas Zeta Global19.71Aug 18 '2520.74 +5.2%
LPAGS:NYSE financefintech PagSeguroA9.06Aug 18 '259.38 +3.5%
LURA:NYSE energynuclear Global X Uranium ETF39.2Aug 18 '2540.32 +2.9%
LENPH:NASDAQ energygrid EnphaseIAT35.77Aug 18 '2536.7+2.6%
LAPP:NASDAQ saas AppLovinIPT438.54Aug 18 '25412.73 -5.9%
LFSLR:NASDAQ energygrid First SolarIPT219.33Aug 18 '25202.82-7.5%
LEOLS:NASDAQ health Evolus6.69Aug 18 '256.18 -7.6%
LKSPI:NASDAQ financefintech KaspiI93.67Aug 18 '2585.79-8.4%
LDLO:NASDAQ financefintech DLocal15.25Aug 18 '2512.69-16.8%
LMETA:NASDAQ mag5 MetaISPT767.37Aug 18 '25593.87 -22.6%
LMELI:NASDAQ airobot MercadoLibreISAP2364.01Aug 18 '251819.74 -23.0%
LRKT:NYSE financefintech Rocket CompaniesIT17.83Aug 18 '2513.49 -24.3%
LAIRS:NASDAQ health AirSculptA6.32Aug 18 '254.61-27.1%
LXPOF:NYSE consumerhealth Xponential FitnessA9.07Aug 18 '256.32-30.3%
LCVRX:NASDAQ health CVRxA6.87Aug 18 '254.74-31.0%
LARRY:NASDAQ energygrid Array TechnologiesI8.42Aug 18 '255.32-36.8%
LAMSC:NASDAQ energygrid American SuperconductorS53.46Aug 18 '2530.52-42.9%
LSTIM:NASDAQ health NeuroneticsA3.54Aug 18 '251.81 -48.9%
LXGN:NASDAQ health Exagen9.75Aug 18 '254.4 -54.9%
LWW:NASDAQ health WW InternationalA30.77Aug 18 '2513.85 -55.0%
LSNWV:NASDAQ health SANUWAVE Health38.36Aug 18 '258.61-77.6%
Non-US / no price700 HK ABBN:SIX airobot
Also watchingNVDA:NASDAQ aisemi CLS:NYSE aisemi LITE:NASDAQ aioptical CIEN:NYSE aioptical COHR:NYSE aioptical CSCO:NASDAQ aisemi ANET:NYSE aisemi FFIV:NASDAQ saas MRVL:NASDAQ aisemi AVGO:NASDAQ aisemi 4966:TWSE aisemi MTSI:NASDAQ aioptical SMTC:NASDAQ aisemi CCOI:NASDAQ saas INTC:NASDAQ aisemi SNBR:NASDAQ consumershopping ANGI:NASDAQ saas HVT:NYSE consumershopping FTDR:NASDAQ consumershopping TILE:NASDAQ consumershopping DORM:NASDAQ consumerauto ARHS:NASDAQ consumershopping ENSG:NASDAQ healthsenior-home CTRE:NYSE healthsenior-home BKD:NYSE healthsenior-home ADUS:NASDAQ health ABVX:NASDAQ health ESPR:NASDAQ health FEIM:NASDAQ space
Full summary 566 words

This August 2025 quarterly review sweeps across the entire CitriniResearch coverage universe, framing 2025 as one of the most thematically dispersed years in memory — unlike 2024's single AI theme — spanning drones/electronic warfare, EU defense, robotics, and Trump-policy trades, while warning that rapid-fire thematic markets produce misfires like 5G, IoT and the Digital Asset Treasury / quantum computing fads. The core AI judgment: GPT-5's release was 'much more incremental than promised,' confirming the transition from Phase 1 infrastructure to Phase 2 implementers — 'we are less focused now on companies building AI and more focused on companies using it' — with hyperscaler capex effectively committed through 2028 and inference the real bottleneck.

Within AI, Citrini makes the case for Google: AGI needs another research S-curve breakthrough (Google spends ~half of GBDM resources on pure research), Gemini went 2.0 to 2.5 in six months vs OpenAI's 24+ months for GPT-4 to GPT-5, TPUs are the only mass-produced Nvidia-competitive chip, and Google earned $200B in search/video ad revenue versus OpenAI's under $4B consumer revenue — yet GOOGL trades at just ~20x forward P/E; a $5-10T AGI call option at 50% probability implies $1T+ of unpriced value. Selectivity in the datacenter has worked: AMD returned 127% since 4/8/25 versus 87% for NVDA and 64% for SMH, driven by memory-bound inference and MI300X's HBM advantage; optical (LITE, CIEN, COHR), memory (MU) and interconnects (CRDO, ALAB, APH) held through drawdowns. Deepseek's R2 is delayed by failed Huawei training chips. Taiwan offers the biggest valuation gap — JPC Connectivity at 13.6x EV/LTM EBITDA vs Amphenol's 28x with identical ~21.7% 3-year sales growth; Lite-On at 10.7x EV/EBITDA vs MPWR at 40x — and small-cap Inseego could hit $200M 2026 revenue at under 0.8x sales.

In Payments, the AI-implementation lens leads to EM super-apps: Kaspi (KSPI, 'Central Asia's Tencent') at 8.3x forward earnings with 61% YoY revenue growth is added along with NU and MELI, while COIN and TBBK exit. In Fiscal Primacy, the July AI Action Plan earmarks ~$50B for fabs, grid and datacenter fast-tracking (with history suggesting each public dollar crowds in 3-7 private), OBBB's expensing rules create a ~$210M year-one federal tax shield per $1B of qualifying equipment and raise the semiconductor manufacturing credit from 25% to 35%, and tariffs generate ~$360B annualized revenue funding the fiscal winners. Citrini swaps nuclear (URA) for solar asymmetry — adding FSLR, ARRY, NXT and ENPH after Treasury Notice 2025-42 — and goes long EWY on Korea's export strength plus the 'KOSPI 5000' governance re-rating.

Robotics tightens around the 'muscle, nerves and power' of embodied AI (adding CGNX, exiting SYM, AMZN, BSY, JUN3), highlighting the Regal Rexnord–ABB 7th-axis cobot partnership and Teradyne's confirmed Vulcan contract. Electronic warfare profits are trimmed in small-cap drones (UMAC, RCAT) while Mobilicom (MOB) is kept. Healthcare presses the 'STAX' quartet to maximum weights: XGN at 3x revenue (35% discount to VCYT), STIM under 2x revenue (75%+ discount to Brainsway), TOI set to grow 25%+ in 2026 versus 16% consensus with M&A comps implying $20-25+/share, and AIRS worth $14+ at peer 15x EBITDA. GLP-1 second-order adds go to WW (under 5x EBITDA, 60%+ EBITDA growth), LLY, XPOF and EOLS. Finally, the Small Themes basket returns — mortgage originators (RKT), elder care REITs, home-furnishing housing plays, and a new 'Virality' retail basket (American Eagle-style social-marketing winners, ZETA, APP) — plus the first community-picks results: longs +11.4%, shorts -7.8% in one month.

Key metrics
Key insights
#103 Macro Memo Jul 27, 2025

Macro Memo: The Powell Struggle

The US economy will keep slowing without breaking while disinflation persists and tariff inflation stays modest and transitory, so the path is toward lower rates. The key dynamic is 'The Powell Struggle': Trump's failed public pressure on Powell is morphing into a strategic fiscal-monetary convergence (tariff truces, back-loaded spending, disinflationary regulatory nudges) that manufactures conditions justifying cuts, opening the door to easing and gradually lower long-term yields, which would eventually unlock housing. Trade tensions continue taking off-ramps (EU/Japan 'deals' as strategic acquiescence; US-China a stabilized strategic divorce). Markets risk either a seasonal late-summer correction or a 1998-style melt-up into a dotcom-like bubble phase. Positioning leans into the obvious rather than fading extremes: SOFR curve spreads betting the next Fed chair cuts more aggressively, long TLT calls as a hedge, and watchlist interest in agency mREITs.

airare-earthfinancefintechindexarindexbondsindexbrindexclindexmx
Positions & performance
+5.1%avg return67% win · 3 tracked · L +5.1%
PositionMentionsEntryLastReturn
LAGNC:NASDAQ financefintech AGNC Investment9.68Jul 28 '2510.59+9.4%
LNLY:NYSE financefintech Annaly Capital ManagementIT20.68Jul 28 '2522.57 +9.1%
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF85.87Jul 28 '2583.25-3.1%
Also watchingMP:NYSE airare-earth TMC:NASDAQ airare-earth RKT:NYSE financefintech UWMC:NYSE financefintech EWW:NYSE indexmx EWZ:NYSE indexbr ECH:NASDAQ indexcl ARGT:NYSE indexar
Full summary 701 words

Published July 27, 2025, 'Macro Memo: The Powell Struggle' opens with a scorecard: most prior calls played out (tariff inflation overstated, services disinflation overwhelming goods inflation, resilient economy with a softening labor market, US-China taking off-ramps, rare earths as strategic leverage), though 'good news' Fed cuts haven't come yet and European FX/equity outperformance hasn't tapered. The upshot: the US economy keeps slowing without breaking, inflation stays flat-to-lower despite tariffs, and 'The Powell Struggle' leads to fiscal-monetary convergence as tariff uncertainty resolves, the Fed signals openness to cuts, and falling long yields eventually unlock housing.

The labor and economy check-in shows resilience masking softening: a 'nobody fired, nobody hired' dynamic with unemployment near cycle lows, but the recent-college-grad jobless rate at a ten-year high, job openings around the 4.5% threshold below which unemployment historically rises, and declining wage growth supporting Citrini's view that rent inflation stays contained. Bloomberg growth and inflation surprise indices turned negative in 2025, and the Atlanta Fed GDPNow points to trend-like Q2 growth, neither recessionary nor reaccelerating.

On trade, Citrini's constraint-based framework (analyzing incentives, especially Trump's) correctly forecast off-ramps. EU and Japan 'deals' (a 15% blanket EU framework except autos) are framed as strategic acquiescence given their reliance on the US defense umbrella and inability to coordinate as a bloc, the product of Trump's 'apply maximum pressure, create chaos, relieve pressure' tactic. US-China is an irreversible strategic divorce stabilized by mutual supply-chain leverage, with the tariff deadline extended 90 days and talks moving to Stockholm; Citrini cautions against mistaking detente for rapprochement. It notes its prior MP Materials (MP) and Metals Company (TMC) picks worked (MP re-rated sharply after the DoD became a large shareholder and Apple signed on as a customer) and recommends taking profit, expecting the truce period to be used to fortify vulnerabilities and any rare-earth sell-off to offer new entries. On inflation, tariffs are a regressive, one-time price-level adjustment, phased in gradually via higher prices or margin compression, not net inflationary given the service-based US economy.

The centerpiece is the Powell Struggle: the trajectory of rates is now shaped by the political economy around the Fed. Trump's public campaign (blaming Powell for 6%+ mortgages, firing rumors, name-checking the 1951 Treasury-Fed Accord) failed to move markets, so confrontation is morphing into coordination via a tariff truce, quieter/back-loaded fiscal spend (OBBB), and disinflationary regulatory nudges (environmental waivers, biofuel credits). Two-year breakevens fell 30bp and the ten-year term premium fell ~20bp from May highs, giving the Fed cover. Dovish members like Waller argue for preemptive cuts (tariffs are one-off), though Citrini suggests Waller's dissent may also be the Fed 'circling the wagons' to give Trump a viable dovish successor option. The call: barring an inflation surprise, Powell opens the door to a September cut at the July FOMC or Jackson Hole; markets price ~1.75 cuts by year-end. Long yields should trend gradually lower regardless of who cuts, as long as inflation stays controlled. On markets, Citrini flags rich pricing and complacency (VIX under 15) plus seasonal August/September weakness, drawing striking parallels to the 1998 correction and recovery, and warns weak market breadth (weakest since late 1998) could mark the start of a dotcom-style 'bubble phase,' while noting margin debt build-up remains benign relative to 2000 and 2007.

Positioning leans into the obvious rather than fading extremes: a new SOFR U5H6H7 fly (selling H6) betting more cuts get priced into March 2026-27 than the nearer window, plus long TLT December 2025 95 calls as fairly-priced upside optionality and a hedge to the STIR play, expecting long yields to fall as cuts are anticipated. Watchlist items: agency MBS REITs (NLY, AGNC) which broke out on spread dynamics (Annaly GAAP NIM 1.04%, economic NIM ex-PAA 1.71%, prepay speeds low), best played on a mild bull steepener; and mortgage originators (RKT, UWMC) which need a 75-100bp rate rally or looser credit (MCAI above 110 or mortgage rates below 6%) before working. Existing positions: short EURUSD was stopped out (still sees a dollar rebound but timing hard); long palladium performed well, sold half above $1,300 with a $1,250 stop; and it exited the Long LatAm (EWW+EWZ+ECH) vs short Argentina (ARGT) trade after ~10% outperformance, flipping tactically bullish Argentina ahead of Milei's mid-terms.

Key metrics
Key insights
#102 Thematic Update Jul 24, 2025

GLP-1s: The Second Serving - Revisiting our GLP-1 Basket

GLP-1 obesity drugs have reached a tipping point of adoption, so the second-order effects Citrini predicted two years ago (which the market has now grown complacent about) are about to show up clearly on income statements. As a critical mass of patients has been on the drugs long enough, lagged effects create investable dislocations: aesthetic/cosmetic surgery demand is inflecting up (loose skin, 'Ozempic Face'), food/beverage consumption is shifting toward protein and away from junk/alcohol, and access/sustainability services and fitness benefit, while sleep-apnea, dialysis and diabetic-complication names face lagged headwinds. Among manufacturers, Eli Lilly is favored over Novo Nordisk on a superior, more durable pipeline. Citrini re-establishes its GLP-1 basket (9% of Citrindex) with longs on beneficiaries, shorts on losers, and selective manufacturer/supply-chain exposure, backed by detailed clinical-trial analysis.

airobotconsumerhealthconsumershoppinghealthGLPhealth
Positions & performance
+6.5%avg return55% win · 31 tracked · L +3.5% · S +10.2%
PositionMentionsEntryLastReturn
LESTA:NASDAQ health Establishment Labs43.15Jul 24 '2588.38+104.8%
LAPYX:NASDAQ health Apyx Medical2.37Jul 24 '254.5+89.9%
LUNFI:NYSE consumerhealth United Natural FoodsA27.52Jul 24 '2549.05 +78.2%
SWING:NASDAQ consumershopping WingstopIT299.63Jul 24 '25135.2+54.9%
SSHAK:NYSE consumershopping Shake ShackAPT133.72Jul 24 '2561.57 +54.0%
LLLY:NYSE healthGLP Eli LillyIPT805.43Jul 24 '251196.03+48.5%
LLTH:NYSE consumerhealth Life Time GroupAT29.09Jul 24 '2542.33+45.5%
SMDXG:NASDAQ health MiMedx Group6.85Jul 24 '254.26 +37.8%
LABBV:NYSE health AbbVieIPT190.83Jul 24 '25256.91 +34.6%
SNVO:NYSE healthGLP Novo NordiskISP70.73Jul 24 '2548.77+31.0%
SDPZ:NASDAQ consumershopping Domino's PizzaIPT476.34Jul 24 '25343.53 +27.9%
SRMD:NYSE health ResMedIPT273.5Jul 24 '25203.08 +25.7%
SINGR:NYSE consumershopping IngredionIT132.74Jul 24 '25101.45 +23.6%
LLWAY:NASDAQ consumerhealth Lifeway FoodsA25.92Jul 24 '2530.44+17.4%
SHRL:NYSE consumershopping HormelIT29.3Jul 24 '2526.05 +11.1%
SFMS:NYSE health Fresenius Medical Care26.76Jul 24 '2524.59+8.1%
LIFF:NYSE consumershopping International Flavors & FragrancesIAT75.88Jul 24 '2576.4 +0.7%
SYUM:NYSE consumershopping Yum! BrandsIPT145.83Jul 24 '25147.8 -1.4%
SQSR:NYSE consumershopping Restaurant Brands InternationalIA70.02Jul 24 '2572.47-3.5%
LATS:NYSE airobot ATS Corporation31.65Jul 24 '2526.42-16.5%
LATR:NYSE healthGLP AptarGroupIT161.82Jul 24 '25132.36-18.2%
LNGVC:NYSE consumerhealth Natural Grocers39.79Jul 24 '2530.01-24.6%
LAIRS:NASDAQ health AirSculptA6.29Jul 24 '254.61-26.7%
SEAT:NYSE consumershopping Brinker InternationalIT152.32Jul 24 '25195.44 -28.3%
SPBPB:NASDAQ consumershopping Potbelly12.64Jul 24 '2517.12-35.4%
LEOLS:NASDAQ health Evolus9.65Jul 24 '256.18 -36.0%
LXPOF:NYSE consumerhealth Xponential FitnessA10.62Jul 24 '256.32-40.5%
LSG:NYSE consumershopping SweetgreenSA14.29Jul 24 '256.0-58.0%
SDVA:NYSE health DaVitaIPT144.77Jul 24 '25235.44-62.6%
LWW:NASDAQ health WW InternationalA38.01Jul 24 '2513.85 -63.6%
LBRBR:NYSE consumerhealth BellRing BrandsI53.95Jul 24 '2513.07 -75.8%
Non-US / no priceLONN:SIX healthGLP PPGN:SIX healthGLP 4587:TSE health GALD:SIX health BN:EURONEXT consumershopping
Also watchingHIMS:NYSE health AHCO:NASDAQ health QIPT:NASDAQ health TFX:NYSE health ALUR:OTC health CNMD:NYSE health PHG:NYSE health GIS:NYSE consumershopping PEP:NASDAQ consumershopping 3933:HKEX healthGLP REGN:NASDAQ health SRRK:NASDAQ health
Full summary 585 words

Published July 24, 2025, 'GLP-1s: The Second Serving' revisits Citrini's third-ever thematic primer ('Upgrading from Overweight,' 2023), which argued GLP-1s would become ubiquitous like Lipitor or Viagra and drive the first downtick in US obesity in four decades, and that the biggest trade would be the second-order effects. Citrini exited the basket in November 2024 for a 75% gain over 14 months, fearing the market was front-running effects amid patent-cliff and compounding risks. Now it re-establishes the basket because adoption has hit critical mass (nearly 4% of US adults had a GLP-1 prescription at end-2024, likely 2-3x higher counting grey-market peptides and compounders), just as the market has become complacent that slower-moving second-order changes won't arrive.

On manufacturers, Citrini brings back Eli Lilly (LLY) as its favorite: tirzepatide has a longer runway before generics than Novo's semaglutide and fewer side effects, and at ~26x a conservative 2026 EPS the valuation is justified by tirzepatide alone at 15% share of a $125B market, with orforglipron, retatrutide and tablet economics 'for free.' The pipeline is detailed: orforglipron (oral) hit -7.9% weight at week 40 in ACHIEVE-1, retatrutide's 'triple-G' showed -24% weight (the category high-score), and bimagrumab+tirzepatide targets lean-mass preservation. Novo trades cheap 'for a reason,' partly due to worrying cagrilintide fatigue/depression signals on trial subreddits. The supply chain (autoinjectors/pens) benefits AptarGroup (ATR), Lonza, Polypeptide, Peptidream and ATS (backlog up ~40% YoY) as capacity constraints ease and orals emerge.

The heart of the report is second-order effects. Aesthetics: after an 18-month cyclical bust (a COVID-era boom-to-bust, misread as GLP-1 demand destruction), demand is inflecting; Google Trends turned positive YoY in January 2025 for the first time since 2022, and McKinsey found nearly two-thirds of post-GLP-1 aesthetic patients are new to the market. Airsculpt (AIRS) is the favorite (network can do $750M+ revenue at full utilization, path to 30% EBITDA margins, under 2x EBITDA), with Apyx (APYX), Establishment Labs (ESTA), and for injectables Galderma (GALD), Evolus (EOLS) and AbbVie (ABBV). Food & beverage: shorts on fast food (Brinker/EAT, Domino's/DPZ, Potbelly, QSR, Shake Shack, Yum, Wingstop) as 'funding shorts' against healthy-food longs (Natural Grocers/NGVC with 5.3% same-store traffic versus Sprouts' ~4%, plus UNFI, Lifeway/LWAY, BellRing/BRBR, Sweetgreen/SG), with additional pair shorts (Hormel, Ingredion) versus Danone and IFF. Access/sustainability: WW International (WW), post-bankruptcy with net debt cut to ~$300M (<3x EBITDA) and a GLP-1 telehealth platform now ~20% of revenue, trading under 4x 2024 EBITDA versus Hims at 6x revenue; plus fitness names Life Time (LTH, MIORA platform) and Xponential (XPOF, ~7x EBITDA versus peers north of 20x). Losers from lagged effects: adding shorts on ResMed (RMD, ~half the sleep-apnea device market), DaVita (DVA), Fresenius (FMS) and MiMedx (MDXG), as sleep apnea, kidney disease and diabetic-ulcer demand faces eventual GLP-1-driven decline plus reimbursement pressure.

The final, extensive section is a clinical/scientific review across 20+ companies and three innovation vectors (oral formulations, novel mechanisms like dual/triple agonists and amylin, and convenience/monthly dosing), including deep dives on Lilly's retatrutide (-24% weight, MASLD data, dose-dependent arrhythmia at 12mg), orforglipron, bimagrumab and eloralintide; Metsera (MTSR, MINT/HALO/MOMENTUM platforms, ~16-19 day half-lives for monthly dosing); Amgen's maridebart cafraglutide; and a raft of Chinese players (BrightGene's BGM0504 at 19.78% placebo-adjusted weight loss at 24 weeks, Innovent's Mazdutide as the first China-approved obesity GLP-1, United Labs' UBT251, Hengrui's HRS9531 at ~18% at 32 weeks). Citrini concludes weight-loss efficacy keeps climbing (early GLP-1s 5-10%, dual agonists 15-20%, next-gen 20%+) and that it will be discerning, favoring LLY and Innovent. Positioning: 9% of the Citrindex is put into the updated GLP-1 basket.

Key metrics
Key insights
#101 Robotics Jul 10, 2025

Robotics Update: Teradyne's Vulcan Win, China Supply-Chain Tour, and Basket Winners

The robotics supply chain is a secular growth story hidden inside cyclically depressed, auto-exposed suppliers, and Citrini's May primer thesis is playing out via three converging forces: a collapsing robot cost curve, VLA models finally giving robots a usable brain, and key suppliers trading at trough valuations. The report's headline reveal (with Hunterbrook) is that Teradyne (TER) supplies the Universal Robots arms behind Amazon's breakthrough Vulcan robot, a potentially catalytic contract on top of a cyclical rebound in TER's semiconductor-test business, implying large upside. A China supply-chain tour confirms rapid Chinese progress and a declining cost curve but a leading edge of autonomy still in the US, so Citrini favors non-China, IP-rich Western/Japanese suppliers with design-win proof. The basket is narrowed toward names converting real orders into booked revenue (sensors/LiDAR, power semis, warehouse bots, actuators) over prototype-stage OEMs.

aimemoryaiopticalairobotaisemidefensecomponentsenergyaienergygridsaas
Positions & performance
+76.2%avg return74% win · 19 tracked · L +76.2%
PositionMentionsEntryLastReturn
LICHR:NASDAQ aisemi Ichor HoldingsPT23.71Jul 10 '2594.0+296.5%
LTER:NASDAQ aisemi TeradyneISPT98.62Jul 10 '25349.92+254.8%
LUCTT:NASDAQ aisemi Ultra Clean HoldingsT25.02Jul 10 '2586.97 +247.6%
LTTMI:NASDAQ aioptical TTM TechnologiesST43.88Jul 10 '25123.71 +181.9%
LALNT:NASDAQ airobot AllientI39.03Jul 10 '2586.78+122.3%
LDCO:NYSE defensecomponents DucommunAP83.93Jul 10 '25177.44+111.4%
LCLS:NYSE aisemi CelesticaIS158.83Jul 10 '25318.24 +100.4%
LNVTS:NASDAQ energyai Navitas SemiconductorSA6.26Jul 10 '2510.92+74.4%
LSTM:NYSE aisemi STMicroelectronicsSP33.14Jul 10 '2553.45 +61.3%
LCW:NYSE defensecomponents Curtiss-WrightIT474.49Jul 10 '25743.83 +56.8%
LON:NASDAQ aisemi ONSemiIT59.52Jul 10 '2589.04 +49.6%
LJBL:NYSE aioptical JabilIST220.96Jul 10 '25312.59+41.5%
LOUST:NASDAQ airobot OusterIS24.46Jul 10 '2534.04+39.2%
LALGM:NASDAQ aisemi Allegro MicroSystems37.51Jul 10 '2546.03+22.7%
LSYM:NASDAQ airobot SymboticA47.81Jul 10 '2540.15-16.0%
LBSY:NASDAQ saas Bentley SystemsT56.68Jul 10 '2533.71 -40.5%
LPONY:NASDAQ airobot Pony.aiI12.89Jul 10 '257.13-44.7%
LAEVA:NASDAQ airobot AevaSA29.21Jul 10 '2514.85-49.2%
LINVZ:NASDAQ airobot Innoviz1.69Jul 10 '250.63 -62.6%
Non-US / no priceMELE:EURONEXT aisemi SENS:SIX aisemi SHA0 GY 2308 TT 7750:TWSE airobot JUN3:XETRA airobot AMS:SIX aisemi 6480:TSE airobot 6481:TSE airobot 6471:TSE airobot 000150:KRX airobot
Also watching9880:HKEX airobot TXN:NASDAQ aisemi IFX GY MRVL:NASDAQ aisemi AVGO:NASDAQ aisemi SXS:LSE airobot RBC:NYSE airobot 6268:TSE airobot 6963:TSE aisemi AEHR:NASDAQ aisemi ACLS:NASDAQ aimemory 090710:KRX airobot BYD:NYSE airobot CATL:NASDAQ energygrid
Full summary 640 words

Published July 10, 2025, 'Robotics Update' follows Citrini's May humanoid primer with three parts: a Hunterbrook Media investigation into Teradyne's (TER) hidden robotics upside, takeaways from a China supply-chain tour, and a review of robotics-basket winners. The framing reaffirms the primer's thesis that robotics is a secular growth story sitting inside cyclically depressed, auto-exposed suppliers, with three converging factors: a collapsing robot cost curve, VLA models giving robots a usable brain, and key suppliers at cyclical-trough valuations.

The Teradyne reveal is the centerpiece. Amazon's new Vulcan warehouse robot, billed as the first with a 'sense of touch' able to pick and stow at near-human speeds, uses arms made by Universal Robots, the Danish cobot maker Teradyne bought for $285M in 2015. Hunterbrook corroborated this via UR/Robotiq labels on Amazon materials and the physical proximity of Teradyne HQ and Amazon Robotics, and noted this was the first quarter since 2018 with no Teradyne insider selling. Napkin math: Amazon stows 14 billion items/year by hand and wants Vulcan to handle 80% (11.2 billion) at 300 items/hour, 20 hours/day, implying ~5,114 robots; at $150K-$250K each, ~5,000 units would be roughly $600M of hardware, and Citrini conservatively estimates $300-400M revenue for TER, adding roughly $1.00 to EPS as deployments scale. On the core business, Citrini argues TER's semiconductor-test segment (which saw peak-to-trough EPS decline over 50%) is inflecting up on auto-test reordering and HBM ramps, with secular tailwinds from edge AI, custom ASIC test (Marvell, Broadcom) and 2nm. Management guides $7.00-$9.50 EPS by 2028; Citrini thinks that's conservative, and using $11.00 EPS at a 20x average multiple implies a price target over $200 (a double), with a bull case near $400 (30x on ~$13 EPS).

The China tour (June 22-July 1, eleven companies) yields four takeaways. First, 'robot fever': dozens of Chinese firms (UBTech, Unitree, Agibot/Zhiyuan, plus Xpeng, Xiaomi) are building humanoid prototypes, driving A-share supplier run-ups. Second, on OEMs (body vs. brains): US leaders Tesla and Figure AI were repeatedly cited as global leaders in AI-integrated autonomy; UBTech pursues a full-stack solution but demos looked slow and it has revealed only one commercial purchase of 20 robots; Unitree offers impressive hardware (G1 humanoid as low as $16,000) but is remote-controlled with pre-wired motions and open-sources its AI rather than developing autonomy in-house. Citrini concludes 'humanoids are hard' and the leading edge of autonomy remains in the US (noting Tesla removed its Optimus head in June amid a production pause/redesign). Third, the supply chain: most components are still small-batch/samples for prototyping, with the most concrete scale-production signals from roller-screw and linear-actuator makers (Ningbo Shuanglin, Zhejiang XCC) building capacity for Tesla Optimus (each Optimus needs 14 linear actuators; Ningbo targeting 300,000 units/year). Fourth, final observations: despite weak domestic consumption, China's advanced-manufacturing pace and falling cost curve are impressive (a Pony.ai/PONY robotaxi ride cost under RMB20).

The performance review shows the market rewarding real orders over prototypes: sensors (especially LiDAR), power semis (SiC/GaN), and warehouse bots led. Sub-basket leaders include sensing/perception (Ouster/OUST shipping 4,700 sensors in Q1 25 with Q2 guidance $32-35M, Aeva, Innoviz, Allegro/ALGM sizing a >$10B humanoid sensor SAM for 2030-2035, Sensirion), contract manufacturing (Celestica, Jabil, Spectris which took a £5.6B KKR bid, TTMI), actuators favoring Western/IP names (Schaeffler/SHA0 selling full joint modules at ~€1,500/bot with only 18% China revenue, Duocommun, Curtiss-Wright, plus Japanese Nabtesco/Nippon-Thompson), motion control (Allient/ALNT up 72% since the Q1 call on its 'Simplify to Accelerate' restructuring, Delta, Syntec), warehouse automation (Jungheinrich, Symbotic/SYM with revenue up 40% to $550M and ~$22B backlog, Bentley/BSY), and wide-bandgap power (Navitas, Onsemi, Rohm, STM, plus subsystem suppliers Ichor/ICHR and Ultra Clean/UCTT, newly added July 1). Basket changes: closing BYD, Harmonic Drive, Ace Pillar, Deere, Zhejiang Rongtai, Metallus, CATL, Aurotek and China Leadshine; adding Japanese actuator names, Sensirion and Teradyne in sensing, Bentley and Jungheinrich in autonomy software, and adding to ALNT, SHA0, SYM and INVZ.

Key metrics
Key insights
#100 Thematic Primer Jun 23, 2025

The New WFH (War From Home): Missile Defense, Counter-UAS, Electronic Warfare, and Surveillance

Modern warfare has hit an inflection point ('War From Home'): cheap drones and long-range strikes let under-resourced actors inflict asymmetric damage on great powers, forcing a massive fiscal realignment toward defense in the US and NATO. The FY2026 US defense budget blueprint broke $1 trillion for the first time, and within it spending is shifting disproportionately toward procurement and technology, specifically the emerging vectors: missile intercept (including a space-based 'Golden Dome'), counter-unmanned aerial systems, electronic warfare, and ISR/surveillance. Because this technology-focused defense spending has bipartisan support and hard geopolitical catalysts (Russia, Israel/US-Iran, China), the beneficiaries are the contractors and specialized suppliers levered to these four pillars. Citrini positions via a Warfare basket and watchlist across these categories, scaling exposure as the legislative bill clears.

airobotdefensecomponentsdefensedefensedronedefenseprimespace
Positions & performance
+51.4%avg return83% win · 18 tracked · L +51.4%
PositionMentionsEntryLastReturn
LONDS:NASDAQ defensedrone Ondas HoldingsS1.43Jun 23 '257.8+445.5%
LUMAC:NYSE defensedrone Unusual Machines8.16Jun 23 '2519.36+137.3%
LMPTI:NYSE defensecomponents M-tron IndustriesA40.16Jun 23 '2585.33 +112.5%
LMRCY:NASDAQ defensecomponents Mercury SystemsIA51.83Jun 23 '25103.27+99.2%
LRTX:NYSE defenseprime RTXISPT145.81Jun 23 '25212.79+45.9%
LBKSY:NYSE space BlackSkyS16.47Jun 23 '2522.07 +34.0%
LLMT:NYSE defenseprime Lockheed MartinISPT472.46Jun 23 '25580.0 +22.8%
LLHX:NYSE defense L3HarrisIPT251.11Jun 23 '25303.48 +20.9%
LSAIC:NASDAQ defense Science Applications InternationalI104.21Jun 23 '25118.48 +13.7%
LKTOS:NASDAQ defensedrone Kratos DefenseIS43.63Jun 23 '2549.45 +13.3%
LNOC:NYSE defenseprime Northrop GrummanISPT499.67Jun 23 '25547.58 +9.6%
LCACI:NYSE defense CACI International457.61Jun 23 '25495.89 +8.4%
LDRS:NASDAQ defense Leonardo DRSIAP44.73Jun 23 '2548.1+7.5%
LRCAT:NASDAQ defensedrone Red Cat HoldingsS7.18Jun 23 '257.64+6.4%
LBA:NYSE defense BoeingISAPT201.31Jun 23 '25211.5 +5.1%
LPSN:NYSE defense ParsonsIA66.37Jun 23 '2558.73-11.5%
LAVAV:NASDAQ defensedrone AeroVironmentISP191.23Jun 23 '25154.24 -19.3%
LLDOS:NYSE defense LeidosIPT150.67Jun 23 '25112.14-25.6%
Non-US / no priceDRO:ASX defensedrone
Also watchingBA/ LN LDO:NASDAQ defense OUST:NASDAQ airobot
Full summary 599 words

Published June 23, 2025, 'The New WFH (War From Home)' argues warfare has structurally changed: cheap drones torch billion-dollar assets and countries wage war from thousands of miles away. Citrini cites Houthi drones blocking Red Sea commerce despite US carriers, Ukraine's 104-drone strike 800km into Russia hitting the Kirishi refinery, and Israel's smuggled-drone attack on Iran, with Iran responding via hundreds of Shahed drones and missiles. Israel's defenses blocked most, but at roughly $45,000 per Tamir interceptor shot, defense is neither free nor unlimited. The thesis: for under-resourced countries this is new leverage; for resource-rich ones a wake-up call, driving a fiscal realignment toward defense.

Why investors should care: a massive fiscal realignment toward defense (US and NATO), military superiority being redefined by technology, and hard catalysts from armed adversaries (Russia into eastern Europe, Israel/US-Iran, China's reunification aim). For the first time the FY2026 US defense budget blueprint broke the $1 trillion ceiling. Citrini frames this as re-industrialization via militarization, noting Trump's 'skinny budget' boosted DoD and DHS while cutting other agencies, and that within the DoD budget procurement, technology development and hard-asset contracts should rise disproportionately (today half the DoD budget is personnel). SecDef Hegseth is culling four-star generals by 20% and redirecting savings to procurement. The OBBBA adds $13 billion for missile defense, authorizes a 'Golden Dome' space layer, and singles out a $693 million C-UAS fund; the Senate markup keeps the $150 billion discretionary defense allocation unchanged. Fiscal asymmetry is the core problem: Shahed drones cost as little as $20,000 with 2,500km range, while SHORADS interceptors (AMRAAM/AIM-120, IRIS-T) cost 20-50x per drone, and FPV drones cost under $1,000. Electronic warfare (lasers with 'unlimited' ammunition, jamming, spoofing, high-power microwaves) levels the field.

The report details the 'four pillars of the modern shield.' Missile intercept spans boost (AEGIS, prime Lockheed/LMT), midcourse (GMD, prime Boeing/BA, 40 interceptors at Fort Greely plus 4 at Vandenberg), and terminal (THAAD, PAC by Lockheed with interceptors from RTX/L3Harris), all reliant on a space sensor layer at the center of budget priorities (HBTSS, PWSA slated for nearly $9B over four years, Resilient MW/MT slated for $5B), with hypersonic defense prime Northrop (NOC) and subcontractor Kratos (KTOS), plus space-focused Leidos (LDOS) and Parsons (PSN). The IRON DOME Act allocated $12B to expand GMD, $1.4B to THAAD, $1.5B to PAC-2/PAC-3, and $1B for Aegis Ashore. Counter-UAS spans finders (RF, radar, EO/IR) and finishers: kinetic guns/interceptors, directed-energy (Leonardo/LDO DE M-SHORAD), and jamming (DroneShield/DRO AU DroneGun Mk4), with Replicator 2.0 opening the door to smaller players Ondas (ONDS), Unusual Machines (UMAC), Redcat (RCAT), and offensive loitering munitions from AeroVironment (AVAV). Electronic warfare leaders include L3Harris (LHX), CACI, Leonardo DRS (DRS), Mercury Systems (MRCY), Northrop, BAE Systems, and niche RF supplier Mtron (MPTI). Surveillance/ISR beneficiaries include BlackSky (BKSY) for high-refresh satellite imagery and SAIC for ground systems and AI analytics.

Positioning: Citrini originally published Electronic Defense and C-UAS in its '25 Trades for 2025' watchlist and now sees Trump's fiscal realignment plus geopolitics creating a durable next leg. It maintains a Warfare thematic basket (added to Citrindex May 13 at 6% weight) plus a 'War From Home' watchlist across the four categories, approaching with modest caution given uncertainty on final bill timing/allocations and allowing more aggressive exposure as the legislative hurdle clears. A key risk flagged: after the US bombed Iranian nuclear facilities, some Republican senators wary of interventionism could threaten the Big Beautiful Bill, though Citrini believes Medicaid/entitlements are likelier Democratic targets than defense. It also notes robotics names like Ouster (OUST) have upside to the trend but are excluded from this watchlist as they are allocated elsewhere.

Key metrics
Key insights
#099 In Conversation Jun 19, 2025

In Conversation: Ouster (OUST)

The US economy is resilient with a slowly cooling but not breaking labor market, and disinflation continues while tariff-driven inflation is transitory, so the Fed should be able to resume 'good-news' rate cuts (Citrini expects Powell to open the window in July). Trade policy should be read through Trump's constraints (bond yields, tax-bill passage, recession risk, and now rare earths) rather than his preferences; those constraints push both the US and China toward off-ramps, though the US-China relationship is a long, drawn-out strategic divorce. Geopolitical shocks (Israel-Iran) are analyzed via the same constraint lens: Trump is highly reluctant to enter a war because higher oil, higher yields and delayed cuts all hurt him. The positioning rotates from an EU-fiscal/rest-of-world tilt back toward select US and commodity exposure (biofuels, grains, palladium), takes profits where trades worked, and adds rate-cut and short-EURUSD plays.

airobot
Positions & performance
+58.1%avg return100% win · 1 tracked · L +58.1%
PositionMentionsEntryLastReturn
LOUST:NASDAQ airobot OusterIS21.53Jun 20 '2534.04+58.1%
Also watchingSERV:NASDAQ airobot PONY:NASDAQ airobot
Full summary 554 words

Published June 17, 2025, 'Macro Memo: Summer Blues' is a monthly macro update in which Citrini says, unlike the prior memo, it has no contrarian view because its prior calls largely played out: recession risk was overstated and receded, the US-China trade war de-escalated, disinflation continued with muted tariff inflation, a SOFR spread trade hit its target (0bps), and WTI crude rose from $57.80 to $75. The overarching message: the US economy remains resilient despite earlier tariff-driven recession fears, and the trend is one of gradual labor-market cooling capping wage growth, with transitory tariff goods inflation offset by services (especially shelter/rent) disinflation.

The labor section paints a 'nobody is quitting and nobody is hiring' picture: continuing jobless claims at multi-year highs while initial claims move sideways, attrition way down, employers reluctant to hire after COVID overhiring, and job seekers unemployed longer. The job openings rate is under 4.5%, a threshold Fed governor Chris Waller has flagged as historically preceding a rising unemployment rate; Citrini expects unemployment to drift higher and is skeptical that reduced immigration/deportations will prevent it.

On US-China, Citrini frames trade through Trump's constraints (debt financing/10yr yield, tax-bill passage, recession risk, and newly added rare earth minerals). It recounts constructive Geneva talks and a Trump-Xi call, but notes the London round yielded only a 'positive framework,' concluding this is a long, drawn-out negotiated divorce underpinned by mutual leverage (US in advanced semis/aircraft parts and its consumer market; China in rare-earth refining). It highlights the negative correlation between Trump's approval and MP Materials' stock as a proxy for trade tensions, and stays bullish on a stable outcome and on China (a 'vibes-boom, real-cession' economy where the stock market bottoms before fundamentals; Xi is under domestic pressure to get to 'yes'). On Israel-Iran, Citrini avoids military analysis and again uses constraints: Trump campaigned on not starting wars, and escalation would raise oil, yields and inflation while delaying cuts, so he is reluctant and seeking an Iranian nuclear deal (and perhaps a Nobel).

On the Fed, Citrini argues inflation ex-tariffs is essentially a solved problem and the Fed should cut on 'good-news' logic, but tariff-driven inflation uncertainty (fear of being 'Arthur Burns') and Trump's hectoring of Powell have stalled it. It compares tariff inflation to Japan's 2014 sales-tax hike (a temporary spike; CPI +3.2% YoY, but 1.5% ex-tax) and expects services disinflation to more than offset goods inflation. The call: Powell opens the window to resuming cuts in July, with some dots moving lower without the median moving much. Positioning changes: hit the target on the SFRM5Z5M6 fly (entry -33bps to +2.5bps) and exit it; new long December 2025 Fed Funds futures (FFZ5) for more year-end cuts; turned more bullish US versus rest-of-world (taking profits on the EU-fiscal-primacy rotation that outperformed by ~16% YTD) and rotating into commodities (biofuels, grains, uranium) and US fiscal winners from the proposed BBB; new short EURUSD (highlighting August 1.13/1.15 Euro put spreads at ~5:1); new long palladium (initiated June 9, replacing an HGZ5 copper long, on auto-cycle/scrap thesis, SBSW as equity play); new long soybeans (X5, on biofuel/crush-spread reflation, ADM and BG in equities); pared the crude long by half at ~$75 (from $57.80, stop up to $68, added CVX and XOM, watching tanker TNK); and took profits on Long South Africa (EZA)/Short Turkey (TUR), which worked ~36% YTD.

Key metrics
Key insights
#098 Macro Memo Jun 17, 2025

Macro Memo: Summer Blues

Ouster (OUST) is a pure-play way to own the robotics/physical-AI megatrend at a cyclical inflection: it is the largest Western LiDAR provider and the inventor of digital LiDAR (LiDAR on CMOS silicon), which rides Moore's law for cost and performance. Because Ouster diversified early across automotive, industrial, robotics and smart infrastructure rather than betting only on consumer autos, it has posted nine straight quarters of revenue growth while peers bleed. As autonomous machines proliferate (from robotaxis to forklifts to humanoids), LiDAR demand grows for decades; non-automotive LiDAR is a larger market than automotive. Ouster's diversification, strong balance sheet, ~40% gross margins and software attach (Blue City, Gemini) position it to reach profitability while capturing a $70B opportunity. This is an 'In Conversation' interview, so it presents management's view rather than an explicit price target.

airare-earthcommoditiesconsumershoppingenergywarindextrindexza
Positions & performance
+28.4%avg return88% win · 8 tracked · L +36.7% · S -29.8%
PositionMentionsEntryLastReturn
LADM:NYSE consumershopping Archer-Daniels-MidlandIAPT54.1Jun 17 '2585.92+58.8%
LTNK:NYSE energywar Teekay Tankers47.22Jun 17 '2567.99+44.0%
LBG:NYSE consumershopping BungeIPT85.69Jun 17 '25121.53+41.8%
LXOM:NYSE energywar ExxonMobilIPT114.0Jun 17 '25154.77 +35.8%
LCVX:NYSE energywar ChevronISPT148.85Jun 17 '25194.79+30.9%
LSBSW:NYSE commodities Sibanye StillwaterA6.82Jun 17 '258.55 +25.4%
LEZA:NYSE indexza iShares MSCI South Africa ETF51.56Jun 17 '2561.94 +20.1%
STUR:NASDAQ indextr iShares MSCI Turkey ETF30.21Jun 17 '2539.2-29.8%
Also watchingMP:NYSE airare-earth SBSW:NYSE commodities
Full summary 573 words

Published June 19, 2025, this is a Citrini 'In Conversation' interview with Ouster (OUST) CEO/co-founder Angus Pacala and SVP Chen Geng, framing the company as a pure-play on the robotics and automation megatrend included in Citrini's May Humanoid Robots primer. Citrini's setup is its standard one: hunt for megatrends but enter at cyclical inflections, when a rebound is underway but sentiment stays depressed. Ouster is the largest Western LiDAR provider and inventor of 'digital LiDAR' (integrating the LiDAR system onto a custom CMOS silicon chip, first commercialized in 2018), which lets its products improve exponentially like other semiconductor products while being cheaper, smaller, more power-efficient and more robust.

The interview lays out the business and thesis. LiDAR is described as 'the eyes of robots,' superior to cameras in reliability and precision, and Pacala argues advances in AI benefit LiDAR as much as cameras. Ouster founded in 2015 on two theses: put LiDAR on low-cost CMOS, and diversify across industries because 'everything that moves will be robotic.' It serves four verticals (automotive, industrial, robotics, smart infrastructure) with roughly even 2024 revenue split. Management set a long-term framework two years ago of 30-50% annual revenue growth, 35-40% gross margins and flat operating costs, and has hit those targets for nine consecutive quarters (grew over 30% in 2024, Q1 25 gross margin ~41%). Ouster went public via SPAC in 2021 and merged with Velodyne in 2023, achieving operational synergies, a cost structure roughly half of the two standalone companies, and one of the industry's strongest balance sheets: $171M cash at end of Q1, ~$37M burn, with sell-side analysts modeling break-even in late 2026/early 2027.

Detail spans product and competitive dynamics. Ouster shipped over 17,000 sensors on $111M revenue in 2024, has 1,000+ end customers and 100+ use cases, with named clients John Deere, Komatsu, Motional, May Mobility, Forterra and Serve Robotics. Robotaxis use ~5 Ouster LiDARs (May Mobility), mining machines up to seven, while smaller robots (Serve, humanoids) use one spinning LiDAR, potentially moving to four solid-state DF sensors. Differentiation versus Luminar, Innoviz and Aeva rests on three points: digital/CMOS technology (SPAD detectors that ride Moore's law), AI software (Gemini and Blue City), and a diversified, commercially validated business at ~$140M annualized run-rate versus peers Pacala says generate 'de minimis revenue with significantly negative gross margin.' Chinese rivals Hesai and Robosense have more revenue but depend on the Chinese auto market; Ouster benefits from geopolitical preference for a US/Western supplier (it works with DoD, divested its Chinese supply chain, manufactures in Thailand at a 10% tariff it calls immaterial). The interview details in-sensor 3D zone-monitoring safety firmware (free on REV7 sensors), the Blue City smart-traffic product (two LiDARs plus an NVIDIA GPU, trained on 4M+ annotated objects, deploying at 100+ Chattanooga intersections), and a deep NVIDIA partnership across Drive, Omniverse and Jetson.

Positioning is implicit given the interview format: Citrini owns Ouster in its Robotics basket as a sensing/perception play. Management sizes the total LiDAR opportunity at $70 billion, expects non-automotive LiDAR adoption to surpass automotive, guided Q2 25 revenue of $32-35M, and stresses margin tailwinds from software attach (Blue City/Gemini are margin-accretive) against the headwind of customers moving to production at lower ASPs/higher volumes. Pacala is candid that humanoids are 'in an iffy spot' like robotaxis circa 2015 and will take longer than hoped, so Ouster hedges its humanoid exposure while planting many bets, consistent with Citrini's view that industrial and warehouse automation come first.

Key metrics
Key insights
#097 Thematic Update May 28, 2025

Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami

Healthcare, especially small-cap medtech, life sciences supply chain and small biotech, has been sold off on policy fear (RFK/MAHA, Vinay Prasad at FDA, a Most Favored Nation drug-pricing executive order) that is far more benign than the market prices. Citrini argues these headline negatives are overstated relative to expectations, and that the real Trump/administration agenda actually strengthens the biopharma industry (domestic reshoring, decoupling from China). This creates dislocations to exploit through domestically-focused, share-gaining smaller companies and catalyst-rich, idiosyncratic medtech names rebounding from their own cyclical busts. As policy clarity arrives in 2H 2025 and rates eventually mean-revert, sentiment turns and M&A accelerates, re-rating these names. The report adds a new derisked-science small-biotech basket to position for the turn.

healthGLPhealthhealthtesting
Positions & performance
+65.2%avg return62% win · 26 tracked · L +65.2%
PositionMentionsEntryLastReturn
LARWR:NASDAQ health Arrowhead PharmaceuticalsT15.56May 28 '2585.6+450.1%
LBTSG:NASDAQ health BrightSpring HealthT23.2May 28 '2572.91+214.3%
LNUVB:NYSE health Nuvation BioI2.2May 28 '256.66 +202.7%
LPTGX:NASDAQ health Protagonist TherapeuticsIT45.75May 28 '25135.56 +196.3%
LCYTK:NASDAQ health CytokineticsP30.28May 28 '2580.62 +166.2%
LAPLS:NASDAQ health Apellis PharmaceuticalsT16.8May 28 '2541.03+144.2%
LCGEM:NASDAQ health Cullinan Therapeutics7.84May 28 '2517.1+118.1%
LSLN:NASDAQ health Silence Therapeutics5.19May 28 '2511.02+112.3%
LDYN:NASDAQ health Dyne Therapeutics11.76May 28 '2524.44+107.8%
LARQT:NASDAQ health Arcutis BiotherapeuticsP13.58May 28 '2527.84 +105.0%
LLRMR:NASDAQ health Larimar TherapeuticsA1.99May 28 '254.0+101.0%
LACLX:NASDAQ health Arcellx61.15May 28 '25115.07+88.2%
LTOI:NASDAQ health The Oncology InstituteA3.12May 28 '255.39+72.8%
LHALO:NASDAQ health HalozymeP54.43May 28 '2581.48 +49.7%
LRGEN:NASDAQ health RepligenIT121.18May 28 '25131.96+8.9%
LAIRS:NASDAQ health AirSculptA4.35May 28 '254.61+6.0%
LACOG:NASDAQ health Alpha CognitionA8.43May 28 '257.9-6.3%
LTKNO:NASDAQ health Alpha Teknova5.8May 28 '254.85 -16.4%
LQTRX:NASDAQ health Quanterix5.28May 28 '254.32-18.2%
LXGN:NASDAQ health Exagen6.7May 28 '254.4 -34.3%
LJANX:NASDAQ health Janux Therapeutics23.7May 28 '2515.33-35.3%
LOPRX:NASDAQ health OptimizeRx12.19May 28 '256.38 -47.7%
LSTIM:NASDAQ health NeuroneticsA3.85May 28 '251.81 -53.0%
LSPRY:NASDAQ health ARS Pharmaceuticals14.85May 28 '255.94-60.0%
LOM:NASDAQ health Outset Medical19.5May 28 '254.04-79.3%
LNOTV:NASDAQ healthtesting Inotiv2.43May 28 '250.08-96.7%
Also watchingLONN:SIX healthGLP DHR:NYSE health SRT3:XETRA health BIOT:OMX health CRL:NYSE healthtesting IQV:NYSE health ICLR:NASDAQ health TXG:NASDAQ health TECH:NASDAQ health AKYA:NASDAQ health NVAX:NASDAQ health PCVX:NASDAQ health ELV:NYSE health SGRY:NASDAQ health XBI health PPH:NASDAQ health
Full summary 542 words

Published May 28, 2025, 'Rough Seas Make Strong Sailors' revisits Citrini's Medtech & Healthcare basket (first published August 2024) amid a barrage of policy-driven 'tape bombs.' Citrini's thesis is that the market has been trading healthcare as if macro (rates, recession) and policy dominate micro, when in fact the sector, especially the smaller companies they favor, is fundamentally insulated. They recount actively managing the basket through dislocations: upsizing during the RFK-induced panic (Markets Gone RF-Krazy), covering shorts in January Musings, doubling down on longs in Insuring Against Insanity, and adding in Talk to Me, Goose, claiming significant outperformance versus healthcare benchmarks.

The original three-pillar thesis was: the market is overly pessimistic on healthcare (especially small cap); this created opportunity in innovative medtech at depressed valuations exiting idiosyncratic downcycles; and a similar setup exists in the life sciences supply chain, where a cyclical bust obscured secular growth. They argue the first two pillars have borne out, citing Neuronetics (STIM, TMS therapy) rebounding from a COVID-era slowdown and Airsculpt (AIRS) rolling out standalone skin-tightening for GLP-1 patients. The life sciences call was early but shows green shoots: Lonza cited 'robust commercial demand,' Repligen (RGEN) returned to double-digit growth for the first time in three years with its 50%+ opportunity funnel up 30% YoY, corroborated by Danaher and Sartorius. KKR paid a 60% premium for Biotage, and healthcare M&A hit a record share of announced deals.

The core of the report dismantles four 'misperceptions.' (1) Trump is anti-biopharma: Citrini argues actions (a domestic-manufacturing EO that drew ~$300B in announced US biopharma capex/R&D from companies that spent under $170B globally the prior five years) and quotes from Trump and Merck's CEO suggest a pro-industry, anti-China reshoring agenda. Trades: Alpha Teknova (TKNO, custom reagents, path to $250M revenue/$75M+ EBITDA versus RGEN at 10x revenue/70x EBITDA), preclinical CRO Inotiv (NOTV, 1x revenue versus peers 2-2.5x, implying $16-17/share versus $2.12), and OptimizeRX (OPRX, 2M+ providers, NRR up from 105% to 121%). (2) New health officials are anti-science: they argue it's reprioritization toward chronic disease, backing STIM (2.1x revenue versus peers 5-8x, North Carolina TMS coverage catalyst) and diagnostics Exagen (XGN, 2.3x revenue versus 4-7x). (3) Cutting costs will kill industry: they cite 10X Genomics and Bio-Techne stabilization, flag Quanterix (QTRX, negative $30M EV, $100M+ revenue) and site-of-care shift names Surgery Partners, Outset Medical (OM), BrightSpring (BTSG), plus Oncology Institute (TOI) for value-based cancer care and AI. (4) Biotech is dead: with four recent large-premium takeouts (BioMarin/Inozyme +266%, Sanofi/Vigil +247%, Novartis/Regulus +108%, Merck KGaA/SpringWorks), they introduce a new 17-name Biotech 2025 basket built on derisked assets (primary endpoint hit in past 18 months), large underserved markets, 2H 2025 catalysts, and acquirability, spanning oncology (Nuvation/NUVB, Arcellx/ACLX, Cullinan/CGEM, Janux/JANX), metabolic/cardiovascular (Arrowhead/ARWR, Cytokinetics/CYTK, Silence/SLN) and specialty/rare disease (Larimar/LRMR, Protagonist/PTGX, Dyne/DYN), plus later-stage/commercial names (Apellis/APLS, Alpha Cognition/ACOG, ARS/SPRY, Halozyme/HALO, Arcutis/ARQT).

Citrindex portfolio changes as of May 28: take profit on 50% of the IBIT long, exit the Insurance Long/Short basket, exit Brazil ETFs (EWZ, EWZS), initiate the 17-name Biotech 2025 basket at 5% weight, leave 1% cash for hedging, and allocate remaining cash to the Robotics basket. The basket is built with breadth across indications so one clinical flop won't sink it, with beta to bonds plus an idiosyncratic kicker from data and M&A.

Key metrics
Key insights
#096 Thematic Primer May 16, 2025

Thematic Primer: Humanoid Robots (Optimus, Unitree and More)

Humanoid and other advanced robots are moving from science fiction to commercial deployment because AI (specifically Vision-Language-Action models) has finally given robots a usable 'brain' and the hardware cost curve has collapsed (Unitree's G1 at $16k versus $500k industrial units in 2023). Most of the companies exposed to the robotics supply chain are advanced-machinery, auto and defense names currently trading at cyclical-trough valuations because analysts extrapolate a brutal auto/analog-semi downcycle forever. Citrini argues you can buy a secular growth story at a cyclical price today, before the consumer robot 'ChatGPT moment' re-rates the group. The bridge to mass adoption does not require full autonomy or AGI: teleoperation (one overseas operator coaching 4-5 robots) plus improving AI can make robots economic now. The trade is a basket of picks-and-shovels suppliers of sensors, actuators, inverters and compute that have upside to robot proliferation as it climbs the industrial to service to domestic ladder.

airobotaisemiconsumertravel
Positions & performance
+55.1%avg return100% win · 5 tracked · L +55.1%
PositionMentionsEntryLastReturn
LON:NASDAQ aisemi ONSemiIT44.92May 16 '2589.04 +98.2%
LNVDA:NASDAQ aisemi NvidiaISPT135.4May 16 '25206.84+52.8%
LRRX:NYSE airobot Regal Rexnord141.43May 16 '25210.87 +49.1%
LTXN:NASDAQ aisemi Texas InstrumentsISPT188.5May 16 '25279.41 +48.2%
LMCHP:NASDAQ aisemi Microchip TechnologyIPT61.21May 16 '2577.9 +27.3%
Non-US / no priceIFX GY
Also watchingGXO:NYSE consumertravel
Full summary 529 words

This is Citrini Research's thematic primer on humanoid robots, published May 16, 2025, framed as 'a future secular story at a current cyclical price.' The motivation is timing: embodied AI has always been the end goal of AI (the purest form of using AI to do physical things and raise productivity), but for years it was only investable via the compute layer. Citrini argues the reason to act 'now' rather than wait is that the most-exposed suppliers are trading on a depressed auto and analog-semiconductor cycle, with estimates that don't price in even a return to growth, let alone a 'robot-shaped right tail.' They note Texas Instruments felt compelled to remind analysts that analog cycles do bottom.

The report answers 'why humanoid' and 'why now.' Humanoids matter because the world is already ergonomically built for two arms, ten fingers and human reach, so a humanoid slots into existing workflows (a BMW body cell, a warehouse) without retrofitting. Early deployment already rhymes with the 2010 Kiva-to-Amazon warehouse pivot: Amazon is deploying Agility's Digit, GXO and Apptronik have piloted pick-and-place humanoids for about a year, and Unitree ships humanoids at $16k/unit. Crucially, Citrini stresses robots don't need to be fully autonomous; teleoperation is the bridge. One tele-operator in India could coach four to five US robots, echoing 2000-era call-center offshoring 'only this time the headset controls a spine,' cutting per-task labor costs before autonomy matures. They foresee brownfield retail and light-industrial sites wanting robot workers under $25/hour, with consumer crossover once costs dip below a used Honda Civic or a robotics-as-a-service subscription runs ~$500/month, a 3-4 year rather than next-decade event.

The 'why now' rests on three legs. The macro/cyclical: robotics suppliers sit in automotive and defense, both beaten down (auto cycle poor, defense sold on DOGE fears), with commentary from RRX, MCHP, ON and IFX suggesting the downtrend has bottomed and inventory purges are over, so incremental demand drops straight to the P&L. The cost curve: Unitree's G1 at $16k is a 97% drop from $500k industrial mannequins of 2023, signaling robots are joining a Moore-style curve. AI innovation: VLA models (multimodal models that turn pixels and plain-language commands into joint torque targets) are advancing with only a slight lag to LLMs. Figure AI's Helix uses one weight file for every task on BMW pilot lines; NVIDIA dominates compute (Jetson Orin NX at 275 TOPS, next-gen Thor tripling that) and released GR00T N1, the first open humanoid-scale VLA, bundled with Isaac Sim synthetic-data pipelines, and trained a 1X robot to do dishes in a week. The moat, in Citrini's 'AI Phase 2' framing, shifts from hard-coded motion to proprietary motion data: whoever owns the fleet logs owns the flywheel.

Positioning follows as a basket of names with upside to robot proliferation as it climbs the industrial-to-service-to-domestic ladder, most of which currently trade as if the down-cycle lasts forever. The piece names Unitree (private), NEO, Agility, Figure, plus supply-chain and compute beneficiaries (NVIDIA, TXN, and the analog/industrial names cited as bottoming). The report is explicitly a scaling-in exercise ('doing the work now') so they are ready before the consumer robot ChatGPT moment; the full basket and universe are behind a paywall/PDF.

Key metrics
Key insights
#095 Macro Memo May 06, 2025

Who Holds the Cards?

Recession risk from the trade war is real but overstated, because every major actor — Trump, Xi, and the Fed — faces binding constraints pushing them toward an off-ramp. Trump is constrained by $6-9 trillion of debt refinancing and the bond market's 'moron risk premium', the need to pass his tax bill through a Congress that requires visible trade-deal progress, and his stated horror of being Herbert Hoover; China's export engine is under unemployment pressure; and the Fed, with core inflation at 2.8%/2.65% and falling, has room to cut once it finds a politically graceful exit. Meanwhile hard data (labor market cooling but not breaking, resilient card spending, ~2 months of front-run inventory) buys time until early June before real damage sets in. The stance is constructively contrarian: stay net long equities with cheap index-put hedges, expect the Fed to cut sooner than the 27% June probability implies, trade the import-data dislocations (long tankers/ro-ro, short parcel networks), and watch Taiwan's 19-sigma FX move as the key systemic risk to Treasuries.

consumerautoconsumertravelenergywar
Positions & performance
+7.1%avg return43% win · 7 tracked · L +92.8% · S -57.2%
PositionMentionsEntryLastReturn
LINSW:NYSE energywar International SeawaysAT36.54May 06 '2590.69 +148.2%
LSTNG:NYSE energywar Scorpio Tankers40.68May 06 '2578.4 +92.7%
LF:NYSE consumerauto FordIAPT10.44May 06 '2514.37+37.6%
SUPS:NYSE consumertravel United Parcel ServiceIPT93.81May 06 '25114.79-22.4%
SFDX:NYSE consumertravel FedExISPT213.41May 06 '25314.96-47.6%
SEXPD:NYSE consumertravel ExpeditorsIPT106.18May 06 '25171.34 -61.4%
SCHRW:NASDAQ consumertravel C.H. RobinsonIPT88.32May 06 '25174.46 -97.5%
Non-US / no priceHAUTO:OSL consumerauto HAFNI:OSL energywar
Full summary 598 words

Published May 6, 2025, this macro memo asks who actually holds the cards in Trade War II and answers with Marko Papic's constraints-over-preferences framework. Citrini leans against consensus: recession risks are presently overstated, though bonds (front end) and oil price far more recession than equities, and indices should chop sideways with violent overreactions and extreme dispersion. The labor market has unmistakably cooled — job openings falling (Indeed data leading), the 4.5% openings rate sitting at Chris Waller's warning threshold, claims and unemployment ticking up slightly — but the softening predates tariffs, and hire/quit rates have actually gone sideways or up. Sentiment is dire (consumer confidence at 2020 or even GFC lows), but Citrini prefers 'watch what they do': Visa shows spending growth flat-to-up after Liberation Day, Fiserv SpendTrend moderated from 3.67% to 2.76% y/y, and Bloomberg Second Measure data on lower-middle-income Midwest households agrees on resiliency, with cutbacks concentrated in discretionary services and big-ticket durables.

March import data reveals who front-ran tariffs: pharmaceutical products jumped 71% month-over-month (+$13 billion, the largest dollar move), organic chemicals and lead articles rose triple digits, luxury/seasonal goods (cut flowers, pearls, furs) fell 25-40% with no front-running, and everyday textiles/footwear barely moved because retailers remain inventory-heavy. The implication: roughly a two-month inventory buffer, meaning genuinely negative economic impact starts appearing by early June — a timeline both the administration and big-box CEOs understand. Trade ideas fall directly out of the data: long long-haul, tariff-agnostic shipping (HAUTO, HAFNI, STNG, INSW — tankers and car carriers price off voyage distance and scarcity) against short time-definite parcel networks hit by the China/HK de-minimis repeal (UPS, FDX, EXPD, CHRW; DHL excluded as better prepared). A Ford earnings-call read-through ($1.5 billion net EBIT tariff impact but guidance otherwise pulled, strong van demand, telematics at 40% of pro unit revenue, new SUVs pricing 18-23% higher with nine days on lots) shows a company under uncertainty but not in COVID-style panic.

Trump's three constraints: (1) the 'moron risk premium' — 10-year yields surged and the dollar plunged after Liberation Day, breaking the flight-to-safety correlation, revealing that the Trump put lives in credit and rates, with $6-9 trillion of federal debt maturing April-June just as price-insensitive East Asian buyers pull back; (2) the tax bill — Bessent's 'three-legged stool' (tariffs, tax cuts, deregulation) and his promised second-half re-acceleration require congressional Republicans, who now have leverage to demand visible trade-deal progress; (3) recession — Trump is quoted saying he doesn't want to be Herbert Hoover. China faces its own export-sector unemployment pressure and wants an off-ramp too. On the Fed: core CPI at 2.8% and core PCE at 2.65% with services disinflation continuing make inflation 'practically a solved problem'; Powell's stagflation talk is read as the only politically safe justification for inaction, and Citrini thinks a June cut is likelier than the 27% market-implied odds.

Positioning: exit the natural gas long for long crude and copper; exit the SFRM6 long above target at 96.825 and the SOFR/EURIBOR spread; new STIR play selling Z5 on the M5Z5M6 fly at -0.33; longer-term bearish USD but waiting to re-short on rallies; net long equities ('bad news, good action') hedged with 2% of NAV in SPX June 5200 and August 4800 puts, with the flip-short signal being the market treating bad news as bad news and the 200-day (~5750) the paranoia line. A bonus section flags Taiwan: USDTWD's 19-standard-deviation, 10%-in-two-sessions move (sharpest since 1992) threatens Taiwanese life insurers' $1.7 trillion, ~70%-USD offshore book — an SVB-like unhedged-assumption blowup whose forced Treasury selling or proxy-hedge unwinds (short KRW/INR) could spill into US rates; watch TWD cross-currency basis.

Key metrics
Key insights
#094 Thematic Primer Apr 23, 2025

Thematic Primer: Artificial Intelligence, Phase 2

AI investing is transitioning from Phase 1 (scaling infrastructure — a trade whose basket more than doubled and which Citrini exited/shorted around the DeepSeek moment) to Phase 2: implementation, where cheap inference and commoditizing models mean the winners are not those building agents but those with the preconditions to make agents useful. The framework is the 4 D's — Data (proprietary, domain-specific datasets generic models can't match), Design (embedding agents into existing workflows), Distribution (owning the channel where the model meets the user), and Deployment (hybrid cloud/on-prem economics as inference volumes spike). Value therefore migrates from GPU suppliers to data-rich incumbents and application-layer operators — healthcare data owners, data/analytics franchises, and 'AI sleeper' industrials — because agentic AI is the only kind that drives real ROI, and margins accrue to whoever owns the interface, not the cluster.

airobotaisemiconsumerautoconsumermediaconsumerreal-estatedefenseenergyaifinancefintechhealthsaas
Positions & performance
+42.4%avg return42% win · 24 tracked · L +42.4%
PositionMentionsEntryLastReturn
LAMD:NASDAQ aisemi AMDISPT90.39Apr 23 '25521.95+477.4%
LVRT:NYSE energyai VertivISPT78.0Apr 23 '25290.36+272.3%
LCLS:NYSE aisemi CelesticaIS88.19Apr 23 '25318.24 +260.9%
LDDOG:NASDAQ saas DatadogIPT94.58Apr 23 '25246.86+161.0%
LRRX:NYSE airobot Regal Rexnord102.59Apr 23 '25210.87 +105.5%
LCSCO:NASDAQ aisemi CiscoPT55.63Apr 23 '25114.17+105.2%
LTOI:NASDAQ health The Oncology InstituteA2.88Apr 23 '255.39+87.2%
LPH:NYSE airobot Parker HannifinIPT580.81Apr 23 '25987.54+70.0%
LCOR:NYSE health CencoraIAPT284.71Apr 23 '25311.15 +9.3%
LMSCI:NYSE financefintech MSCIIAPT533.41Apr 23 '25550.79+3.3%
LUNH:NYSE health UnitedHealthISPT427.96Apr 23 '25417.64 -2.4%
LSPGI:NYSE financefintech S&P GlobalIAPT470.23Apr 23 '25426.4-9.3%
LELV:NYSE health Elevance HealthIAPT426.87Apr 23 '25377.68-11.5%
LMELI:NASDAQ airobot MercadoLibreISAP2139.92Apr 23 '251819.74 -15.0%
LLDOS:NYSE defense LeidosIPT142.0Apr 23 '25112.14-21.0%
LEFX:NYSE financefintech EquifaxIAT249.31Apr 23 '25177.31 -28.9%
LFICO:NYSE saas Fair IsaacIPT1926.06Apr 23 '251280.57 -33.5%
LRELX:NYSE saas RELXIP52.7Apr 23 '2534.41-34.7%
LSRAD:NASDAQ saas SportradarA23.11Apr 23 '2514.85-35.8%
LFIS:NYSE financefintech FISIAPT79.41Apr 23 '2543.16 -45.6%
LCSGP:NASDAQ consumerreal-estate CoStarIAPT81.83Apr 23 '2527.66-66.2%
LDUOL:NASDAQ saas DuolingoISAT370.0Apr 23 '25122.24-67.0%
LCVNA:NYSE consumerauto CarvanaIAPT220.94Apr 23 '2564.04 -71.0%
LNFLX:NASDAQ consumermedia NetflixIPT1049.59Apr 23 '2570.09-93.3%
Also watchingNVDA:NASDAQ aisemi XYZ:NYSE financefintech APO:NYSE financefintech
Full summary 569 words

This April 23, 2025 primer formally rewrites Citrini's AI thesis for 'Phase 2: From Infrastructure to Implementation.' It opens with a track-record recap: the original May 2023 initiation framed Phase 1 as a simple bet that AI datacenter capex estimates were too low, focusing on picks-and-shovels (Nvidia, SuperMicro, Dell, Broadcom, SK Hynix), bottleneck-wideners (Credo, Monolithic Power, Coherent, Ciena, Constellation Energy) and enablers (Meta, Amazon, Microsoft, Alphabet, Oracle); the Phase 1 basket more than doubled in 18 months. Citrini exited NVDA entirely on December 8, 2024 at $140, went short SMH and NVDA on January 24, 2025 into the DeepSeek episode, avoided a 20%+ Q1 drawdown, and has now covered the shorts — but isn't long again, preferring select infrastructure (AMD, CLS, VRT, CSCO).

The Phase 2 thesis: all shortages lead to gluts, and the AI revolution now unfolds amid cheap inference and commoditizing models — 'if Phase 1 was about who could get a GPU, Phase 2 is about who knows what to do with one.' Open-source models approaching frontier capability erode model-layer moats (Palo Alto CEO Nikesh Arora is quoted: for efficiency tasks 'I don't want to pay a dollar for that. I'd rather pay five cents'). The winning layer is the one closest to the user — the Apple analogy of charging $100 for $20 of NAND by owning the interface. The defining Phase 2 capability is agency: autonomous systems that decide and act, which Citrini argues is 'the only kind of AI that can drive significant ROI.'

The 4-D framework organizes stock selection. Data is deemed most important: proprietary domain datasets (TOI's oncology outcomes database is the exemplar) create defensible verticals; named data-moat beneficiaries include ELV, UNH, COR and TOI in healthcare, plus FICO, EFX, SPGI, MSCI, CSGP and SRAD; hard-to-replicate UX flywheels favor DUOL, CVNA, FIS, NFLX, MELI; and 'AI sleepers' with unpriced data moats include RELX, RRX, PH and LDOS. Design means agents embedded inside existing workflows, with a five-question 'design-ready' test (interaction data capture, three-clicks surfacing, kill-switch dashboards, API/low-code exposure, scoped memory) — incumbents slapping agents into industry-standard platforms beat disruptors in slow/regulated industries. Distribution is the compounding edge as technical differentiation compresses (Microsoft force-feeding Copilot shows reach alone isn't enough). Deployment covers unit economics: inference costs falling 30-40% annually, on-prem GPUs at roughly one-third the cost of cloud over three years driving a 'train in the cloud, run in the rack' hybrid norm, fragmenting pricing (seats giving way to outcome-based fees), and gross margins clustering at 60-75% for infrastructure, 70-85% for foundation models (drifting lower), and 65-90% for applications — with observability (DDOG cited) becoming mandatory as agentic workloads scatter costs.

On recent developments: Manus and Devin — both built on Claude — suggest foundation layers are evolving into something like an operating system, reinforced by Anthropic's Model Context Protocol; MCP has real developer uptake (Block and Apollo integrations; Zed, Replit, Codeium, Sourcegraph) but won't matter in boardrooms until agents demonstrably save money. A roadmap sketches the progression: augmentation (Nov 2022-end 2024), independent reasoning and autonomous tasks (Q4 2024-present, with DeepSeek R1's RL-taught reasoning the breakthrough), workflow management (perhaps end-2026), with people and processes — not technology — the adoption bottleneck, and a possible 'mini-trough of disillusionment' ahead. The conclusion: NVDA is probably not the whipsaw rebound trade; the alpha now lies with 'actual companies, with actual AI use cases, seeing actual margin improvement,' collected in the new Phase 2 AI basket.

Key metrics
Key insights
#093 Deep Dive Apr 18, 2025

A Tale of Two Tariffs

A rare non-actionable history essay arguing that Trump's tariff regime is not a Smoot-Hawley rerun but something novel: the deliberate conversion of US hegemony into a fee-for-service business. Using Douglas Irwin's 'three R's' of tariff history — Revenue, Restriction, Reciprocity — Citrini shows all three have returned at once and adds a fourth, 'Rent': tariffs as a toll charged for access to the system the US built ('Globalization-as-a-Service'). The historical lesson (Fordney-McCumber 1922 vs Smoot-Hawley 1930) is that tariffs are recession accelerants whose damage depends on starting conditions and retaliation dynamics; today's difference is that the world has never tried de-integrating a genuinely globalized economy, the US is both debtor and restrictor, and the resulting unpredictability is itself a tax on capital formation. Practical takeaways: this won't be over in three months, 2-3 months of inventory masks the real impact, and the dollar has entered a secular bear market as reserve managers diversify.

Positions & performance
No single-stock positions tracked in this report.
Full summary 592 words

Published April 18, 2025 after the author spent one of the two post-Liberation-Day weeks in the US and one in China talking to tariff-affected businesses, this is Citrini's first history piece in over two years. The ground truth is stark: a top-100-by-volume Shanghai trading company reports receiving zero holiday-season orders that would normally be ramping now (ordering starts eight months ahead), and while Chinese factories believe they can cut prices enough to preserve their post-tariff cost advantage, 'that doesn't matter much when nobody is transacting.'

The essay's framework comes from Douglas Irwin's 'Clashing over Commerce': US tariff history moves through Revenue (tariffs were >90% of federal revenue in the 1800s, the 'original stealth tax' before the 1913 income tax), Restriction (post-WWI protection of domestic industry), and Reciprocity (post-1934 bargaining toward liberalization). Two case studies carry the argument. Fordney-McCumber (1922) raised tariffs into a booming economy: manufacturing output rose nearly 50% from 1922-29 and unemployment fell from 6.7% to 3.2%, but farm income collapsed from $22 billion (1919) to $13 billion (1922) as Europe retaliated — concentrated benefit, diffuse harm. Smoot-Hawley (1930) raised duties on over 20,000 goods to a 59.1% average dutiable rate into a collapsing economy, over the written protest of 1,028 economists and pleas from Thomas Lamont and Henry Ford; 25+ countries retaliated (Canada alone hit 16 products covering ~30% of US exports to it), US imports fell from $4.4B to $1.3B and exports from $5.4B to $1.6B by 1932, and world trade fell roughly two-thirds. The lesson: tariffs are recession accelerants — the same policy is survivable in a boom and catastrophic into fragility, with retaliation and signaling effects doing the worst damage. The essay then traces the repair: the 1934 RTAA (executive negotiating authority, bilateral cuts up to 50%, MFN), Bretton Woods 1944 (Keynes' bancor vs Harry Dexter White's dollar-gold plan; $35/oz), GATT 1947 (tariffs treated 'like nuclear weapons'; global average tariffs fell from 22% to under 4% by the WTO's 1994 creation), and Nixon's 1971 gold-window closure, which counterintuitively cemented dollar reserve dominance and locked the US into structural trade deficits (Triffin dilemma), with the 'exorbitant privilege' as compensation.

Applying the framework to 2025: all three R's have returned simultaneously — revenue (billions of new federal intake), restriction (a blanket 'wall at the port' populist aesthetic), and reciprocity (a scoreboard grudge match tallied in deficits) — but none capture the novelty. Citrini proposes a fourth R, Rent: the administration views reserve-currency status and system maintenance (shipping lanes, deep markets, the reserve asset) as an unpaid service and is billing the world for it — 'Globalization-as-a-Service.' The 125-145% China tariff makes sense only as a fee-framing opening bid; ideas like a coerced century-bond swap (floated around a 'Mar-a-Lago accord,' which the author still deems very unlikely and Stephen Miran has disavowed) illustrate how rent could be extracted, at the cost of undermining Treasury creditworthiness. Consequences already visible: declining foreign official Treasury holdings, expected diversification into gold, euros, francs and yen, and a secular dollar bear market.

The conclusion is a warning about unpredictability itself: the 90-day pause is tactical, not resolution; 2-3 months of US warehouse inventory will blunt then reveal the real impact; and unlike 1930, the world has never attempted to de-integrate genuinely globalized just-in-time supply chains. US market resilience rests on trade centrality, political stability, rule of law, the dollar, and luck — an equilibrium that regime-level 'plumbing' changes (1971 the precedent) historically convert into protracted volatility rather than buy-the-dip moments. Trade policy, and above all US-China talks, will drive cross-asset returns for the year.

Key metrics
Key insights
#092 Market Memo Apr 13, 2025

Market Memo: Talk to Me, Goose

While the market obsesses over tariffs, a series of healthcare policy developments — the FDA shake-up, the animal-testing/organoid initiative, and CMS's surprisingly large Medicare Advantage rate increase — are being misread by a 'shoot first, ask questions later' market, creating asymmetric opportunities in small-cap life sciences and medtech. Citrini's thesis is that the new health administration is biased toward lowering barriers to innovation (even if not every policy works), NIH/FDA cuts have been far smaller than feared, and panic selling has left names like QTRX at negative enterprise value and NOTV/CRL priced as if animal testing ends tomorrow when the organoid transition is realistically 5-10+ years away. The MA rate increase is a direct tailwind for brokers (EHTH, SLQT), value-based care (TOI, PRVA), and above all Talkspace, whose Medicare expansion and payer-model economics make it the basket's most compelling risk/reward.

financefintechhealthGLPhealthhealthtestinginsurance
Positions & performance
-26.1%avg return37% win · 19 tracked · L -1.2% · S -119.5%
PositionMentionsEntryLastReturn
LTOI:NASDAQ health The Oncology InstituteA1.95Apr 14 '255.39+176.4%
LCRL:NYSE healthtesting Charles River LaboratoriesIT106.6Apr 14 '25226.58+112.6%
LTALK:NASDAQ health TalkspaceI2.79Apr 14 '255.22 +87.1%
SNVO:NYSE healthGLP Novo NordiskISP66.06Apr 14 '2548.77+26.2%
LRDNT:NASDAQ health RadNetT53.36Apr 14 '2561.57+15.4%
LPRVA:NASDAQ health Privia HealthIT24.05Apr 14 '2525.5+6.0%
LPACB:NASDAQ health Pacific Biosciences1.32Apr 14 '251.36+3.0%
LVRTX:NASDAQ health Vertex PharmaceuticalsIPT495.83Apr 14 '25477.36-3.7%
LTKNO:NASDAQ health Alpha Teknova5.67Apr 14 '254.85 -14.5%
SGILD:NASDAQ health GileadIPT106.5Apr 14 '25129.31-21.4%
LQTRX:NASDAQ health Quanterix5.6Apr 14 '254.32-22.9%
LCVRX:NASDAQ health CVRxA6.53Apr 14 '254.74-27.4%
SAMGN:NASDAQ healthGLP AmgenIPT293.92Apr 14 '25376.04-27.9%
LCERT:NASDAQ health CertaraT14.4Apr 14 '257.51-47.8%
LSTIM:NASDAQ health NeuroneticsA3.81Apr 14 '251.81 -52.5%
LSLQT:NYSE insurance SelectQuote3.16Apr 14 '250.72 -77.1%
LEHTH:NASDAQ insurance eHealthA6.14Apr 14 '251.34-78.2%
LNOTV:NASDAQ healthtesting Inotiv1.55Apr 14 '250.08-94.8%
STXG:NASDAQ health 10x GenomicsI8.28Apr 14 '2545.92 -454.9%
Also watchingJNJ:NYSE health NARI:NASDAQ health GOCO:NASDAQ insurance QNST:NASDAQ financefintech EVER:NASDAQ insurance
Full summary 591 words

Published April 13, 2025 after two weeks of historic tariff-driven volatility, this memo explains why Citrini increased exposure to its Healthcare Innovation basket — its largest allocation — despite (and because of) the turmoil. Valuation sets the scene: the Russell 2000 healthcare sub-index and NASDAQ biotech index both hit levels that marked bottoms repeatedly in recent years, and small caps are the only part of the market pricing in bad news, while healthcare demand is inelastic and relatively trade-insulated. The drawdown is attributed to technicals — five bad years for sector specialists, long exposure at January lows and short exposure at new highs — an 'explosive cocktail' if sentiment turns.

On life sciences policy, the memo works through the controversy: Peter Marks' forced FDA resignation is weighed against a Jefferies analyst noting drugs are still being approved on schedule and Commissioner Makary supports conditional rare-disease approvals; RFK adviser Calley Means is quoted arguing the FDA 'boxes out' small innovators with billion-dollar approval costs. Data from FDA/Oppenheimer shows biopharma R&D spend doubled over ten years while approvals stagnated. Cuts have been smaller than feared: NIH reductions landed at 1,200 (mostly administrative) versus 3,500-5,000 initially estimated, and funding has begun flowing again — PACB (newly added long) beat Q1 estimates despite funding pressure, with TXG shorted against it to neutralize academic-funding exposure. QTRX is the standout asymmetry: a NEGATIVE $50 million enterprise value despite an industry-leading ultra-sensitive diagnostics platform with recurring revenue and a path to profitability.

The FDA's initiative to reduce animal testing via AI models and organoids cratered NOTV and CRL, but Citrini holds NOTV and adds CRL, arguing the announcement is more flash than substance: the FDA already waived animal-testing requirements in 2022, the new program is merely a public workshop toward a toxicology pilot for monoclonal antibodies (~one-third of the pipeline), and industry contacts expect 5-10 years before protocols are clear enough to switch. Both companies' proprietary datasets and incumbent advantages could make them long-run AI beneficiaries (the Walmart-to-eCommerce analogy), while CRL's CDMO segment alone, at peer multiples, covers its entire market cap. TKNO gets another catalyst — it supplies the foundational reagents for producing organoids and just signed its first partnership with a stem-cell company — while CERT (biosimulation, expanded into discovery via the Chemaxon acquisition) and VRTX (proprietary cystic fibrosis data moat, added long against AMGN/NVO/GILD shorts) round out the AI-in-trials theme.

In medtech, STIM and CVRX have domestically-insulated supply chains (Southern California equipment; Minnesota manufacturing); CVRX's post-guidance selloff is seen as an overreaction given BAROSTIM's ~$3 billion opportunity, 80%+ gross margins, JNJ as largest shareholder, and an Inari-style acquisition multiple implying ~$20/share. The biggest industry development is Trump's CMS dramatically raising Medicare Advantage payments — well above expectations and counter to the 'slash and burn' narrative. Beneficiaries: MA brokers EHTH and SLQT (added at combined equal weight; SLQT's Senior segment is ~80% of EBITDA), RDNT (~25% Medicare revenue, estimates should revise up), and value-based care (TOI overweight — PRVA's trailing multiple on TOI revenue implies $5+/share — with PRVA added). The capstone is an 'In Conversation' interview with Talkspace CEO Jon Cohen: TALK is the largest in-network telehealth mental-health provider (nearly two-thirds of Americans covered, versus $175-$400/month out-of-pocket elsewhere), its payer business has more than doubled in two years, guidance calls for 20-25% annual revenue growth and 12-15% EBITDA margins by 2026 — before a transformational Medicare deal adding tens of millions of covered lives — and it trades under 9x 2026 guided EBITDA with a quarter of its market cap in cash and no debt.

Key metrics
Key insights
#091 Market Memo Apr 03, 2025

Market Memo: Seeing the Stag

Trump's Liberation Day tariffs — a universal 10% levy plus 'reciprocal' rates set by trade-deficit math rather than actual foreign tariffs — function like the 1970s oil shocks: a supply-side cost shock that raises prices while destroying productivity and growth, and one the Fed cannot fix with rates. Because the tariffs are formula-driven and deficit-targeting, they are stickier than a bargaining chip, and their costs cascade non-linearly through global supply chains (the 2018 washing-machine episode saw 12% price hikes from metals that were only ~5% of costs). Citrini's base case remains that tariffs are ultimately deflationary/recessionary and the 'Reciprocity Paradox' may cause the policy to collapse under its own contradictions, but stagflation is a distinct enough risk to build a dedicated basket: long domestic-revenue, pricing-power, inelastic-demand names; short globally-supply-chained, thin-margin, discretionary hardware and logistics names.

aineocloudaiopticalconsumermediaconsumershoppingconsumertravelcybersecurityhealthmag5quantumsaas
Positions & performance
-85.8%avg return9% win · 23 tracked · S -85.8%
PositionMentionsEntryLastReturn
SPODD:NASDAQ health InsuletIAPT256.8Apr 03 '25163.26+36.4%
SZS:NASDAQ cybersecurity ZscalerT192.21Apr 03 '25142.32+26.0%
SIOT:NYSE saas SamsaraIT34.11Apr 03 '2535.34 -3.6%
SHPQ:NYSE consumershopping HPIPT23.78Apr 03 '2525.75-8.3%
SPTON:NASDAQ consumershopping PelotonIP5.4Apr 03 '256.08-12.6%
SDXCM:NASDAQ health DexComIPT61.8Apr 03 '2571.54-15.8%
SMASI:NASDAQ health MasimoA152.37Apr 03 '25179.95-18.1%
SGRMN:NYSE consumershopping GarminT185.34Apr 03 '25242.47 -30.8%
SSAIA:NASDAQ consumertravel Saia319.97Apr 03 '25423.68-32.4%
SIONQ:NYSE quantum IonQS23.25Apr 03 '2535.92 -54.5%
SWERN:NASDAQ consumertravel Werner EnterprisesT27.34Apr 03 '2542.42-55.2%
SAAPL:NASDAQ mag5 AppleISPT203.19Apr 03 '25333.02-63.9%
SSONO:NASDAQ consumershopping SonosIA8.9Apr 03 '2514.69-65.1%
SKNX:NYSE consumertravel Knight-SwiftI39.57Apr 03 '2572.5-83.2%
SRGTI:NASDAQ quantum RigettiS8.15Apr 03 '2515.64 -91.9%
SPANW:NASDAQ cybersecurity Palo Alto NetworksIAPT165.17Apr 03 '25323.79-96.0%
SNTAP:NASDAQ aineocloud NetAppPT81.61Apr 03 '25169.8 -108.1%
SQBTS:NYSE quantum D-Wave QuantumS7.16Apr 03 '2516.21-126.4%
SARCB:NASDAQ consumertravel ArcBest64.25Apr 03 '25148.87 -131.7%
SROKU:NASDAQ consumermedia RokuIT60.26Apr 03 '25141.97-135.6%
SJBL:NYSE aioptical JabilIST123.49Apr 03 '25312.59-153.1%
SFLEX:NASDAQ aineocloud FlexT29.32Apr 03 '25116.07 -295.9%
SDELL:NYSE aineocloud DellISAPT77.23Apr 03 '25426.91 -452.8%
Full summary 574 words

Written April 3, 2025, immediately after Liberation Day, this memo quantifies stagflation risk from the most comprehensive restructuring of US trade policy in centuries — levies beyond Smoot-Hawley: a universal 10% tariff effective April 5, reciprocal tariffs on largest-deficit partners effective April 9, carve-outs for copper, pharma, semis, lumber and energy, USMCA provisions, and escalation authority. Critically, the reciprocal rates are computed as trade deficit divided by imports — not actual foreign tariff levels — implying the policy targets deficit reduction and may persist far longer than markets hope. It builds on the earlier 'Tariff-ied' memo's warning not to expect Trump to retreat before significant impact.

A 1970s history section frames tariffs as the new oil shock: OPEC quadrupled oil from $3 to $12 in six months in 1973-74, then doubled it again to $39.50 in 1979; Burns treated inflation as transitory until wage-price spirals entrenched, and Volcker's cure required 20% rates and a near-depression. Tariffs recreate supply-shock economics through a different channel — but with broader reach, since modern supply chains mean costs compound at each production stage (a 10% steel tariff becomes 12% in parts, 15% in vehicles). The 2018 washing-machine case is the empirical anchor: 12% price increases despite tariffed metals being only ~5% of costs. Differences from the 1970s cut both ways: today's shock is an intentional policy choice hitting all sectors simultaneously, but labor has less wage-bargaining power.

The 'market's blind spots' section attacks three consensus assumptions. First, easy supply-chain adjustment: Citrini's analysis of capacity utilization shows the domestic capacity to replace even 25% of imports simply doesn't exist, a multi-year build during which consumers eat inflation without growth; losers include outsourced manufacturers FLEX and JBL and truckers (ARCB, WERN, SAIA, KNX) facing a demand air-pocket after inventory front-running. Second, tech's supposed insulation: hardware-dependent names (AAPL, GRMN, PTON, SONO, DELL, HPQ, ROKU) face cost inflation into weak demand; nominally 'software' companies like NTAP, PANW (13x revenue, 58x earnings, Asia-concentrated component supply) and ZS depend on hardware; IOT trades at 17x revenue with Taiwan-sourced hardware; medtech names PODD and DXCM just moved production to tariff-hit Malaysia; MASI's consumer wearables/audio mix is 'worst of all'; and speculative quantum names RGTI, QBTS, IONQ still carry $2B+ market caps. The WTO e-commerce tariff moratorium (since 1998) is also effectively dead, exposing US big tech to retaliation. Third, productivity destruction: every 10-point increase in domestic sourcing drops sector productivity ~3.7%, and pervasive uncertainty is itself a tax. Monetary policy is frozen: 1-year inflation swaps repriced to the highest since Q1 2022, with the year moving from ~2.5% expected inflation and 2-3 cuts to 3.5% and 4-5 cuts — Citrini expects continued dollar weakness and curve flattening.

The trade: a 2025 Stagflation Risk basket — ideal longs have domestic revenue dominance, proven pricing power, supply-chain resilience and inelastic demand; ideal shorts have global supply-chain dependency, thin margins, limited pricing power, discretionary exposure and high fixed costs. Intellectual honesty gets a full section: the 'Reciprocity Paradox' (defining unfairness by deficits while demanding reciprocity implies zero tariffs globally, contradicting the protectionist intent) suggests the regime may end in superficial wins and a vanilla slowdown rather than stagflation — which is why the portfolio keeps a significant long-bond position betting the Fed and investors look through inflation to the slowdown. Catalysts: initial implementation April 5-9 (rapid reductions would signal negotiation), first retaliation April-May (would force the bluff), and Q2 earnings in July-August as the first hard corporate evidence.

Key metrics
Key insights
#090 Market Memo Mar 31, 2025

Market Memo: Insuring Against Insanity

Published the day before 'Liberation Day', this Q2 memo argues investors must play offense and defense simultaneously: offense by concentrating into unfairly-punished high-conviction healthcare and natural-gas infrastructure names after a record drawdown in high-volatility stocks, and defense via new long/short baskets that profit from consumer normalization and boring-beats-flashy insurance regardless of whether the high-income consumer cracks. The through-line is that recent sector carnage is technical (high-vol positioning) rather than fundamental, creating dislocations to buy, while post-COVID consumer distortions — housing frozen by rate lock-in and top-20% services spending 45% above pre-pandemic — will mean-revert toward essentials and lower-income categories either way.

airobotconsumerautoconsumerhealthconsumermediaconsumerreal-estateconsumershoppingconsumertraveldefenseenergygridenergynuclearenergywarfinancefintechhealthGLPhealthhealthtestinginsurancesaas
Positions & performance
+5.7%avg return48% win · 83 tracked · L +23.7% · S -18.9%
PositionMentionsEntryLastReturn
LTOI:NASDAQ health The Oncology InstituteA1.14Mar 31 '255.39+372.8%
LAGX:NYSE energygrid ArganT131.17Mar 31 '25568.92+333.7%
LECG:NYSE energygrid Everus Construction37.09Mar 31 '25127.56 +243.9%
LFIVE:NASDAQ consumershopping Five BelowI74.92Mar 31 '25207.14 +176.5%
LWBD:NASDAQ consumermedia Warner Bros DiscoveryIPT10.73Mar 31 '2525.28 +135.6%
LTALK:NASDAQ health TalkspaceI2.56Mar 31 '255.22 +103.9%
LESOA:NASDAQ energygrid Energy Services of America9.45Mar 31 '2518.94+100.4%
LROST:NASDAQ consumershopping Ross StoresIT127.79Mar 31 '25238.89+86.9%
SSG:NYSE consumershopping SweetgreenSA25.02Mar 31 '256.0+76.0%
LGM:NYSE airobot General MotorsISPT47.03Mar 31 '2582.64+75.7%
LDLTR:NASDAQ consumershopping Dollar TreeIPT75.07Mar 31 '25125.54 +67.2%
SDOCS:NYSE health DoximityIT58.03Mar 31 '2520.99 +63.8%
SLULU:NASDAQ consumershopping LululemonISAPT283.06Mar 31 '25114.28+59.6%
SROOT:NASDAQ insurance RootA133.44Mar 31 '2557.95+56.6%
LFLR:NYSE energygrid FluorIP35.82Mar 31 '2551.7 +44.3%
LF:NYSE consumerauto FordIAPT10.03Mar 31 '2514.37+43.3%
SUPST:NASDAQ financefintech UpstartIAT46.03Mar 31 '2527.49 +40.3%
SSMR:NYSE energynuclear NuScale PowerSA14.16Mar 31 '258.54 +39.7%
LRNR:NYSE insurance RenaissanceReI240.0Mar 31 '25329.1+37.1%
STRUP:NASDAQ insurance TrupanionT37.27Mar 31 '2524.87 +33.3%
SOXM:NYSE consumershopping Oxford Industries58.67Mar 31 '2540.29 +31.3%
SSHAK:NYSE consumershopping Shake ShackAPT88.17Mar 31 '2561.57 +30.2%
LPVH:NYSE consumershopping PVHIT64.64Mar 31 '2583.93 +29.8%
LULTA:NASDAQ consumershopping Ulta BeautyIPT366.54Mar 31 '25475.36+29.7%
LRDNT:NASDAQ health RadNetT49.72Mar 31 '2561.57+23.8%
LXGN:NASDAQ health Exagen3.59Mar 31 '254.4 +22.6%
SCPRI:NYSE consumershopping Capri HoldingsA19.73Mar 31 '2515.44+21.7%
LCB:NYSE insurance ChubbPT301.99Mar 31 '25358.91 +18.8%
SONON:NYSE consumershopping On HoldingAP43.92Mar 31 '2537.07+15.6%
SDECK:NYSE consumershopping DeckersIT111.81Mar 31 '2596.04+14.1%
STOST:NYSE financefintech ToastIT33.17Mar 31 '2529.04+12.5%
SSPOT:NYSE consumermedia SpotifyISP550.03Mar 31 '25482.66+12.2%
LRKT:NYSE financefintech Rocket CompaniesIT12.07Mar 31 '2513.49 +11.8%
LEPD:NYSE energywar Enterprise Products PartnersP34.14Mar 31 '2538.12 +11.7%
LSKX:NASDAQ consumershopping Skechers56.78Mar 31 '2563.13+11.2%
LSYY:NYSE consumershopping SyscoIAT75.04Mar 31 '2583.11+10.8%
LET:NYSE energywar Energy TransferIP18.59Mar 31 '2520.36+9.5%
LQSR:NYSE consumershopping Restaurant Brands InternationalIA66.64Mar 31 '2572.47+8.7%
LWRB:NYSE insurance W.R. BerkleyAPT71.16Mar 31 '2575.46+6.0%
LACGL:NASDAQ insurance Arch CapitalAPT96.18Mar 31 '2597.54+1.4%
SLPLA:NASDAQ financefintech LPL FinancialIPT327.14Mar 31 '25328.7-0.5%
SDASH:NASDAQ consumershopping DoorDashISPT182.77Mar 31 '25184.37 -0.9%
SBMY:NYSE health Bristol Myers SquibbIPT60.99Mar 31 '2562.56 -2.6%
LFOX:NASDAQ consumermedia Fox CorpAP52.71Mar 31 '2550.81 -3.6%
LCQP:NYSE energywar Cheniere Energy Partners66.04Mar 31 '2562.94 -4.7%
LTKNO:NASDAQ health Alpha Teknova5.19Mar 31 '254.85 -6.6%
LPARA:NASDAQ consumermedia Paramount11.96Mar 31 '2511.04-7.7%
LHD:NYSE consumershopping Home DepotIPT366.49Mar 31 '25336.09 -8.3%
LLOW:NYSE consumershopping Lowe'sPT233.23Mar 31 '25207.64-11.0%
SHIPO:NYSE insurance Hippo25.56Mar 31 '2529.15 -14.0%
SGIL:NYSE consumershopping Gildan ActivewearIP44.22Mar 31 '2550.68 -14.6%
SABNB:NASDAQ consumertravel AirbnbIPT119.46Mar 31 '25141.1-18.1%
LTREE:NASDAQ insurance LendingTree50.27Mar 31 '2540.4 -19.6%
LFOXF:NASDAQ consumerauto Fox Factory23.34Mar 31 '2518.51-20.7%
SAMGN:NASDAQ healthGLP AmgenIPT311.55Mar 31 '25376.04-20.7%
SRJF:NYSE financefintech Raymond JamesIT138.91Mar 31 '25169.3-21.9%
SABBV:NYSE health AbbVieIPT209.52Mar 31 '25256.91 -22.6%
LKBR:NYSE defense KBR IncIA49.81Mar 31 '2536.93-25.9%
LEFX:NYSE financefintech EquifaxIAT243.56Mar 31 '25177.31 -27.2%
SJLL:NYSE consumerreal-estate Jones Lang LaSallePT247.91Mar 31 '25325.45-31.3%
LQTRX:NASDAQ health Quanterix6.51Mar 31 '254.32-33.6%
SWRBY:NYSE consumershopping Warby ParkerI18.23Mar 31 '2524.56-34.7%
SCOMP:NYSE consumerreal-estate CompassI8.73Mar 31 '2511.8 -35.2%
SCEG:NASDAQ energygrid Constellation EnergyISPT201.63Mar 31 '25274.35-36.1%
SLYV:NYSE consumertravel Live NationIPT130.58Mar 31 '25179.4 -37.4%
SVST:NYSE energygrid VistraIST117.44Mar 31 '25163.38-39.1%
LTSCO:NASDAQ consumershopping Tractor SupplyIPT55.1Mar 31 '2531.8 -42.3%
LOLLI:NASDAQ consumershopping Ollie's Bargain OutletIT116.36Mar 31 '2566.31-43.0%
SNRG:NYSE energygrid NRG EnergyIT95.46Mar 31 '25136.5 -43.0%
LBLND:NYSE financefintech Blend LabsA3.35Mar 31 '251.69-49.6%
LSTIM:NASDAQ health NeuroneticsA3.68Mar 31 '251.81 -50.8%
LHCAT:NASDAQ health Health CatalystA4.53Mar 31 '252.15 -52.5%
LZ:NASDAQ consumerreal-estate ZillowISAT68.56Mar 31 '2532.0 -53.3%
LUWMC:NYSE financefintech UWM HoldingsA5.46Mar 31 '251.84 -66.3%
SUBS:NYSE financefintech UBSP30.63Mar 31 '2552.54 -71.5%
LPAR:NYSE saas PAR TechnologyAPT61.34Mar 31 '2515.44-74.8%
LHAIN:NASDAQ consumerhealth Hain CelestialS4.15Mar 31 '250.53-87.2%
LNFLX:NASDAQ consumermedia NetflixIPT932.53Mar 31 '2570.09-92.5%
SOKLO:NYSE energynuclear OkloISA21.63Mar 31 '2541.81 -93.3%
LNOTV:NASDAQ healthtesting Inotiv2.21Mar 31 '250.08-96.4%
SLMND:NYSE insurance LemonadeA31.43Mar 31 '2561.99 -97.2%
SYOU:NYSE consumertravel Clear SecureT25.91Mar 31 '2553.23 -105.4%
SHOUS:NASDAQ consumerreal-estate Anywhere Real Estate3.33Mar 31 '2517.64-429.7%
Non-US / no priceWOSG:LSE consumershopping BRBY:LSE consumershopping ATZ:TSX consumershopping BMW:XETRA consumerauto MBG:XETRA consumerauto
Also watchingDEC:NYSE energywar EQT:NYSE energywar MDU:NYSE energygrid
Full summary 555 words

This March 31, 2025 memo operationalizes the previous day's 'Haves vs. Have Nots' collaboration into tradeable baskets, published deliberately before Trump's tariff reveal. Citrini notes the drawdown in high-volatility stocks was the most significant in a decade — exceeding the COVID panic — with Russell 3000 healthcare and energy down toward 50% from highs, which they attribute to technical positioning (those sectors have the most high-vol small caps) rather than deteriorating fundamentals. The response: concentrate into best ideas, take losses on marginal positions, and add defensive long/short exposure that has positive expected value even in a recovery.

The new Consumer Normalization basket bets on essentials over optional spending. In housing, low-income households are rate-locked (only 12% relocated vs 22% of high-income), so falling rates should release pent-up transactions benefiting the financing supply chain: longs RKT, TREE, UWMC, EFX, Z, and BLND (whose non-mortgage banking products are projected at a 40% CAGR and which inflects to profitability this year), against shorts in high-end real estate and wealth management (COMP, HOUS, JLL, UPST, RJF, UBS, LPLA). In services — where top-20% spending is +45% vs pre-pandemic while bottom-20% is -6% — they short YOU, SPOT, LYV, and ABNB against accessible-entertainment longs WBD, FOX, PARA, NFLX. Retail longs are bombed-out low-income names (OLLI, ULTA, FIVE, DLTR, TSCO, ROST, FOXF, LOW, PVH, HD, SKX) against premium apparel shorts (LULU, CPRI, ONON, DECK, OXM, WOSG, BRBY, ATZ, GIL, WRBY); restaurants pair QSR/PAR/HAIN/SYY long against DASH/TOST/SG/SHAK short, plus long F/GM vs short BMW/Mercedes on auto tariffs. A revived 'Insurance Redux' basket goes long proven underwriters at discounted valuations (ACGL, CB, RNR, WRB) against unprofitable insurtechs at nosebleed multiples (LMND, ROOT, HIPO, TRUP).

In healthcare, the memo high-grades into highest conviction: mental-health names STIM (Google Trends interest exploding, new payer coverage of millions of lives, trading at a 25-80% discount to peers on trailing revenue) and TALK (nearly 200 million Americans can access therapy for ~$15 average out-of-pocket, 50% y/y core growth, a quarter of market cap in cash, no debt), funded by exiting MNMD and TDOC — with Dr. Oz's expected CMS confirmation seen as a policy tailwind for both. In life sciences, NIH cut fears are called overblown (1,200 confirmed job cuts, 6% of staff, versus 3,000-5,000 initially reported); TKNO (path to ~30% EBITDA margins, backed by ~$85 billion of announced domestic biopharma manufacturing investment), NOTV, and QTRX (negative-value operations implied by the market) are added to, funded by exiting seven other names. A new health-data-plus-AI subtheme adds TOI, RDNT, HCAT, and XGN (1x revenue, insider buying, path to profitability this year). Insurer and vaccine shorts (CNC, ELV, UNH, DVA, UHS, PCVX, MRNA) are covered; new shorts target tariff/tax-exposed legacy pharma (ABBV, AMGN, BMY) and DOCS.

The NatGas basket pivots from LNG exporters and tariff-exposed component makers (exiting PSIX) toward infrastructure builders: AGX's blowout quarter is cited as proof of a multi-year gas power plant buildout, and ESOA (single-digit P/E, insider buying) and spinoff ECG (halved since spin despite cost-plus contracts) go overweight, alongside FLR, KBR, EPD, CQP, and ET. Nuclear 'AI power' highfliers (SMR, OKLO, VST, CEG, NRG) are suggested as an optional short pairing — VST added $30B of market cap without a single data-center deal. Finally, the AI basket's SMH and NVDA shorts are covered and, for the first time since December 2024, the portfolio goes unhedged.

Key metrics
Key insights
#089 Thematic Primer Mar 30, 2025

Haves vs. Have Nots (with The Last Bear Standing)

The US economy has bifurcated so severely that the top 10% of earners — who now drive roughly 50% of all consumer spending and hold record equity exposure — are the economy's single point of failure. Because the bottom 90% have already been in a 'rolling recession' since 2021 (depleted savings, multiple jobs, cut discretionary spending), the next downturn would be a wealth-effect recession: a sustained stock market decline cuts high-income spending through direct wealth, psychological, income (bonuses/options), and housing channels, transmitting market stress into real contraction. Trump 2.0's populist policy mix (tariffs, immigration reversal, no-tax-on-tips) further tilts the pain toward the affluent. The trade is therefore not classic staples-vs-discretionary but long companies serving already-recessed lower-income consumers (favorable base effects, bombed-out valuations) against short premium/'premiumization' names most sensitive to affluent spending.

financefintech
Positions & performance
+11.8%avg return100% win · 1 tracked · L +11.8%
PositionMentionsEntryLastReturn
LRKT:NYSE financefintech Rocket CompaniesIT12.07Mar 31 '2513.49 +11.8%
Full summary 533 words

Published March 30, 2025 as Citrini's first newsletter collaboration since 2023 (with fellow Substack author The Last Bear Standing), the piece extends the wealth-effect recession concept introduced in Citrini's 'After the Trump Bump' macro memo. With the fiscal impulse fading and recession chatter rising, the authors argue that guessing recession probabilities is useless; what matters is what KIND of recession, and this one would be driven by the top of the income distribution. TLBS draws the parallel to China's policy-driven $50 trillion property deflation; today a $60 trillion asset class — the US stock market — plays the same role as the primary store of American wealth, with an administration that may be serious about 'Main Street vs. Wall Street'.

The macro setup: the top 10% of earners (households above ~$250,000) account for roughly 50% of US consumer spending, a concentration compared to the 1920s. Total COVID stimulus of $4.6 trillion pales against $35 trillion of household financial wealth accumulation since 2019, more than half of which accrued to the top 1% (net worth +$17 trillion). Stocks are a larger share of household financial assets than at any time since the 1940s data begins. Fed research is cited showing lower interest expenses and corporate tax rates mechanically explain over 40% of real corporate profit growth from 1989-2019, while tech margins expanded from 10% (2004) to 27% (2024). Meanwhile the bottom 90% face an 'invisible recession': 15% of bottom-quintile workers hold multiple jobs (+87.5% since 2019), low-income debt service ratios are up 5 points since 2019, and the bottom 20% now spend 94% of their budget on necessities versus 85% pre-pandemic. A 'Bank of Mom and Dad' argument holds that official income data is distorted by boomer-to-millennial wealth transfer, which itself would slow if stocks fall.

The report also layers in an AI angle: white-collar work faces an LLM 'Sword of Damocles' — large law firms have cut entry-level hiring ~25%, Grammarly laid off 20% of staff citing AI, and Vanguard reports hiring for $96,000+ jobs at a decade low — while hands-on lower-wage work is harder to automate, potentially inverting the usual recession-resilience hierarchy. A key sentiment inversion is flagged: high-income consumers now expect unemployment more than low-income ones, historically rare and underpriced because aggregate confidence indices average across brackets. The transmission math: a 20% sustained drawdown could cut high-income spending 5-8%, a 2.5-4% hit to total consumption — enough for contraction. Second-order effects hit aspirational luxury, premium subscriptions (high-income households hold 8x more), trading-down cascades, and high-fixed-cost premium services; traditional defensives may not protect because staples have premiumized and trade at peak multiples.

Positioning: a systematic five-factor scoring framework (customer demographics, price elasticity, geographic concentration, trading-down vulnerability, operating leverage) builds a long basket of value-positioned, necessity-focused, lower-income-serving names already priced for recession (mortgage originator RKT is given as an example beneficiary of improved low-income mobility) against a short basket of premium-priced, wealth-effect-sensitive companies. A backtest shows the long/short tracking the spread between bottom-third and top-third consumer sentiment, accelerating when high-income confidence falls below middle-income confidence. Crucially, the trade doesn't require a recession — it also wins if low-income spending recovers and inequality narrows; the authors even invite skeptics to invert the baskets.

Key metrics
Key insights
#088 State of the Themes Mar 18, 2025

State of the Themes: Q1 2025

This is Citrini's quarterly 'State of the Themes' review for Q1 2025, released deliberately right before the March FOMC during the first real market drawdown since the prior summer. The core message is portfolio attribution: active management across 30+ thematic baskets kept the Core Thematic Portfolio positive (+4.17% YTD) even in a drawdown, because gains in Chinese equities, hedges, and European fiscal beneficiaries offset losses in connectivity, natural gas, and medtech. The actionable content — a thematic chartbook and suggested basket adjustments — sits below the paywall, so the public text is primarily a performance scoreboard for the Citrindex.

Positions & performance
No single-stock positions tracked in this report.
Full summary 166 words

This is a short quarterly-review wrapper, with most of the substance (the Q1 2025 Thematic Chartbook covering the 30+ themes in Citrini's coverage, plus commentary and suggested basket adjustments) behind the paywall. Released March 18, 2025 — intentionally timed right before the March FOMC and during the first real market drawdown since the previous summer, continuing Citrini's habit of publishing these reviews when attention is elsewhere.

The visible content is attribution for the Citrindex Core Thematic Portfolio, which had returned +4.17% year-to-date as of March 14, 2025. Top contributors: the Chinese Equity Barbell (+21.15% total return YTD, 10.96% average weight, +2.32% contribution), Hedges (+38.41% return, 3.32% weight, +1.83% contribution), and Fiscal Primacy (+13.07% return, 11.23% weight, +1.46% contribution). Top detractors: Connectivity (-8.17%, 5.61% weight, -0.55% contribution), NatGas (-9.56%, 7.38% weight, -0.74%), and Medtech & Healthcare Innovation (-15.43%, 14.00% weight, -1.06%). The chartbook's stated goal is a quick visual overview of the thematic landscape, and readers are pointed to the live Citrindex sheet for current basket allocations.

Key metrics
Key insights
#087 Thematic Primer Mar 06, 2025

European Fiscal Primacy: A Cure for the Sick Man?

Trump's America First turn — ending military support for Ukraine and threatening trade war — has forced Europe to abandon fifteen years of austerity: Germany's €500bn infrastructure fund and debt-brake reform, the EU's €800bn ReArm Europe plan, and Draghi-report industrial policy amount to 'fiscal primacy crossing the pond.' Just as US fiscal spending drove US equity winners from 2022-2024, European deficit spending along Draghi's sectoral lines should re-rate European industrials, chemicals and construction — where Citrini sees better risk/reward than the already-run defense trade — and the same logic supports a stronger euro (EURUSD target 1.15), lower relative US rates, and a potential durable break in rest-of-world versus US equity performance. Citrini launches an EU Fiscal Primacy basket and pairs it with long EUR/JPY vs short USD/CHF and a long SOFR/short EURIBOR STIR spread.

defense
Positions & performance
Non-US / no priceRHM:XETRA defense
Also watchingSAF:EURONEXT defense HO:EURONEXT defense
Full summary 507 words

Published March 6, 2025, this report ports Citrini's September 2023 'US Fiscal Primacy' megatrend framework to Europe. The setup: Europe is the friend who peaked in high school — fifteen years of post-GFC austerity, underinvestment, deindustrialization and regulatory burden left it trailing the US and China. But Trump's rapid upending of the security and trade order (ending military support for Ukraine, tariff threats) has triggered a genuine vibe shift: what was once unthinkable — large deficits, joint debt issuance, expansive state aid — is now official policy direction. The report catalogs the announcements: the European Commission's €800bn 'ReArm Europe' plan with €150bn in loans for defense investment and €150bn of proposed new joint EU borrowing; invocation of the Stability and Growth Pact's national escape clause, potentially creating ~€650bn of fiscal space over four years; and Germany's watershed under incoming Chancellor Merz — a €500bn infrastructure fund, debt-brake reform, and defense spending potentially reaching 3.5% of GDP by 2027. Citrini frames the analytical touchstone as Mario Draghi's September 2024 competitiveness report, whose €750-800bn annual investment program and sector-specific industrial policy provide the sectoral map for where money will flow — the same way IRA/IIJA/CHIPS mapped US fiscal winners. Three policy pillars structure the basket: military defense; reindustrialization and reversing headwinds (about 6% of European chemical capacity has been announced for closure or review, and the German stimulus is comparable in scale, relative to €4.5 trillion GDP, to America's $891bn IRA plus $1.2tn IIJA combined); and rebuilding Ukraine, whose World Bank/UN/EC-assessed cost has risen 7% to $524bn — 2.8x Ukraine's 2024 GDP, with 13% of housing stock damaged affecting 2.5 million households. Citrini's positioning history matters here: it recommended long EU Defense/short US Defense in its March 2024 election basket (the year's best-performing policy basket), and while it doesn't doubt Rheinmetall, Thales and Safran can go higher (5%-of-GDP German defense spending 'probably makes RHM a €3,000 stock'), it sees better risk/reward in the broadening trade — industrials, diversified chemicals and construction — echoing the profitability boost US infrastructure names enjoyed. The new EU Fiscal Primacy basket is explicitly an incremental-improvement play, not a bet that Europe fully escapes its slumber, and doubles as a hedge to US momentum longs the way the Chinese equity basket has been. The macro section ('Marshall Plan 2.0 — MEGA') argues the ECB will backstop the fiscal push: conditional QE/OMT eligibility for defense-linked national issuance is easy to imagine, the Maastricht 3%/60% limits were always arbitrary, Eurozone inflation is anchored (5y5y swaps near target) and German capacity utilization is at recessionary levels, so real resources exist. FX views: EURUSD target 1.15 supported by German-vs-US yield direction, five-year-extreme negative speculative EUR positioning as a contrarian signal, and falling natural gas prices; current exposure is 50% long JPY, 50% long EUR, 100% short USD, with the Hungarian forint flagged as a sleeper Ukraine-rebuild play. In rates, Citrini keeps the long SFRZ5/short ERZ5 spread rather than trading BTP-Bund, and notes rest-of-world versus US equities may finally break a 15-year downtrend since fiscal deficits drive aggregate corporate profits.

Key metrics
Key insights
#086 Macro Memo Feb 25, 2025

Macro Memo: After the Trump Bump

Fiscal primacy — Citrini's September 2023 thesis that government spending drives the US cycle — now cuts the other way: DOGE cuts, federal buyouts, rollback of Biden industrial programs like BEAD, tariff chaos and housing weakness are tightening fiscal impulse and freezing business investment, so risk shifts from inflation back to growth and bad news is now bad news for stocks. The January macro trades all worked (10y from 4.8% to 4.3%, SOFR M5M6 hit target, CHFJPY at 2024 lows), and the firm doubles down: stay long duration (TLT lifted from 6.5% to 24.5% of the Citrindex), short USD, short homebuilders, with the twist that the biggest risk to the economy is the stock market itself — a wealth-effect ouroboros where a sustained drawdown among top-10% households becomes self-fulfilling.

aisemiconsumerreal-estateindexbonds
Positions & performance
+15.4%avg return71% win · 7 tracked · L -0.9% · S +22.0%
PositionMentionsEntryLastReturn
SBLDR:NYSE consumerreal-estate Builders FirstSourceIAT140.78Feb 25 '2572.86+48.2%
SDFH:NYSE consumerreal-estate Dream Finders HomesT24.76Feb 25 '2515.63 +36.9%
SLEN:NYSE consumerreal-estate LennarIPT124.32Feb 25 '2584.64+31.9%
LXLRE:NYSE consumerreal-estate Real Estate Select Sector SPDR42.87Feb 25 '2545.95+7.2%
SITB:NASDAQ consumerreal-estate iShares U.S. Home Construction ETF101.0Feb 25 '2597.09+3.9%
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF91.42Feb 25 '2583.25-8.9%
SDHI:NYSE consumerreal-estate D.R. HortonPT132.11Feb 25 '25146.76-11.1%
Also watchingNVDA:NASDAQ aisemi
Full summary 466 words

This February 25, 2025 Macro Memo, subtitled 'Fiscal Primacy Cuts Both Ways,' takes a victory lap and then extends the thesis. Since January's memo, all three macro positions worked: bonds rallied violently with the 10-year falling from 4.8% to 4.3% (near the 4.2% target), the SOFR M5M6 flattener went from pricing zero cuts to the -34.5bps target, and CHFJPY returned to its 2024 lows. The core argument: the September 2023 'Fiscal Primacy' framework — that aggressive fiscal spending (CHIPS, IIJA, IRA) drives the US cycle — now operates in reverse under Trump. DOGE contract freezes, roughly 50-75K federal worker buyouts (DC unemployment claims up 150K this year), a DoD 8% savings target, only ~6% of federal employees full-time under RTO, and the likely rollback of programs like BEAD (fully awarded but barely disbursed, vulnerable to Musk's Starlink preference) all constitute fiscal retrenchment whose mere threat slows the economy. The memo marshals soft data — services and composite PMIs turning sharply lower post-inauguration, NFIB optimism retreating and uncertainty rising, the Citi economic surprise index going negative, Conference Board job plentifulness and consumer confidence round-tripping to pre-election levels — and hard data: hiring and quit rates at multiyear lows below pre-COVID levels, slowing wage growth, and anchored real-time rents that should keep feeding CPI disinflation. Housing gets special attention: new-home supply has risen to historically recessionary levels, the gap between home inventory and construction employment is unsustainable, and the 25 Trades for 2025 homebuilder short (DHI, LEN, BLDR, DFH, targeting 20-30% downside) has drastically outperformed; new macro expressions are long XLRE/short ITB and long lumber/short ITB, since lower rates help real estate more than builders and deportation threatens builder labor costs. Forecasts: slower real growth, modestly higher unemployment, lower inflation (favorable PCE base effects could put headline at 1.9% YoY by the April report), lower 10-year yields, and a Fed that skips (possibly again in March) but could deliver a make-up 50bps cut in May. The most original section is the 'macroeconomic ouroboros': with the wealth effect the strongest in decades and the economy increasingly sensitive to top-10% households earning over $250K, a stock drawdown lasting more than a month could become a self-fulfilling growth shock — making the market's reaction to Nvidia earnings a better six-month economic indicator than any data release. Trades: FX shifts to long 70% JPY, 20% EUR, 10% BRL versus short 50% CHF, 50% USD (CNH short eliminated, EUR added); the SOFR flattener is half-monetized with the M5 short covered, leaving long SFRM6 targeting 96.60; bonds retain asymmetry (30bps against you if wrong, 100bps+ if right — 'Elon Musk is on the same side of this trade'); and the Citrindex moves most of its ~18% cash into TLT, lifting the position from 6.5% to 24.5% as 'cash+' duration to hedge the equity book.

Key metrics
Key insights
#085 In Conversation Feb 16, 2025

In Conversation: Neuronetics (STIM)

An interview-driven deep dive arguing Neuronetics (STIM) is at a GLP-1-style adoption inflection: its TMS depression therapy has proven efficacy (62% remission odds after multiple drug failures versus 6.9% on a fourth antidepressant) but has been held back by awareness, restrictive labels and psychiatrist-only reimbursement — barriers CEO Keith Sullivan's team is now dismantling via the Better Me provider program, the Greenbrook acquisition, improving payer coverage, and a favorable policy environment (Dr. Oz at CMS, a North Carolina access bill). With $22.6M of merger synergies essentially actioned, cash-flow breakeven targeted for Q3 2025, and the stock at ~2x revenue versus peer BWAY at 4x and comps like CLPT above 12x, Citrini sees significant near-term upside even after a 700%+ run, plus a path to $500M+ revenue by 2030.

health
Positions & performance
-63.8%avg return0% win · 1 tracked · L -63.8%
PositionMentionsEntryLastReturn
LSTIM:NASDAQ health NeuroneticsA5.0Feb 18 '251.81 -63.8%
Also watchingBWAY:NASDAQ health CLPT:NASDAQ health
Full summary 460 words

This February 16, 2025 installment of Citrini's 'In Conversation' series pairs a bull-case update on Neuronetics (STIM) with a transcript of the firm's sit-down with CEO Keith Sullivan. STIM, first covered in the August 2024 Healthcare & Medtech primer and repeatedly bought on dips, has soared more than 700% from its mid-November low, yet Citrini argues the company is at the start of its adoption curve, not the end. The framing analogy is GLP-1s: drugs whose obesity efficacy was long known but which only exploded once labels, coverage, awareness and adoption were deliberately built — TMS (transcranial magnetic stimulation) for depression sits at the same inflection, addressing a huge underserved market where SSRIs deliver only ~27% remission on first use, falling to 6.9% by the fourth drug, while TMS lifts remission odds to 62% with over 80% of patients responding and only 36 reported seizures across 200,000+ treated patients. The interview covers the company's history (FDA clearance 2008, major-payer reimbursement 2016, IPO 2018, Sullivan's 2020 arrival motivated by personal losses to depression), the mechanics of the 19-minute, 36-session treatment course, and the awareness problem: patient awareness was under 9% twelve years post-clearance, and an early TV campaign generated 43,000 inquiries but only 123 treatments because providers never answered the phone. Sullivan's fix is the Better Me program — five standards including a staffed phone line, 24-hour lead response, full 36-session treatment, co-op-funded web presence and Neurostar University training — which now has 350 providers with 120+ waiting, has cut patient lead time from 87 to 17 days, and tripled patients treated per practice from 3 to 10 per quarter. The Greenbrook acquisition adds a 188-clinic national network being rationalized (site closures raised from 60 to 88, leaving 550+ points of access including Better Me practices), new revenue streams (Spravato buy-and-bill, potentially psilocybin), and synergies that grew from $10M initially identified to $22.6M, all but $1.3M already actioned. A recent $18M equity raise strengthens the balance sheet — partly to win trade credit for Spravato inventory — alongside a Perceptive debt facility of $50M expandable to $90M. Management targets cash-flow breakeven by Q3 2025 (with executive stock bonuses tied to hitting it as early as Q2), and policy tailwinds abound: payer drug-failure requirements have fallen from four to two (sometimes one), a North Carolina bill would open reimbursement beyond psychiatrists — critical since primary care writes 70% of antidepressant prescriptions — and incoming CMS head Dr. Mehmet Oz has repeatedly featured Neurostar on television. Citrini's valuation case: STIM should meet or beat its $145-155M 2025 revenue guidance, trades at roughly 2x revenue versus inferior TMS peer BWAY at 4x and comp Clearpoint Neuro above 12x sales, and can compound 20%+ organic revenue growth with expanding margins toward $500M+ revenue by 2030.

Key metrics
Key insights
#084 Market Memo Feb 09, 2025

Market Memo: Healthcare's AI-Powered Trump Card

With the January healthcare catch-up call working and earnings season winding down, policy narratives from Trump 2.0 and RFK's HHS will drive healthcare returns next — so the basket is repositioned around the administration's agenda. RFK's focus on mental health, alternative therapies, telemedicine and chronic disease creates tailwinds for STIM, TALK, TDOC, healthcare-IT and diagnostics names, while biopharma-supply-chain onshoring favors domestic providers like TKNO, NOTV and FTRE. The cost-cutting side cuts the other way: international reference pricing threatens Novo Nordisk, PBM reform overhangs CVS/CI/UNH, and DOGE's fraud and discretionary-payment crusade endangers dialysis operators, behavioral health, hospital DPP recipients, and Gilead via USAID/PEPFAR. AI enablers in healthcare are layered on top using Citrini's data-design-distribution Phase 2 framework.

consumerhealthconsumershoppinghealthGLPhealthhealthtesting
Positions & performance
+9.8%avg return51% win · 39 tracked · L +21.5% · S -3.8%
PositionMentionsEntryLastReturn
LTOI:NASDAQ health The Oncology InstituteA1.0Feb 10 '255.39+439.0%
LGH:NASDAQ health Guardant Health44.4Feb 10 '25147.33+231.8%
LEXAS:NASDAQ health Exact SciencesPT52.38Feb 10 '25104.91+100.3%
LGRAL:NASDAQ health Grail33.37Feb 10 '2566.77 +100.1%
SNVO:NYSE healthGLP Novo NordiskISP83.91Feb 10 '2548.77+41.9%
LLLY:NYSE healthGLP Eli LillyIPT868.88Feb 10 '251196.03+37.7%
SPCVX:NASDAQ health VaxcyteI85.94Feb 10 '2554.66+36.4%
SMOH:NYSE health Molina HealthcareIT286.42Feb 10 '25197.55+31.0%
SARDT:NYSE health Ardent Health Partners14.72Feb 10 '2510.64+27.7%
LFTRE:NASDAQ health FortreaI15.07Feb 10 '2519.2 +27.4%
LTALK:NASDAQ health TalkspaceI4.1Feb 10 '255.22 +27.3%
SACHC:NASDAQ health Acadia HealthcareIA42.85Feb 10 '2532.5 +24.2%
SUNH:NYSE health UnitedHealthISPT533.37Feb 10 '25417.64 +21.7%
SUHS:NYSE health Universal Health ServicesIPT185.35Feb 10 '25159.31 +14.0%
LICAD:NASDAQ health iCAD3.6Feb 10 '253.87+7.5%
LPRVA:NASDAQ health Privia HealthIT23.83Feb 10 '2525.5+7.0%
SELV:NYSE health Elevance HealthIAPT396.14Feb 10 '25377.68+4.7%
SPEP:NASDAQ consumershopping PepsiCoIPT144.35Feb 10 '25139.79 +3.2%
LTBRG:NASDAQ health TruBridgeA25.52Feb 10 '2526.2+2.7%
SCI:NYSE health CignaIPT292.82Feb 10 '25291.02 +0.6%
LPCRX:NASDAQ health Pacira BiosciencesAT26.1Feb 10 '2525.88-0.8%
SFMS:NYSE health Fresenius Medical Care24.17Feb 10 '2524.59-1.7%
SMDLZ:NASDAQ consumershopping MondelezIPT58.53Feb 10 '2560.52-3.4%
SCNC:NYSE health CenteneIPT58.91Feb 10 '2564.08 -8.8%
LHQY:NASDAQ health HealthEquityP112.15Feb 10 '2594.64-15.6%
LDXCM:NASDAQ health DexComIPT88.27Feb 10 '2571.54-19.0%
SHCA:NYSE health HCA HealthcareIAPT318.26Feb 10 '25382.19-20.1%
SGILD:NASDAQ health GileadIPT95.48Feb 10 '25129.31-35.4%
LTDOC:NYSE health TeladocI13.86Feb 10 '258.91 -35.7%
SDVA:NYSE health DaVitaIPT173.52Feb 10 '25235.44-35.7%
LNGVC:NYSE consumerhealth Natural Grocers46.76Feb 10 '2530.01-35.8%
LCERT:NASDAQ health CertaraT14.0Feb 10 '257.51-46.4%
LTKNO:NASDAQ health Alpha Teknova9.17Feb 10 '254.85 -47.1%
LSTIM:NASDAQ health NeuroneticsA3.86Feb 10 '251.81 -53.1%
SMRNA:NASDAQ health ModernaIT31.87Feb 10 '2554.07-69.7%
LDH:NASDAQ health Definitive Healthcare5.35Feb 10 '250.68-87.2%
LARAY:NASDAQ health AccurayA2.45Feb 10 '250.23 -90.8%
LNOTV:NASDAQ healthtesting Inotiv4.1Feb 10 '250.08-98.1%
SCVS:NYSE health CVS HealthIPT54.29Feb 10 '25107.74-98.5%
Also watchingDHR:NYSE health AVTR:NYSE health THC:NYSE health
Full summary 476 words

Published February 9, 2025, this memo updates the Medtech & Healthcare Innovation basket for the Trump 2.0 policy era and the post-DeepSeek AI landscape. It opens by noting the January Musings sector catch-up call has been rewarded — the basket outperformed healthcare indices through the JP Morgan conference and earnings season — and argues that with the catalyst calendar now empty, DC policy narratives will dominate returns. Citrini explicitly disclaims policy opinions: 'we are investors, not policy wonks.' The first theme is mental health and alternative therapies. RFK's advocacy — including 'wellness farms' for getting people off both illegal and psychiatric drugs — puts Neuronetics (STIM) squarely in the sweet spot: its non-invasive TMS therapy for major depressive disorder has been held back by requirements to fail multiple drugs and psychiatrist-only reimbursement, and a North Carolina bill expanding TMS to primary care could migrate to the national stage. Pacira (PCRX, non-opioid pain) and Talkspace (TALK, B2B telehealth with partners like Amazon) also benefit. Second, technology and AI: Trump has appointed healthcare investors to CMS roles and RFK champions telemedicine and AI; Citrini recently added healthcare IT names DH, PRVA and TBRG plus CERT, an AI-enabled CRO that touches over 90% of FDA-approved novel drugs. Teladoc (TDOC) is a featured turnaround — profitable, unlike 2021-era peers — whose Catapult Health acquisition fits Citrini's Phase 2 'data, design, distribution' AI framework: longitudinal data on 3M+ covered lives (nearly 50% with chronic conditions), an 81+ NPS experience with a 77% reduction in crisis-level hypertension and 56% medication-compliance improvement, distribution across 93.9 million US integrated-care members, and $1,400 verified savings per member over three years. Third, onshoring biopharma supply chains: China weakness still bites (DHR and AVTR comments), decoupling is just beginning, and Brad Setser's observation that the US trade deficit with Ireland roughly equals its EU pharma deficit signals EU exposure too — all favoring domestic providers TKNO, NOTV (bookings accelerating) and FTRE. Relatedly, Citrini expects Trump 1.0's international reference pricing to re-emerge (estimated $10B+ annual savings); Novo Nordisk is the standout loser since US semaglutide list prices run 3-5x Europe, while LLY June 1000 calls are kept for pipeline optionality. Fourth, cost-cutting: PBM reform has bipartisan support (RFK cited 60+ senators; the FTC found the Big 3 PBMs booked $7.3B above acquisition cost on specialty generics in 2017-2022), an overhang for CVS, Cigna and UnitedHealth. DOGE's fraud hunt threatens dialysis (DVA, FMS), behavioral health (ACHC, UHS), and Directed Payments Program hospital recipients (UHS, ARDT, HCA, ACHC — THC excluded for its Conifer AI asset); Gilead is flagged as USAID/PEPFAR collateral damage; and Medicaid work-requirement risk makes Citrini cautious on CNC, MOH and ELV. Finally, RFK's chronic-over-infectious-disease pivot supports DXCM, oncology diagnostics EXAS/GRAL/GH, oncology turnarounds ARAY, ICAD and TOI, and wellness longs NGVC and HQY — against losers MRNA and PCVX (vaccine funding) and packaged-food shorts PEP and MDLZ.

Key metrics
Key insights
#083 Market Memo Feb 03, 2025

Market Memo: Tariff-ied

Trump's weekend announcement of 25% tariffs on Mexico and Canada (10% on Canadian energy) plus 10% incremental duties on China proves the trade war is not a bluff: it is an intentionally manufactured pain trade designed to demonstrate credibility, with the fentanyl/IEEPA pretext offering no clear path to appeasement. Because the market priced tariffs as negotiating bluster, tightly-correlated long/short pairs — domestic substitutes versus import-dependent and Mexico/Canada-exposed names — can now diverge violently, creating asymmetric basket trades across autos, consumer goods, steel, energy, and lumber/homebuilders. On macro, Citrini treats tariffs as a tax increase rather than an inflation shock — net deflationary via the hit to discretionary spending — so unlike consensus it stays bullish bonds, adds to its 2s10s flattener, goes long lumber against homebuilders, and expects near-term USD strength.

airobotcommoditiesconsumerautoconsumerreal-estateconsumershoppingdefenseenergygridenergywarindexbonds
Positions & performance
-2.3%avg return43% win · 61 tracked · L +36.8% · S -21.4%
PositionMentionsEntryLastReturn
LDK:NYSE energywar Delek US18.06Feb 03 '2563.2+249.9%
LPBF:NYSE energywar PBF EnergyIA27.72Feb 03 '2561.63+122.3%
LSTLD:NASDAQ commodities Steel DynamicsIPT127.92Feb 03 '25250.27 +95.6%
SORLY:NASDAQ consumerauto O'Reilly AutomotiveIPT1316.06Feb 03 '2587.4+93.4%
LCMI:NYSE energygrid CumminsIT348.21Feb 03 '25661.84 +90.1%
LNUE:NYSE commodities NucorIPT131.3Feb 03 '25247.56+88.5%
LDAN:NYSE consumerauto Dana15.73Feb 03 '2528.13+78.8%
SWHR:NYSE consumershopping WhirlpoolIPT99.21Feb 03 '2537.27+62.4%
SSTLA:NYSE consumerauto StellantisIPT12.62Feb 03 '255.69+54.9%
LX:NASDAQ commodities US Steel36.44Feb 03 '2554.84+50.5%
SNKE:NYSE consumershopping NikeISAPT76.59Feb 03 '2541.7+45.6%
LYETI:NYSE consumershopping Yeti HoldingsI36.03Feb 03 '2550.38+39.8%
SBCC:NYSE commodities Boise CascadeT125.14Feb 03 '2577.84+37.8%
LDVN:NYSE energywar Devon EnergyIPT33.75Feb 03 '2545.04+33.5%
SLEN:NYSE consumerreal-estate LennarIPT126.19Feb 03 '2584.64+32.9%
SVFC:NYSE consumershopping VF CorpI24.62Feb 03 '2517.03+30.8%
SSTZ:NYSE consumershopping Constellation BrandsIPT174.41Feb 03 '25130.16+25.4%
LFANG:NASDAQ energywar Diamondback EnergyAPT164.48Feb 03 '25204.68+24.4%
SLOW:NYSE consumershopping Lowe'sPT256.5Feb 03 '25207.64+19.0%
SHD:NYSE consumershopping Home DepotIPT408.76Feb 03 '25336.09 +17.8%
LEOG:NYSE energywar EOG ResourcesPT126.4Feb 03 '25146.39+15.8%
SUAA:NYSE consumershopping Under ArmourA8.25Feb 03 '257.08 +14.2%
SITB:NASDAQ consumerreal-estate iShares U.S. Home Construction ETF104.44Feb 03 '2597.09+7.0%
SFDP:NYSE consumershopping Fresh Del MonteT30.91Feb 03 '2529.22+5.5%
STM consumerauto ToyotaPT183.65Feb 03 '25177.42+3.4%
STSN:NYSE consumershopping Tyson FoodsIAT57.74Feb 03 '2557.45+0.5%
SDOLE:NYSE consumershopping DoleA13.34Feb 03 '2514.05-5.3%
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF88.16Feb 03 '2583.25-5.6%
SBBY:NYSE consumershopping Best BuyIPT83.78Feb 03 '2588.45 -5.6%
LPCH:NASDAQ consumerreal-estate PotlatchDelticI44.5Feb 03 '2541.73-6.2%
SDHI:NYSE consumerreal-estate D.R. HortonPT137.46Feb 03 '25146.76-6.8%
SGPC:NYSE consumerauto Genuine PartsIPT115.92Feb 03 '25124.21-7.2%
SHMC:NYSE consumerauto HondaP26.9Feb 03 '2529.13 -8.3%
SWMT:NASDAQ consumershopping WalmartISAPT99.54Feb 03 '25109.47-10.0%
LBF:NASDAQ consumershopping Brown-Forman31.91Feb 03 '2527.96-12.4%
STHRM:NASDAQ consumerauto GenthermT36.2Feb 03 '2542.07 -16.2%
LRYN:NYSE consumerreal-estate RayonierI25.94Feb 03 '2521.58-16.8%
LTSLA:NASDAQ airobot TeslaISPT383.68Feb 03 '25313.03-18.4%
SPHM:NYSE consumerreal-estate PulteGroupIT109.15Feb 03 '25130.59 -19.6%
SBA:NYSE defense BoeingISAPT175.87Feb 03 '25211.5 -20.3%
LAOUT:NASDAQ consumershopping American Outdoor BrandsI16.52Feb 03 '2512.95-21.6%
LWY:NYSE consumerreal-estate WeyerhaeuserIAT30.75Feb 03 '2523.94-22.1%
LUFPI:NASDAQ consumerreal-estate UFP IndustriesPT115.32Feb 03 '2587.94-23.7%
STJX:NYSE consumershopping TJX CompaniesIPT124.31Feb 03 '25154.22-24.1%
LSAM:NYSE consumershopping Boston BeerI246.63Feb 03 '25183.6 -25.6%
SCNQ:NYSE energywar Canadian Natural Resources30.02Feb 03 '2539.49-31.5%
SDE:NYSE airobot DeereIPT467.05Feb 03 '25628.16-34.5%
SF:NYSE consumerauto FordIAPT9.89Feb 03 '2514.37-45.3%
SBZH:NYSE consumerreal-estate Beazer Homes21.33Feb 03 '2533.05 -54.9%
SLEA:NYSE consumerauto LearI90.99Feb 03 '25143.6-57.8%
SDG:NYSE consumershopping Dollar GeneralIPT71.47Feb 03 '25117.23-64.0%
SADM:NYSE consumershopping Archer-Daniels-MidlandIAPT50.02Feb 03 '2585.92-71.8%
SGM:NYSE airobot General MotorsISPT47.9Feb 03 '2582.64-72.5%
SSU:NYSE energywar Suncor EnergyI37.56Feb 03 '2565.81-75.2%
SDLTR:NASDAQ consumershopping Dollar TreeIPT71.63Feb 03 '25125.54 -75.3%
SPSX:NYSE energywar Phillips 66IAPT117.86Feb 03 '25206.77-75.4%
SMGA:NYSE consumerauto Magna InternationalIP37.15Feb 03 '2565.66-76.7%
SCVE:NYSE energywar Cenovus Energy14.11Feb 03 '2528.04 -98.7%
SBWA:NYSE consumerauto BorgWarnerIS31.16Feb 03 '2564.39-106.6%
SVLO:NYSE energywar Valero EnergyIPT136.18Feb 03 '25304.93 -123.9%
SCAT:NYSE energygrid CaterpillarIPT361.55Feb 03 '25873.28 -141.5%
Also watchingADN:TSX commodities CFP:TSX commodities WFG:TSX commodities IFP:TSX commodities WEF:TSX commodities
Full summary 480 words

Published February 3, 2025, hours after Trump's Saturday announcement of 25% tariffs on Mexican and Canadian goods (10% on Canadian energy) and an incremental 10% duty on Chinese goods, this unpaywalled memo argues the market fundamentally misread tariffs as campaign bluster or a Bessent/Miran-style gradual approach. Citrini frames the move — ostensibly tied to fentanyl and triggered via IEEPA — as an intentionally manufactured pain trade: Trump believes the asymmetry favors the US (trade is 67% of Canada's GDP, 73% of Mexico's, 37% of China's, but only 24% of America's, even with the world's largest goods deficit at over $1 trillion in 2023), and the ambiguous pretext lets him grant 'reprieve' at his discretion while training partners to believe his threats for the rest of his term. The numbers: the three countries are ~40% of US international trade; 2024 imports from them totaled $1,358 billion (42% of total) and exports $832 billion (40%); the new tariffs amount to over $250 billion in annualized duty, with announced retaliation adding over $150 billion on exports. The trading logic is that tightly-correlated pairs can now diverge violently, so Citrini builds a Tariff Long/Short basket around four buckets: long domestic substitutes gaining pricing power (US lumber, steel, agriculture), long relative pricing power with the US consumer, short import-dependent cost-takers, and short Mexico/Canada-exposed exporters facing demand destruction. Sector by sector: in autos, the Big Three's border-crossing supply chains are exposed — short GM, Ford, Lear, Magna, Toyota, Honda, Stellantis, BorgWarner, ORLY, GPC, Gentherm; long insulated TSLA, Cummins, Dana. In consumer, short importers WMT, HD, LOW, STZ (Corona/Modelo brewed in Mexico), Dole, Fresh Del Monte, BBY, NKE and others; long domestic producers SAM, Brown-Forman, AOUT, YETI. On retaliation, short high-profile targets CAT, Deere, Boeing, Whirlpool, ADM, Tyson; long domestic steel NUE, STLD, X. In energy, the 10% Canadian duty (~$6/bbl) tightens the WCS-WTI differential, benefiting US producers and light-crude refiners (long FANG, EOG, DVN, PBF, DK) at the expense of Canadian producers and heavy-crude refiners (short CVE, SU, CNQ, VLO, PSX). In housing, tariffed Canadian softwood squeezes homebuilder margins already pressured by mortgage rates — long RYN, PCH, UFPI, WY; short builders DHI, LEN, PHM, BZH and Canadian lumber names. The macro section is deliberately contrarian: tariffs function more like a tax hike than a price shock, so the net effect is deflationary via the hit to discretionary spending and growth — the immediate bond reaction agreed. Citrini increases the DV01 of its 2s10s flattener (entered January 10 at +38.6bps, target +20bps) by 50% and cites the Fed's 2018 'look through tariffs' staff analysis, noting the labor market is looser now than in September 2018. It expects a Tariff Tantrum in equities, flight to safety, short-term USD strength resolving to longer-term strength, and flags the risk that China devalues the renminbi rather than retaliating conventionally — likely part of why China's opening tariff was only 10%.

Key metrics
Key insights
#082 Market Memo Jan 26, 2025

DeepSeeking Answers: Beyond "How Does This Impact NVDA?"

DeepSeek's open-source V3 and R1 models prove that top-tier AI can be trained and run far more cheaply — via FP8 precision, mixture-of-experts, and pure reinforcement learning without human feedback — which Citrini had anticipated as China's hardware handicap forcing architectural breakthroughs. Cheaper, commoditized LLMs are bearish for companies whose value rests on ever-escalating capex (a key reason Citrini already sold NVDA) but strongly bullish for AI commercialization, because training/inference cost was the biggest barrier to profitable AI software. This marks the starting gun for 'Phase 2' of the AI trade: rotate from picks-and-shovels infrastructure toward software, agents, and application-layer winners, stay long Chinese semis and Chinese AI names, and tactically short SMH to fund the additions.

aisemi
Positions & performance
-138.0%avg return0% win · 1 tracked · S -138.0%
PositionMentionsEntryLastReturn
SSMH:NASDAQ aisemi VanEck Semiconductor ETF235.81Jan 27 '25561.19-138.0%
Also watchingNVDA:NASDAQ aisemi
Full summary 443 words

Written January 26, 2025 as markets convulsed over Chinese lab DeepSeek's release of the open-source V3 and R1 models, this memo pushes past the reflexive 'what does this mean for NVDA?' question. Citrini notes it had explicitly predicted this in its June 2024 Citrindex anniversary piece: China's restricted access to NVIDIA-class hardware would force architectural breakthroughs that could leapfrog the current paradigm. The memo explains the technology in lay terms: DeepSeek used pure reinforcement learning — a simple right-answer-gets-a-reward scheme starting from the math-savvy Qwen2.5-Math-7B, using only 8,000 math problems where others use millions — plus FP8 8-bit precision training, multi-token prediction, KV-index compression, and a mixture-of-experts design whereby the 671B-parameter V3 activates only about 37B parameters per inference task, allowing consumer-grade GPUs to run it. R1 Zero showed test-time-compute reasoning can emerge from RL alone, without human-supervised fine-tuning, and distilled versions (a 1.5B-parameter Qwen distillation outperforming GPT-4o and Claude on some reasoning tasks) can run locally on a pair of Mac Minis. Citrini addresses the psyop question directly: the final training-run numbers are replicable, even if total resource claims may be misleading — the famous $6M figure covers only pretraining, and the firm employs a couple hundred engineers. Its PCIe architecture also suggests NVLink is not required, a slight crack in NVDA's chokehold. The investment read: this is the starting gun for LLM commoditization Citrini had been waiting for — the transition from Phase 1 (picks and shovels, where the firm cast a wide net of ~120 potential data-center winners then narrowed 60-70%) to Phase 2 (products, software, agents). Cheaper models are bearish for names whose value derives from ever-escalating capex estimates — the memo restates the 25 Trades for 2025 rationale for selling NVDA, that risk/reward was no longer asymmetric — but bullish for AI commercialization, since training and inference cost has been the biggest barrier to profitable AI software. The Jevons paradox bull case (Dylan Patel: 'Now we can have even more AI') is acknowledged: efficiency gains may simply expand demand and keep capex intact, but Citrini is less enthused, noting the market's muted reaction to half a trillion dollars of announced investment shows little room for incremental capex to surprise. Positioning: tactically short SMH to fund Phase 2 additions in software and agent-enablers; stay long the Chinese semiconductor industry and the Chinese AI basket first added in May 2024 and doubled in October's 'Another Brick in the Wall (of Worry)'; and explore companies building a new application layer designed for AI-agent interaction rather than humans. The conclusion is enthusiastic: open-source, commoditized LLMs mean more nerds in basements, more AI products, and the real test of what AI can do.

Key metrics
Key insights
#081 Macro Memo Jan 16, 2025

Macro Memo: January 2025

The market has swung to peak perceived Fed hawkishness after hot jobs and inflation prints drove the 10-year yield to 2023 highs, but the underlying disinflation drivers — shelter disinflation anchored by slowing wage growth — remain intact, as the latest CPI confirmed. The Fed will skip, not pause, at the January meeting and likely resume cutting in March, so being early on the 10-year call is not the same as wrong: Citrini expects the 10-year to retrace from 4.8% toward the multi-decade mode of 4.2%. Positioning follows via TLT call options, a long SFRM6/short SFRM5 flattener, and a short CHF/long JPY FX trade, with the LA fires flagged as the main new upside risk to measured shelter and services inflation.

indexbonds
Positions & performance
-4.4%avg return0% win · 1 tracked · L -4.4%
PositionMentionsEntryLastReturn
LTLT:NASDAQ indexbonds iShares 20+ Year Treasury Bond ETF87.04Jan 16 '2583.25-4.4%
Full summary 489 words

This January 16, 2025 Macro Memo updates Citrini's 'Schrödinger's soft landing' framework after a rough stretch: the firm admits its 10-year yield forecast was wrong as yields surged post-Fed-cuts on hot jobs and inflation prints, wobbling stocks through Christmas. Yet it argues the disinflation thesis is intact — the January CPI validated continued shelter disinflation anchored by slowing wage growth — and notes that while broad indices erased post-election gains, Citrini's thematic baskets (AI, Trump trade) held theirs and made new highs, evidence that themes can dominate traditional macro forces. The core call: the market has hit peak perceived monetary policy hawkishness and peak US growth optimism while under-discounting Trump-policy risks to growth. The Fed will skip, not pause, in January — it wants to 'protect a good thing' and still sees policy above neutral — and likely resumes cutting in March once disinflation re-emerges. The memo walks through the data: core PCE has drifted the wrong way since easing began, but CPI core services ex-shelter printed 0.21% MoM (effectively at target) and shelter 0.26%, the second-lowest in six months; hire and quit rates keep declining and Atlanta Fed wage growth trends lower, anchoring rents. Goods inflation is seen anchored by China's weak economy and excess capacity, tariff threats notwithstanding. A dedicated section builds a preliminary framework for the LA fires' inflationary impact: LA County is roughly 8-9% of national CPI, so a spike in temporary lodging, then gradually-captured rent increases over one to two years, vehicle and furnishings inflation from simultaneous supply destruction and replacement demand, and multi-year construction labor cost pressure (worsened if immigration is restricted) could all distort CPI upward even as the shock is initially deflationary through employment. On rates, Citrini says it was early, not wrong: the 10-year should retrace from the over-extended 4.8% toward 4.2%, the multi-decade mode, which it deems more relevant than the oft-cited 5.8% mean. It recalls that the macro narrative has flipped every quarter since the start of 2024 and remains skeptical of extrapolating 'no cuts in 2025 / hikes are back.' Trades: rather than shorting bonds (poor asymmetry), burn premium on wingy TLT upside calls — hedges pared from equity puts to TLT calls on January 8 — since bonds hedge the book's cyclical equity risk; a long SFRM6/short SFRM5 STIR flattener (entry -0.04, stop 0.015, target -0.345) that wins if the hawkish repricing unwinds violently as in late 2023; and in FX, reiterate short CHF/JPY, as the BoJ will likely have higher overnight rates than the SNB before Q1 ends and the franc is extremely overvalued to the yen on PPP. The memo closes with a historical rhyme: in 1998-99 the Greenspan Fed cut four times then paused while inflation and the 10-year rose — and stocks melted up into the Dotcom bubble. Citrini isn't predicting a repeat but notes secularly higher rates don't mean imminent collapse, and 5-15% drawdowns were routine in the late-90s bull market.

Key metrics
Key insights
#080 Market Memo Jan 09, 2025

Market Memo: January Musings

Two threads for January 2025: healthcare and natural gas power generation. Healthcare has been crushed by tax-loss selling and record-low sentiment even as bioprocessing and medtech fundamentals inflect, so year-end de-grossing ends, the JP Morgan conference brings catalysts, and record M&A dry powder meets depressed valuations — the whole sector should re-rate, favoring small innovative life-science and medtech names. Separately, AI data centers, LNG exports, and gas-fueled transportation are creating structural natural gas demand that supply and infrastructure cannot easily meet, so Citrini launches a NatGas/Power Generation basket focused on companies that relieve bottlenecks (turbines, compression, LNG, transport) rather than betting on the gas price itself. The memo also rotates the AI basket toward beaten-down semicap, analog and electrical-component names, dips a toe into solar, and hedges cyclical risk with bond calls.

aimemoryaiopticalaisemienergyaienergygridenergywarhealthhealthtesting
Positions & performance
+59.8%avg return58% win · 33 tracked · L +65.7% · S -127.0%
PositionMentionsEntryLastReturn
LMU:NASDAQ aimemory MicronISAPT99.34Jan 10 '25920.95+827.1%
LGRAL:NASDAQ health Grail17.73Jan 10 '2566.77 +276.6%
LAGX:NYSE energygrid ArganT159.42Jan 10 '25568.92+256.9%
LMXL:NASDAQ aioptical MaxLinearST20.63Jan 10 '2571.59+247.0%
LMASS:NASDAQ health 908 Devices2.26Jan 10 '257.13 +215.5%
LGEV:NYSE energygrid GE VernovaIPT367.1Jan 10 '251014.75+176.4%
LNXT:NASDAQ energygrid NextrackerT41.1Jan 10 '25103.73 +152.4%
LPSNL:NASDAQ health PersonalisA5.59Jan 10 '2511.78+110.7%
LOSCR:NYSE health Oscar HealthISA14.18Jan 10 '2528.19+98.8%
LSEI:NYSE energyai Solaris EnergySAP28.64Jan 10 '2554.03+88.7%
LEXAS:NASDAQ health Exact SciencesPT56.5Jan 10 '25104.91+85.7%
LESOA:NASDAQ energygrid Energy Services of America11.61Jan 10 '2518.94+63.1%
LNPCE:NASDAQ health NeuroPace11.94Jan 10 '2515.3 +28.1%
LPUMP:NYSE energywar ProPetro10.19Jan 10 '2511.8+15.8%
LIRTC:NASDAQ health iRhythm97.7Jan 10 '25109.2+11.8%
LGTLS:NYSE energygrid Chart IndustriesI195.11Jan 10 '25209.91+7.6%
LFSLR:NASDAQ energygrid First SolarIPT189.24Jan 10 '25202.82+7.2%
LSTIM:NASDAQ health NeuroneticsA1.71Jan 10 '251.81 +5.8%
LFTRE:NASDAQ health FortreaI18.19Jan 10 '2519.2 +5.6%
LEXE:NASDAQ energywar Expand EnergyIPT102.15Jan 10 '2590.51 -11.4%
LMDWD:NASDAQ health MediWound16.72Jan 10 '2514.23-14.9%
LLBRT:NYSE energywar Liberty EnergyA21.4Jan 10 '2517.36-18.9%
LDEC:NYSE energywar Diversified EnergyA16.47Jan 10 '2512.71 -22.8%
LOBIO:NASDAQ health Orchestra BioMedA5.47Jan 10 '253.82 -30.2%
LGDRX:NASDAQ health GoodRxI4.55Jan 10 '253.05 -33.0%
LTKNO:NASDAQ health Alpha Teknova8.06Jan 10 '254.85 -39.8%
LENPH:NASDAQ energygrid EnphaseIAT66.74Jan 10 '2536.7-45.0%
LWVE:NASDAQ health Wave Life SciencesA11.54Jan 10 '255.92 -48.7%
LQDEL:NASDAQ health QuidelOrthoT45.75Jan 10 '2516.05-64.9%
LCVRX:NASDAQ health CVRxA14.17Jan 10 '254.74-66.5%
LRXST:NASDAQ health RxSight33.43Jan 10 '255.19-84.5%
LNOTV:NASDAQ healthtesting Inotiv4.37Jan 10 '250.08-98.2%
SSMH:NASDAQ aisemi VanEck Semiconductor ETF247.18Jan 10 '25561.19-127.0%
Non-US / no priceENR:XETRA energygrid
Also watchingNARI:NASDAQ health SYK:NYSE health ANGO:NASDAQ health CVS:NYSE health HUM:NYSE health AVGO:NASDAQ aisemi CIEN:NYSE aioptical WDC:NASDAQ aimemory COHR:NYSE aioptical LITE:NASDAQ aioptical NVDA:NASDAQ aisemi TAN:NYSE energygrid
Full summary 505 words

Published January 9, 2025, this Market Memo lays out Citrini's two highest-conviction January ideas: a healthcare re-positioning and a new natural gas / power generation basket, plus AI basket and solar changes. The healthcare setup builds on the firm's earlier Healthcare Cyclical Inflection primer and the Markets Gone RF-Krazy update. The sector's S&P weighting is the lowest this century, Bank of America's Fund Manager Survey shows the worst sentiment in nearly a decade, less than 7% of healthcare stocks have recently outperformed the index (worst in 25 years), and medtech trades at a 20% discount to the S&P versus a long-term 15-25% premium. Citrini argues much of this is technical — heavy tax-loss harvesting and de-grossing into year-end after healthcare finished 2024 as the second-worst sector — and that the calendar flip removes that pressure just as the J.P. Morgan healthcare conference opens the busiest catalyst and M&A window of the year, with record dry powder. Having delivered alpha in 2024 via catalysts, the basket now leans into beta: shorts are covered to raise net exposure. Adds include QDEL (turnaround diagnostics at a low valuation), tax-loss-victim small caps MASS, PSNL and WVE, and in medtech NPCE (responsive neurostimulation for drug-resistant epilepsy nearing profitability), RXST (adjustable IOL) and OBIO. Stryker's premium bid for NARI signals more cardiology M&A, so IRTC and CVRX go back to overweight; MDWD and STIM are doubled. In managed care, longs in CVS and HUM are exited in favor of OSCR plus new add GDRX. The natural gas section argues demand keeps stacking: Mitsubishi Power expects a 50% increase in gas-turbine orders over two years, EQT sees data centers driving load growth, the Data-Center Power Gap is estimated at 15GW by 2026, and new LNG export terminals plus gas-fueled trucking and shipping add more. Supply is constrained by producer capital discipline and concentrated acreage, but Citrini explicitly takes no view on the gas price — the trade is anything that relieves bottlenecks in turbines, compression, processing, LNG export/hub balancing and gas marketing. Existing holdings (GEV, Siemens Energy, GTLS, AGX, ESOA, DEC, EXE) are combined with SEI, LBRT and PUMP from 25 Trades for 2025 into a new basket, funded by exiting the H2O basket. In the AI basket, after Broadcom's 43% December and Ciena's 21.6% gain versus Micron -14% and WDC -18%, Citrini rotates toward cyclically-depressed names with AI tails — semicap, analog and passive/active electrical components — highlighting MaxLinear's power-conversion and optical DSP optionality and turning incrementally bullish on Micron again, while trimming Connectivity by 10% after CIEN/AVGO/COHR re-rated. In the Fiscal basket, solar gets a toe-hold: TAN fell roughly 70% over Biden's term and leading names dropped 15-20% on Trump's win, yet solar capacity grows over 20% annually and FSLR trades at 16x and NXT at 11x trailing earnings, with ENPH a coiled spring. The macro coda expects a volatile Q1 of Trump Tantrums, notes tariffs were deflationary in the 1920s-30s, and swaps some March equity index puts into bond calls as a cheap hedge with 30-year yields near 5%.

Key metrics
Key insights